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VACCINATION NATION: A BIOETHICAL FEMINIST INQUIRY INTO THE POLITICAL,
SOCIAL, AND ETHICAL CONTROVERSY SURROUNDING THE HUMAN
PAPILLOMAVIRUS VACCINE
by
KIRSTEN KELLER MORIN
(Under the Direction of Delores Liston)
ABSTRACT
This theoretical inquiry has explored the political, social, and ethical controversy
surrounding the government’s push to mandate the human papillomavirus (HPV) vaccine for
adolescent girls. This vaccine has the potential of preventing cancer, specifically cervical cancer.
There is a growing debate in this country whether this new HPV vaccine, Gardasil, should be
added to the list of school-mandated vaccines.
Karen Houppert (2007) has stated that this particular “vaccine protects girls and women
from cervical cancer and genital warts caused by the human papillomavirus (HPV)” (p. 17). So,
what is the controversy? It all started with the fact that this vaccine is the first immunization
produced to prevent cancer caused by a sexually transmitted disease (STD). There are several
U.S. politicians that want to make the HPV vaccine a compulsory vaccine. Because an STD
causes this disease there is a debate, according to Houppert, “by compassionate conservatives
and abstinence-only hardliners who object to mandating the vaccine since the disease was the
result of a lifestyle decision” (p.17). On the other hand, according to the Centers for Disease
Control (CDC), “Gardasil has proven 100% effective in preventing the four strains of HPV that
are responsible for most cases of cervical cancer”(Manning, 2007, p. 11). So why not mandate it
for adolescent girls? This question was explored further in this work using bioethical feminist
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theory as a theoretical framework. This study was grounded in the works of Rosemarie Tong and
Susan Sherwin.
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CHAPTER 1
INTRODUCTION
We live longer than we used to. No single medical advance had a greater impact on human
health than vaccines.
-Paul A. Offit, M.D. (2005a, p. xi)
The year was 1855. A Massachusetts law was drafted that stated that all school-aged
children must be vaccinated for the viral disease, smallpox, before they enter public school. This
law was the beginning of the government’s school mandated vaccination program. James
Colgrove, a medical historian at the Columbia University Mailman School of Public Health, has
stated, “School-based laws began in the 19th century, at about the same time as mandatory
education laws…when people realized that schools were breeding grounds for illness”
(Hendricks, 2007, ¶13). Today, in order for a person to attend most U.S. schools and colleges the
individual state governments mandate several vaccines, like polio, measles, mumps, and rubella.
Arthur Allen (2007) has asserted, “In America, vaccination is the first act the state requires of a
person; without it, or legal exemption, a kid can’t even get into nursery school” (p. 15). This
“act” starts before an infant even leaves the hospital; at only 2 days old all infants born in the
United States receive the Hepatitis B vaccine.
This 1855 compulsory vaccination order was also the beginning of a web of emotional,
political, bioethical, legal, religious, and medical issues. The use of vaccines has been considered
both controversial and beneficial to humankind. Vaccines have been touted as the eradicator of
some of the deadliest diseases humans have ever encountered; they have also been accused of
causing autism and poisoning our children with mercury, or as Marla Morris (2008) has stated,
“Both poison and cure” (p. 28).
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Jacob Heller (2008) has opined, “Aside from AIDS, most people have little or no firsthand contact with deadly epidemic disease” (p. 9); and today, there is a new vaccine at the
forefront of use and contributing to the continued immunization dispute. This vaccine is the first
of its kind because it is FDA approved to be administered to adolescent girls in hopes of
preventing cervical cancer caused by the sexually transmitted human papillomavirus (HPV). In
this bioethical feminist inquiry, I have explored the political, social, and ethical controversy that
surrounds the government’s attempt to mandate the HPV vaccine for adolescent girls.
Context of Study
I can remember a few years ago sitting one warm summer evening watching the national
news. The end story was about a new vaccine for women produced by Merck & Co.
Pharmaceutics. The vaccine was called Gardasil. The newscast described Gardasil as a vaccine
that could provide immunity to certain types of cervical cancer and genital warts. The newscaster
touted Gardasil as a medical breakthrough in women’s health research, but it was not without
controversy. At the time, I thought to myself, “How could this vaccine be controversial? This
was the first cancer-preventing vaccine ever discovered, and better yet, it was produced just for
women.” The controversy swirled around the fact that the government wanted to mandate the
vaccine for adolescent girls. Parents were expressing discontent because this vaccine prevented
cancer caused by HPV, a sexually transmitted disease (STD). From the time I heard this
discordant story, I found my new passion, my course of study, or as Reynolds and Webber
(2004) called it, my “line of flight” (p. 2). I decided that I wanted to research this vaccine and
find out why it was being publicized as the new controversial immunization.
After doing the preliminary research, when presented with the information about the
incidence of HPV and the efficacy of the HPV vaccine, I find it is hard not to argue that this
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immunization is one of the best public health accomplishments for women in 50 years
(Houppert, 2007). Jonathan Temte (2007), a professor at the University of Wisconsin School of
Medicine and Public Health, has stated, “A medical intervention that is a true preventative tool
and a good reason for anticipatory guidance and education does not come along often; the new
HPV vaccine is both” (¶1). Unfortunately, the country is trapped in the controversy of
mandating this vaccine instead of determining the best ways of making it affordable and
accessible – both to U.S. girls and to those in developing countries who may never get the
regular Pap smear exams they desperately need for early detection of cervical cancer.
The Political Context of the HPV Vaccine
The HPV vaccine debate highlights the balance between the government’s obligation to
safeguard the health of its people and the rights of individuals to make their own decisions about
matters affecting their health and their children’s health. All vaccine mandates pose this
dilemma, but the question of an HPV vaccine presents more medical and ethical wrinkles. Unlike
other contagious diseases, HPV cannot be spread by casual contact like a sneeze or cough. It is
transmitted through close sexual contact. So mandating the HPV vaccine lacks the rationale that
one student can be infected with HPV by sitting next to another student in the classroom. Under
U.S. law, only the individual governing states, not the federal government, have the authority to
mandate vaccinations, so the battle over HPV is being waged state by state. Currently, about 20
states and Washington, D.C. have proposed legislation that would require vaccinating all
adolescent girls with the HPV vaccine (Savage, 2007).
The vaccine was developed and marketed by the well-known drug company Merck &
Co., Inc. of Whitehouse Station, NJ. In June 2006, the Food and Drug Administration (FDA)
approved Merck’s new vaccine called Gardasil. Karen Houppert (2007) has stated that this
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particular “vaccine protects girls and women from cervical cancer and genital warts caused by
the human papillomavirus (HPV)” (p. 17). How can preventing cancer be controversial? Why are
chicken pox or polio vaccines not making the nightly news or headlines in the local papers? It all
starts with the fact that the vaccine is the first of its kind produced to prevent cancer caused by an
STD. There are several U.S. politicians who want to make the HPV vaccine a compulsory
immunization. Because an STD causes this disease, there is a debate, according to Houppert
(2007), “by compassionate conservatives and abstinence-only hardliners who object to
mandating the vaccine since the disease was the result of a lifestyle decision” (p.17). On the
other hand, according to the Center for Disease Control (CDC), “Gardasil has proven 100%
effective in preventing the four strains of HPV that are responsible for most cases of cervical
cancer” (Manning, 2007, p. 11). So why not mandate it for adolescent girls?
The American College of Pediatricians opposes requiring the vaccination for school
attendance saying that such a mandate would represent “a serious, precedent setting action that
trespasses on the rights of parents to make medical decision for their children as well as on the
rights of the children to attend school” (O’Beirne, 2007, p. 20). One could apply this statement to
all vaccines. The difference is that HPV is not transmitted by a cough or sneeze like polio,
rubella, or the measles.
Currently, the Centers for Disease Control and Prevention (CDC) recommend that the
HPV vaccine be administered to girls between the ages of 11 and 12. To be most effective in
preventing HPV infection, the HPV vaccine would need to be administered before the onset of
sexual activity. According to physician Shobha Krishnan (2008), “…nearly 50% of girls and
boys are sexually active before graduating from high school” (p. 5). So it would be imperative to
administer the vaccine to a girl before she reaches high school.
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Currently, in today’s political climate, if the government makes the HPV vaccine a
mandatory immunization for all adolescent girls, there will be a backlash from parents,
bioethicists, and civil rights advocates. A prime example of such a backlash occurred when
Texas governor, Rick Perry, issued an executive order in February of 2007 that required all
adolescent girls be vaccinated against HPV. The Texas House and Senate unanimously
overturned the order in April of 2007 due to the hostile response of fellow politicians, civil rights
groups, and Texas parents.
While many laws infringe on a person’s rights, under the Constitution most states allow
exemptions to the mandated vaccines. For example, 48 states allow exemptions for religious
beliefs (Mississippi and West Virginia do not), 17 exempt for philosophical beliefs, and all states
allow medical exemptions (Kohrs, 2002). Those claiming religious exemptions base their
arguments on the right to free exercise of religion encompassed in the First Amendment of the
U.S. Constitution. However, the U.S. Supreme Court has not recognized the First Amendment
exemption to mandatory vaccination programs for infectious diseases (Kohrs, 2002). The U.S.
Supreme Court states, “We have never held that an individual’s religious beliefs excuse him
from compliance with an otherwise valid law prohibiting conduct that the State is free to
regulate” (Kohrs, 2002, p. 241). Philosophical exemption is based on an individual’s objection to
vaccines for personal, philosophical, moral, or other beliefs. The medical exemption requires a
written declaration by a licensed physician stating the vaccination is dangerous to the
individual’s health. The final verdict for these three types of exemptions is left in the hands of
the courts. Throughout history, the courts have, in matters of health, consistently put the common
good before individual rights (Kohrs, 2002).
There is no question the compulsory vaccination policy is a violation of a person’s right
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to autonomy and privacy as stated by the Fourteenth Amendment of the U.S. Constitution, but
we can thank vaccination policy for the complete eradication of smallpox, with polio not too far
behind. It has also significantly reduced the incidence of several of the most devastating
communicable diseases because of herd immunity. The HPV vaccine has the potential of
offering herd immunity to men and women (Biedrzycki, 2007). Herd immunity describes a type
of immunity that occurs when the vaccination of a portion of the population (or herd) provides
protection to unvaccinated individuals. In diseases that can be passed from person to person, it is
more difficult to pass that disease easily when there are those who are immune to it. Heller
(2008) has asserted specifically on HPV:
The vaccination law applies to each individual in order to protect the larger community.
The idea of herd immunity implies that any student who refuses to be vaccinated, then,
risks more than her own health – she puts at risk the larger community’s ability to protect
itself from an epidemic. (p. 11)
The more immune individuals there are, the less likely it is that a susceptible person will come
into contact with someone who has the disease. We, as Americans, must realize in the matter of
health and well being that the good of the many sometimes outweighs the interest of a few.
The Social Context of the HPV Vaccine
Mandating the HPV vaccine has been criticized not only by parents but also by family
organizations, like Focus on the Family, abstinence-only hardliners, evangelical groups, and
right-wing conservatives (Houppert, 2007; see also Daley & McDermott, 2007; O’Beirne, 2007).
They are touting the familiar argument: Safe sex leads to more sex. Conservative California State
Senator George Runner told the Los Angeles Times recently that he objected to the immunization
because the disease was a result of lifestyle decisions, as opposed to a contagion (Houppert,
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2007). Senator Runner went on to state, “Is there a more productive way for us to spend the
money that may help someone who’s in a health situation that has nothing to do with their
personal choices? Where do you want to focus your resources?” (Houppert, 2007, p. 17). Senator
Runner has avoided extending this same argument to other lifestyle decisions, such as smoking
or drinking alcohol.
Is giving a vaccine for a sexually transmitted disease tantamount to promoting sexual
activity? This belief is not based on hard data and in fact has been disproved in studies
examining contraceptive use and sexual activity. Douglas Kirby (2002) has stated, “There have
been only four published studies of school condom-availability programs. All four of these
studies found that making condoms available in schools did not significantly increase the rates of
sexual activity in children” (p. 27). Still, abstinence programs such as True Love Waits and
Brave Heart, primarily aimed at Christians, have produced limited but measurable results in
lowering sexually transmitted infections rates, delaying sexual activity, reducing the number of
sexual partners, and helping teens abstain until marriage. Religious faith does not guarantee
protection from HPV. The sexual behavior of Christian teenagers is not all that different from
that of their non-Christian peers (Christianity Today, 2007). According to researcher Mark
Regnerus (2007) in his new book, Forbidden Fruit: Sex and Religion in the Lives of American
Teenagers, “Evangelical teenagers don’t display just average sexual activity patterns, but rather
above-average ones” (p. 119).
STDs have always served as a valuable tool for the abstinence lobby. HPV is especially
handy because it can be contracted even when condoms are used. Of course, from a scientific
perspective, there is no way to prove that inoculating girls against an STD will encourage
promiscuity. However, Kelly Capes, an Oakland California mother, believes that having her
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daughter immunized for HPV is sending the wrong message. Capes has stated, “I do not want my
daughter to think I am condoning sex because I am immunizing her against a sexually
transmitted disease” (Udesky, 2007, p. 979). Maurice Markman, the vice president for clinical
research at the M.D. Anderson Cancer Center, has stated, “This is not about sex. This is about
preventing cancer” (Atkinson, 2007, p. 56). Using the argument, “it will promote sex” is not a
valid reason to deny immunizing adolescent girls. What if Merck had developed a vaccine that
prevented lung cancer? Would the same people oppose it, claiming that it would encourage
smoking? I go into further detail in regards to this argument in chapter 6.
The public must first be educated about the virus, the ways to prevent it, and the
treatment options before the government starts playing big brother and mandating vaccines
against sexually transmitted diseases. If parents are educated about the vaccine and its role in
preventing cervical cancer, it is very likely of their own volition that they will choose to have
their daughters immunized.
The Ethical Context of the HPV Vaccine
Mandating the HPV vaccine also raises ethical issues. Under current proposals, mandates
would force people to undergo drug therapy (vaccination) when they have no disease, under the
presumption that they might get a disease based on future behavior. One might argue that we do
have, as public policy, mandatory vaccinations for some infectious diseases like mumps,
measles, and rubella (MMR). The difference is that MMR are contagious diseases that can be
caught by sitting next to an infected person in a classroom. HPV is not spread by casual contact.
Bioethical feminists have brought up another ethical issue at the forefront of the debate.
Currently, the vaccine is gender-specific, recommended for girls only. The American Academy
of Pediatrics does not support a school-linked mandate because “there are people who are
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concerned about gender discrimination because it’s a policy that would keep girls out of school
and not boys, because it’s a vaccine for girls” (Udesky, 2007, p. 980). Renee Jenkins, presidentelect of The American Academy of Pediatrics, has stated, “Holding off on the mandate will give
time for educating the public about the vaccine’s benefits so parents do not feel like it is being
shoved down their throats” (Udesky, 2007, p.980). Mothers and bioethical feminists look at the
move to mandate the vaccine for girls but not boys as yet another example that women, not men,
are made responsible for reproductive health (Houppert, 2007).
In the twentieth century, Oliver Sacks deemed L-DOPA, used on patients with
Encephalitis lethargica, a “sort of medicine, of a wholly different kind: something deeper, older,
extraordinary, almost sacred, which will restore to us our lost health and wholeness, and give us
a sense of perfect well-being” (1973, p. 29). The HPV vaccine could be deemed the twenty-first
century’s extraordinary drug. Daley and McDermott assert, “One might assume that a welldocumented, safe, and effective vaccine against the second leading cause of cancer death in
women worldwide not only would be hailed as one of the greatest public health achievements,
but also would be distributed with lightening speed” (2007, p. 178). Unfortunately, such
accolade and action are not occurring. Some caution is necessary in any new achievement that
affects public health however, this immunization program is linked to a sexually transmitted
pathogen. With this being said, two questions come to mind. First, if this vaccine were approved
for a virus that was non-genital, or not associated with sexual behavior, would we see delay in its
deployment? Second, if this vaccine combated a virus that caused precancerous and cancerous
conditions in boys and men only, would we be confronted with the same level of controversy and
caution about its deployment? There is something fundamentally uncomfortable to Americans
who might have to consider that adolescent girls will become sexually active and acquire a
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sexually transmitted disease, which evokes emotion, discomfort and criticism (Daley &
McDermott, 2007). Some women will die from this disease, and at least 70% of those deaths
could be prevented through the administration of procedures similar to those that have eradicated
smallpox and minimized the public health threat of polio and numerous other viral diseases. We
must separate politics from science and begin an open dialogue on the best course of action for
our children.
The Science Behind HPV, Cervical Cancer, and Vaccines
I would be remiss if I did not provide an overview of HPV, cervical cancer, and the
science behind vaccines. These three subjects are discussed extensively throughout this paper,
and an explanation of each of them is provided in this section of the inquiry.
What is the human papillomavirus (HPV)?
According to the Center for Disease Control, there are 45 million cases of undetected HPV in
the United States, and current data indicate that 60 to 80 percent of people will be infected by
HPV in their lifetime.
-Gregory Henderson, M.D. & Batya Yasgur
HPV is a species-specific and tissue-specific DNA virus that infects surface cells that
cover the skin, mouth, esophagus, upper airways, urethra, anus, vagina, and the cervix (Fiander
& Tristram, 2007; Henderson & Yasgur, 2002). Papilloma viruses have co-evolved with animal
hosts over millions of years. HPV is made up of a collection of about 130 evolved viruses, 30 of
which are passed via skin-to-skin sexual contact (Henderson & Yasgur, 2002). Of these 30, two
cause 70% of cervical cancers (an additional 11 viruses are responsible for the rest), and 2 others
cause 90% of genital warts (Atkinson, 2007). HPV is the most common sexually transmitted
disease in the United States and generates about six million new infections a year (Biedrzycki,
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2007). Henderson and Yasgur (2002) have stated, “Your chances of becoming infected or of
already being infected with HPV are one in two” (p. 1). It has been estimated that 20 million
Americans (both men and women) carry active infections at any given time. It is estimated that
75% of women will have some form of the virus during their lifetime (cited in Atkinson, 2007).
Weinstock, Berman, and Cates (2000) state, “The young are especially at risk as nearly 75% of
HPV infections occur in 15- to 24- year-old persons” (p. 6). Physician Jonathan Temte has
stated, “Consequently, HPV infection is the most common sexually transmitted disease in
American youth” (2007, p. 117).
HPV types 1 and 2 are responsible for producing benign skin warts, or papillomas, on the
hands and feet. Warts are transmitted through casual skin-to-skin contact. A group of about 30
HPVs are transmitted through sexual contact and infect the anogenital region. There are no
treatments to cure HPV infections, but for most women, the body’s defense system will clear the
virus (Krishnan, 2008). Most HPV types that infect the genitals do not produce any noticeable
symptoms (Krishnan, 2008).
Henderson and Yasgur (2002) have asserted, “A painfully unjust reality of HPV infection
is that the majority of actual disease resulting from infection occurs in women” (p. 2). HPV types
6 and 11 cause genital warts and are considered “low-risk” for cervical cancer development.
There are about 13 types that are classified as “high-risk” sexually transmitted HPVs, which
include types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 (Fiander & Tristram, 2007).
Cutts et al. stated, “Cervical cancer is estimated to affect approximately 500,000 women each
year, of whom 80% live in developing countries” (2007, p. 719). Worldwide, 99.7% of cervical
cancers are caused by high-risk HPV, and types 16 and 18 are responsible for 70% of all cervical
cancers in women (Fiander & Tristram, 2007). These high-risk types not only lead to cervical
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cancer, but also anal, vulvar, and penile cancer. Type 16 has been associated with oropharyngeal
carcinoma, a form of head and neck cancer. Infectious diseases cause approximately one out of
five human cancers (Ault, 2006). Cervical cancer is the second most common cancer in women,
second only to breast cancer (Nicoletti & Tonelli, 2006). According to the National Cancer
Institute (2007), 1 in 142 women will be diagnosed with cervical cancer during their lifetime.
Krishnan (2008) has asserted:
The virus invades the human body with great ease and then exerts a strong and permanent
hold, bringing with it varying degrees of medical, emotional, and sexual upheaval. Its
three-way threat – a silent infection, an incurable infection, and an infection that can
cause cancer – can lead to tremendous emotional turmoil in many men and women. (p.
75)
With this being said, there is a tremendous disconnect between public awareness of the disease
and the prevalence of HPV infection. This confirms the notion that the general propensity of our
society is to avoid dialogue and education on any topic that can be considered taboo or personal
by the political and religious institutions.
What is Cervical Cancer and How is it Detected?
Without him [Dr. Harald zur Hausen] there would have been no vaccine.
-Stephen Pincock
The 2008 Nobel Prize for medicine was awarded to a German scientist who discovered
that HPV causes cervical cancer (Pincock, 2008). The scientist responsible for the discovery is a
German native named Harald zur Hausen. Physician Diane Harper from the Dartmouth Medical
School in New Hampshire has stated, “His [Hausen] methods were thorough, detail oriented,
following scientific rigor through every subsequent question he postulated and answered about
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the biological relationship between HPV and cervical cancer” (Pincock, 2008, p. 1375). From
Dr. zur Hausen’s work, it became medically accepted that HPV was the causative agent of
cervical cancer.
After breast cancer, cervical cancer is the most common cancer found in women
(Hughes, 2009). The cervix is located at the base of the uterus. It has two functions: (a) to keep
bacteria and viruses out of the uterus; and (b) to keep fetuses securely in the uterus until they are
ready to be born (Henderson & Yasgur, 2008). Cervical cancer is caused when cells of the cervix
are attacked by certain strains of HPV. The cells of the cervix begin to grow and divide
uncontrollably. Normal cervical cells are pushed aside by these rapidly dividing cells, which
start to pile up on each other (Henderson & Yasgur, 2008). If this uncontrollable cell division
goes unchecked, then the cancerous cells can penetrate the bloodstream and lymphatic system
causing the cancer to proliferate throughout the body. A sexually active woman’s best defense
against cervical cancer caused by all “high-risk” or virulent strains of HPV is an annual
gynecological exam called the Pap smear (Krishnan, 2008).
The Pap smear or Papanicolaou test is a medical screening method that has been used
since the 1940s to detect cervical cancer and other uterine abnormalities. Katz and Wright (2006)
state, “The Pap smear had transformed cervical cancer from a leading killer to a rare disease in
the United States” (p. 1110). Physician George Papanicolaou, a Greek cytologist, whose
specialty was early cancer screening and detection, developed the Pap smear. While this
technology is widely available and has reduced cervical cancer incidence in industrialized
nations, it is not readily available in third world nations in which cervical cancer incidence and
mortality is high (Brinkman, Caffrey, Muderspach, Roman, & Kast, 2005). In many developing
countries it is the leading cause of cancer death among women (Siddiqui & Perry, 2006).
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The development of HPV-induced cervical cancer is a slow process that can take many
years to develop. During the developmental phase, dysplasia (precancerous cells) of the cervix
can be detected. During a Pap smear a sample of exfoliated cells is taken from the opening of the
cervix (Brinkman et al., 2005). Once the cells are collected, a pathologist stains and examines
them for the presence of koilocytosis (Brinkman et al., 2005). Koilocytic cells have a distinctive
abnormality in their appearance in which some of the nuclei in the cells are surrounded by tiny
"halos" (Military Gynecology and Obstetrics, 2005). Most commonly, these changes occur in the
presence of HPV, but occasionally are associated with more serious problems such as cervical
dysplasia or even early cellular malignancy. The Pap smear is 85-95% effective in detecting
koilocytic cells (Brinkman et al., 2005).
The American College of Obstetricians and Gynecologists, the American Cancer Society,
and the U.S. Preventive Services Task Force recommend that women should get their first Pap
smear no later than 3 years after their first sexual encounter and no later than 21 years of age
(U.S. Department of Health and Human Services, 2006). Women should have an annual Pap
smear until the age of 30 (U.S. Department of Health and Human Services, 2006). After 30,
women should discuss with their doctors how often a Pap smear should be done.
Cervical screening has reduced the incidence of cervical cancer deaths by 70% over the
last 50 years. In the U.S., approximately 60 million women receive a Pap smear each year,
which results in the diagnosis of 1.25 million women with pre-cancers (Siddiqui & Perry, 2006).
However, Nicoletti and Tonelli (2006) have stated, “On average, there are about 9,710 new cases
of cervical cancer in the United States each year and 3,700 deaths are attributed to it” (p. 423).
The lethality of cervical cancer is even greater worldwide, causing over 470,000 new cases each
year and 233,000 deaths (Nicoletti & Tonelli, 205). The discrepancy is largely due to the
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decreased availability of affordable screening and treatment in many countries. According to
Franco and Harper (2005), Eastern and Southern Africa have the highest incidence and mortality
of HPV in the world.
Few countries have the resources and infrastructure necessary to run organized screening
programs, so the poorest regions of the world bear the brunt of the disease. Most women in lowincome countries do not have access to routine screening: only 5% have undergone a Pap smear
in the past 5 years (Katz & Wright, 2006). In parts of Latin America and the Caribbean, more
women die from cervical cancer than from complications of childbirth (Population Reference
Bureau, 2006).
The Container for the Thing Contained – The Definition of a Vaccine
So, what defense do women have against an HPV infection? The first line of defense is
the woman’s own immune system. In humans, lymphocytes, or white blood cells, wage war on
pathogens like viruses. The immune system is a complicated network of cells that work together
to fight foreign invaders and can provide continual immunity from future attacks. This second
line of defense is acquired immunity from certain viral infections that come in the form of a
vaccine.
Arthur Allen (2007) has defined a vaccine as, “A substance that introduces a whole or
partial version of a pathogenic microorganism into the body in order to train the immune system
to defend itself when the organism threatens to cause an infection through natural means” (p.
14). A vaccine works by stimulating the immune system to create antibodies and immune cells
that recognize the pathogen and are thus prepared to battle it when it presents itself at the portals
of the body. In this sense, those that receive vaccinations contribute to our posthuman future.
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Vaccines enhance normal immunological function by modifying the reactivity time of the
immune system when it comes into contact with a foreign entity. From a scientific perspective,
vaccination has evolved from a purely experimental procedure into a biotechnology that benefits
from our growing ability to understand and manipulate microorganisms and our immune
systems. Nicholas Agar (2007) has asserted, “The universal value of preventing and curing
disease is not inconsistent with valuing humanity. There is nothing spookily posthuman about
someone reaching old age without succumbing to [cervical] cancer” (p. 16). Katherine Hayles
(1999) has stated, “The posthuman view thinks of the body as the original prosthesis we all learn
to manipulate, so that extending or replacing the body with other prostheses becomes a
continuation of a process that began before we were born” (p. 3). Vaccines can be seen as
immunological prostheses that allow us to endure in a world filled with life threatening
pathogens.
The use of vaccines has saved millions of lives and even eradicated certain diseases like
smallpox and polio. Nevertheless, vaccines have been the center of controversy ever since
Edward Jenner, the scientist who discovered the smallpox vaccine, scraped pus from the sore of
a dairymaid infected with cowpox into an incision on a healthy boy’s arm. This event marked
the birth of the smallpox vaccine, and the beginning of vaccinology.
The Development of the HPV Vaccine
The FDA approved the HPV vaccine, Gardasil, on June 8, 2006. Currently Gardasil is
the only FDA approved HPV vaccine available. A second HPV vaccine, Cervarix, produced by
GlaxoKlineSmith, is in Phase III clinical trials and has not been approved by the FDA for
distribution in the United States. Gardasil is the first vaccine approved to target the HPV types
(6, 11, 16, and 18) that are associated with the development of 70% of the cases of cervical
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cancer and 90% of the cases of genital warts (Krishnan, 2008). Medical and public health
professional associations have endorsed the vaccine, including the American College of
Obstetrics and Gynecology, the American Academy of Pediatrics, the Society for Adolescent
Medicine, and the American Cancer Society (Daley & McDermott, 2007). Nearly 2 decades ago,
researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and
other institutions began searching for the underlying causes of cervical cancer. The vaccine is
based on the work of physician Douglas Lowry and his colleague John Schiller. Lowry is the
laboratory chief of the National Cancer Institute Laboratory of Cellular Oncology. About 20
years ago, Lowry began working with Schiller on a vaccine for HPV. Lowry said the idea came
to him after attending a lecture on hepatitis B virus vaccine. Lowry’s goal was to produce HPV
particles that could elicit a strong neutralizing antibody response, a method that had worked
previously in the development of hepatitis B vaccines. “Most preventative vaccines depend on
serum neutralizing antibodies,” Lowry has stated (cited in Traynor, 2007, p. 452). A serum
neutralizing antibody is a form of antibody that reacts with an infectious agent (usually a virus)
and destroys or inhibits its infectivity and virulence; it may be demonstrated by means of mixing
serum (protein-rich liquid that separates out when blood coagulates) with the suspension of
infectious agent, and then injecting the mixture into animals or cell cultures that are susceptible
to the agent in question.
Genetic engineering, technology involving the manipulation of genetic material, was used
to create this vaccine. A postdoctoral fellow in Lowry’s laboratory discovered that the L1
structural protein of bovine papillomavirus, an HPV cousin, could be produced in insect cells and
would interact with another structural protein to “self-assemble” into human papillomavirus-like
particles minus the pathogenic agent. The L1 protein induced high levels of neutralizing
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antibodies in an animal model system, a critical step in potential vaccine development. Lowry
has stated, "These hollow spheres, formed by a single protein from the virus (L1 protein), trigger
an antibody response that is capable of protecting the body against infection by the targeted virus
types" (National Cancer Institute, 2006, ¶3).
Because the National Institutes of Health (NIH) perform basic research but do not
develop finished drug products, Lowry said his group “tried to engage different pharmaceutical
companies to work with us” to produce a marketable vaccine” (cited in Traynor, 2007, p. 452).
Merck and MedImmune were the first takers, and the companies conducted their own
experiments to prove the technology worked. NIH eventually licensed the technology to those
companies, and GlaxoSmithKline later became involved through a sublicense from MedImmune.
“Future improvements, such as expanding the number of HPV strains in the vaccine, can make
the next-generation product even better,” Lowry has stated, adding that he expects Merck and
GlaxoSmithKline to take this approach (cited in Traynor, 2007, p. 452).
Lowry has asserted, “Although critical early HPV vaccine research was conducted at
NIH, the story of the efficacy of the vaccine really is the story of the pharmaceutical companies
and not the story of the NIH” (cited in Traynor, 2007, p. 452). This statement is an example of
biocapital at work. Kaushik Rajan (2006) has stated that biocapital is:
… concerned with tracking and theorizing the co-production of an emergent
technoscientific regime – that of biotechnology in the context of drug development – with
an emergent political economic regime that sees the increased prevalence of such
research in corporate locales, with corporate agendas and practices. (p.78)
The U.S government spends an enormous amount of money on biomedical research which is
funded through the NIH (site of Lowry’s laboratory) “consequent to the declaration of a war on
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cancer in the early 1970” (Rajan, 2006, p. 6). The government’s research was then used by
Merck to develop and patent the blockbuster vaccine. The use of the government’s research to
produce a drug for commercial sale is allowed through the 1980 Bayh-Dole Act. Rajan (2006)
states, “…The 1980 Bayh-Dole Act, [is] legislation that facilitates the transfer of technology
between academe and industry and thereby enable[s] rapid commercialization of basic research
problems” (p. 6). The NIH performed the preliminary research and because they do not have the
ability to produce finished drug products they licensed the technology to Merck. Merck is
making billions of dollars based on the original research produced by a federal government
laboratory, specifically the NIH. Currently, Merck is charging the government roughly $360 per
vaccination (most other recommended vaccines cost less than $50) given to girls on Medicaid
and the Vaccines for Children program. Marcia Angell has called this a “real scandal” (2005, p.
56). Merck is banking billions of dollars on publicly funded research. It seems to me that Merck
is “double-dipping” – in terms of not only benefiting from government research to make a very
expensive drug; it is profiting from the government every time a child on Medicaid and the
Vaccines for Children Program is vaccinated.
Gardasil was evaluated and approved in 6 months under the FDA’s priority review
process – a process for products with potential to provide significant health benefits. The priority
review process must have made Merck very happy, because according to Marcia Angell (2005),
“Clinical trials usually take a few years, and during that time the drug cannot be sold. That
means clinical testing eats into a drug’s twenty year patent life—the time it can be sold without
competition” (p. 28).
Gardasil is given as three intramuscular injections over a 6-month period, costing $120
per injection. According to Dr. Neil Goodman, a pediatrician who offers the vaccine, “the actual
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cost of a single injection is closer to $175 when you factor in the excise tax, storage and
handling, and the office costs of administering the vaccine” (personal communication, July 3,
2007). Gardasil is currently the most expensive pediatric vaccine (Snow, 2007). The vaccine
has been approved for females ages 9 to 26, and currently the CDC recommends that all 11-or
12- year old girls be immunized. The vaccine works best if given before the female is sexually
active.
Women are not protected if they have been infected with the HPV types prior to vaccination.
Gardasil was evaluated and approved in 6 months under the FDA’s priority review
process – a process for products with potential to provide significant health benefits. The priority
review process gives Merck an advantage, because according to Marcia Angell (2005), “Clinical
trials usually take a few years, and during that time the drug cannot be sold. This means clinical
testing eats into a drug’s twenty year patent life—the time it can be sold without competition” (p.
28). For the last 3 years, Merck has had a monopoly on the HPV vaccines approved in the U.S.
On September 9, 2009 an advisory panel of the FDA voted that research data from
GlaxoSmithKline pharmaceuticals’ version of the HPV vaccine, Cervarix®, demonstrated safety
and efficacy. Cervarix® is currently marketed in 100 countries and is waiting for final approval
by the FDA to market it in the U.S.
Four studies, one in the United States and three multinational, were conducted on 25,000
women ages 16-26 by giving them either the vaccine or an inactive injection (placebo). In
women who had not already been infected with HPV, Gardasil was nearly 100% effective in
preventing pre-cancerous cervical lesions, pre-cancerous vaginal and vulvar lesions, and genital
warts caused by infection with the HPV types against which the vaccine is directed (Siddigui &
Perry, 2006). The women were followed for 2 years, and while the study period was not long
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enough for cervical cancer to develop, the prevention of these cervical pre-cancerous lesions is
believed to result in the prevention of those cancers. Currently, it is believed that the vaccine has
efficacy for 5 years, after that a booster shot may be required (Siddiqui & Perry, 2006).
Gardasil works by inducing a strong humoral immune response, which involves the
body producing specific antibodies to fight disease. The vaccine consists of a mixture of four
types of DNA-free virus like particles derived from the capsid proteins of HPV types 6, 11, 16,
and 18 (Siddiqui & Perry, 2006). The capsid of a virus forms an envelope or shell around the
genetic material. In order for a virus to replicate, it must attach to a host cell, in this case a
cervical cell, and inject its genetic material (DNA) into the host cell. The genetic material of the
virus takes over the machinery of the host cell in order to carry out viral DNA replication and
production of multiple copies of the capsid protein subunits. The viral components, DNA and
capsid proteins, begin to assemble themselves into new viruses. Once the host cell becomes full
of newly assembled viral particles, it bursts open releasing hundreds or thousands of new viruses
that are ready to attack other host cells. The cervical cells die as a result. When a person is
immunized with Gardasil, the immune system recognizes the particles in the vaccine as foreign,
destroys them, and forms antibodies against HPV types 6, 11, 16, and 18 (see Figure 1). When an
immunized person comes into contact with HPV 6, 11, 16, and 18, the body’s immune system
recognizes the virus and destroys it before it can infect cervical cells.
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Figure 1. An illustration of the effects of immunization against HPV.
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Statement of the Problem
How can a medical breakthrough for women be controversial? How can a vaccine for a
type of cancer that kills more then 300,000 women worldwide be controversial? Both doctors
and patients want marvels in modern medicine to be unambiguous and uncomplicated.
Unfortunately, in a complex field such as medicine, the potential benefits or perils of new
discoveries are seldom seen in black and white. When a new drug is introduced into the market,
some welcome it with open arms while many are skeptical. Vaccines are no exception. Kurt Link
(2005) has stated, “Vaccination is more than 100 years old and has been controversial from the
start. Of all the benefits of medical science, vaccination is at or near the summit. It is also the
most controversial of routine medical procedures” (p. 38).
There are obstacles inherent in the science of vaccinology, but the field has special
societal obstacles: fear of the unknown, of mandates, of a highly litigious environment,
bureaucracy, self-serving politization, political turf wars, a very powerful pharmaceutical
industry, and irrational policy decisions. Every new vaccine brings new controversies – the HPV
vaccine is a prime example. The scientists manipulating the genes of pathogens are exploring
the essence of life, and we can only wonder what new wonders and new grief they will find. My
study uncovers the complex layers of political, social, and bioethical controversies surrounding
the HPV vaccine. My goal in undertaking this inquiry has been to analyze each of these layers in
order to help all those confronted with the HPV vaccine controversy make a well-informed
decision about the immunization and its effectiveness.
The Purpose of the Study
“You have to admire its simplicity. It's one billionth our size and it's beating us”
(Henderson, Kopelson, Katz, & Peterson, 1995). This quote came from the 1995 movie,
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Outbreak, about how fast a virus can mutate and spread throughout a human population. Viruses
are bits and pieces of protein and nucleic acid. Not fitting into any of the six taxonomic
kingdoms, biologists do not classify them with all other carbon-based organisms. However, they
are a part of our biosphere that has wreaked havoc since the “fall of man.” Viruses can be
defined as nonliving parasitic entities that use the cells of other organisms to reproduce. Viruses
invade and infect a host taking over cellular organelles for their own survival and procreation.
They are silent, they can be deadly, and they have the ability to mutate to survive in almost any
environment. Their evolution has produced over 5000 different strains, and viruses are
responsible for diseases like smallpox, chicken pox, influenza, acquired immune deficiency
syndrome (AIDS), ebola, rabies, yellow fever, polio, mumps, measles, rubella, common cold,
avian flu, herpes simplex I and II, severe acute respiratory syndrome (SARS), and some types of
cancer (Allen, A., 2007; Koplow, 2003).
This discussion of this miniscule anomaly is the focus of this study. To conduct it, I have
investigated the history, medical, and political/social controversy that surround the virus and its
vaccine. I specifically focused on the HPV vaccine called Gardasil. Gardasil is the first anticancer vaccine of any kind approved for human use (Daley & McDermott, 2007).
My intention for undertaking this inquiry was to educate women and adolescent girls on
one of the most widespread sexually transmitted diseases in the United States. I will take an in
depth look at HPV and its vaccine. I investigated the health curriculum in U.S. schools and found
a lack of proper education when it comes to sexually transmitted diseases. Having taught health
to high school students, I have firsthand experience with the lack of emphasis placed on
educating students about sexually transmitted diseases. Most of the emphasis is placed on drug
and alcohol abuse. Educating young adolescent girls about sexually transmitted diseases is
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paramount to preventing the spread of HPV. The Georgia health curriculum stresses abstinence
as the best prevention against sexually transmitted diseases. This is true, but as educators we
must be realistic. Not all adolescents are going to refrain from sex until they are married.
According to Shobha Krishnan, an obstetrician and gynecologist, “Thirteen percent of American
teens are sexually experienced by the time they are 15 years old, and 70 percent are sexually
experienced by 19 years of age” (2008, p. 151).
Research Questions
The primary research question examined in this theoretical inquiry was “Why is there a
contentious debate in the U.S. over mandating the first vaccine developed to prevent cancer?”
The secondary questions that were addressed are:
(1) What are the political ramifications of the U.S. government mandating the HPV
vaccine for adolescent girls?
(2) What are the social and the ethical controversies behind the drug company Merck’s
introduction of Gardasil for adolescent girls and not boys?
Autobiographical Roots of My Inquiry
From the small boy with a scraped knee to an elderly women fighting breast cancer,
everyone has a pathography. Bioethical feminist Rosemarie Tong (2000) has written, “Because
all human beings have bodies, minds, and spirits, all human beings are capable of feeling pain
and experiencing suffering” (p. 27). Everyone has a story about illness, disease, or injury. But
according to Virginia Woolf (1930), “…it becomes strange indeed that illness has not taken its
place with love and battle and jealousy among the prime themes of literature” (pp. 3-4). Why are
we hesitant to talk about our illnesses? Is it because we realize we are only human? Is it that we
realize that death is inevitable? Bernard Miall (1920) has acknowledged, “What makes for the
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fullness and perfection of life, for beauty and happiness, is good; what makes for death, disease,
imperfection, suffering, is bad” (p. 244). Society often regards the ill person as useless and
devoid of worth. Arthur Kleinman (1989) described illness as “the seemingly relentless march
toward becoming an invalid” (p. 35). Unfortunately, I have had some personal experience with
HPV and abnormal cervical changes. My autobiographical roots are embedded in a form of
inquiry called pathography – a story of illness.
There is often a stigma placed on the ill body. Marla Morris (2008) has stated, “In some
cases, the easiest way to approach the illness of another is to blame the victim. ‘It must be your
fault, you did it to yourself’” (p. 3). A person with Hepatitis C may be accused of being a drug
abuser, or a person who has heart disease may be blamed for having a poor diet. We often look
to blame the person for their illness, for it seems we must find fault somewhere. Why not the
person with the illness? They brought it upon themselves, right? They caused their illness. Susan
Sontag (1977) has asserted, “Patients who are instructed that they have, unwittingly, caused their
disease are also being made to feel that they have deserved it” (p. 57). No one “deserves” to be
ill. Unfortunately, illness is part of life and is something that binds us all as human beings. We
all get ill sometime in our lives. Sontag (1977) eloquently has expressed:
Illness is the night-side of life, a more onerous side of citizenship. Everyone who is born
owns dual citizenship, in the kingdom of the well and the kingdom of the sick. Although
we all prefer to use only the good passport, sooner or later each of us is obliged, at least
for a spell, to identify ourselves as citizens of that other place. (p. 3)
It is when we take the passport to the “other place” that pathography is born.
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When Ill Bodies Need Voices – The Definition of Pathography
-Stories are antibodies against illness and pain.
Anatole Broyard
This section focuses on the meaning of pathography as a piece of literature and a form of
narrative inquiry. Our personalities and our identities are intimately bound up with the stories
that we tell to organize and to make sense of our lives. To understand the human meaning of
illness, we therefore must turn to the stories we tell about illness, suffering, and medical care.
Anne Hunsaker Hawkins (1999a) has defined pathography as, “…a form of autobiography or
biography that describes personal experiences of illness, treatment, and sometimes death” (p. 1).
Pathographies characterize questions like “what is it like to be diabetic” or “what it means to
have cancer.” These stories of illness can provide the reader with direct insight into the realm of
pain and suffering.
Pathographies have many functions. They not only articulate fears, hopes, and anxieties
about illness, but they also serve as a roadmap to the medical experience as a whole. Anne
Hunsaker Hawkins (1999b) has noted, “Pathographies are a veritable goldmine of patient
attitudes and assumptions regarding all aspects of illness” (p. 127). Pathographies can also
provide an outlet of expression for the ill person. Anatole Broyard, an American literary critic,
wrote a pathography about his battle with prostate cancer. Broyard (1992) called his pathography
a type of “literary aspirin” (p. 18). He believed that a patient should not sink into depression, but
treat his or her illness as a narrative. He has stated, “Anything is better than an awful silent
suffering” (1992, p. 20).
Pathography is a type of narrative inquiry and is often called illness narrative. Michael
Connelly and D. Jean Clandinin (1991) often refer to narrative inquiry as a “storied experience”
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(p. 121). Narrative is a form of expression recognizable as a story of “discourses with a clear
sequential order that connect events in a meaningful way” (Elliott, 2005, p. 26). The telling of
stories is an integral part of human social communication – occurring in all types of textual,
verbal, nonverbal, and creative expressions – as a means to describe, reflect, share, perform or
entertain (Ricoeur, 1984). Storytelling in general, appears to be sparked by experiences of a
breach or disruption, however minor, in our usual patterns of life. Stories, therefore, gain a
particular relevance at times of life transition or change, seemingly as a way of sense making or
attempting to reshape and manage the shifting ground of our lives. In a pathography, the time of
transition or change comes in the form of an illness. Anatole Broyard (1992) has stated, “The
patient has to start by treating his illness not as a disaster, an occasion for depression or panic,
but as a narrative, a story” (p. 20).
An illness represents a major instance of “biological disruption” (Bury, 1982) where
balance between the body, mind, and everyday life are threatened. The study of illness narrative
is an exploration of this disrupted experience, as well as its meanings and the actions related to
dealing with it. Marla Morris (2008) has written, “Making the best of illness means writing about
it so that others might learn about what it means to be sick” (p. 5). Cheryl Mattingly noted that
the suffering of illness and facing death tends to demand a story. Mattingly (1998) has stated, “It
is the one liminal place within the human condition that calls for sense making and this often
takes narrative form” (p. 1).
Types of Pathography
According to Anne Hunsaker Hawkins, pathographies can be divided into four distinct
categories: Testimonial pathographies, angry pathographies, “pathographies advocating
alternative modes of treatment” (1999a, p. 4), and ecopathography. Testimonial pathographies,
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also called didactic pathographies, are narratives motivated by the explicit wish to help others.
Often they blend practical information with a personal account of the experience of illness and
treatment. Hawkins (1999a) states, “Pathographies written with an overtly didactic intent blend a
personal account of illness with practical information” (p. 4). For example, descriptions of breast
cancer experience have enabled women to become aware of therapeutic alternatives both within
and outside conventional medical practice. A prime example of this type of pathography is
Marilyn Snyder’s An Informed Decision, a book written for women with breast cancer who
might be helped by surgical reconstruction. Another example of this type of pathography is the
actress and comedian Gilda Radner’s book, It’s Always Something, on her battle with ovarian
cancer.
The second type is the angry pathography. Authors of this type are motivated by a strong
need, based on personal experience, to point out deficiencies in various aspects of patient care.
Hawkins (1999a) has opined:
Angry pathographies are intended to expose and denounce atrocities in the way illness is
treated in America today. These books testify to a medical system out of control,
dehumanized, and sometimes brutalizing; and they are written from a sense of outrage
over particular and concrete instances of what is perceived to be the failure of medicine
to care adequately for the ill. (p. 6)
Pathographies of this kind are important in alerting all of us to important problems in medical
practice. They vividly depict how an ill person today can be at the same time the beneficiary and
the victim of a healthcare system whose very excellence – its superb technological and
pharmacological achievements – is at the same time potentially dehumanizing.
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The third type of pathography is called the “alternatives pathography.” This type of
illness narrative is also critical of our medical system, but without angry criticism and doctor
bashing. These pathographies stem from dissatisfaction with medicine. They differ in that the
author is concerned not so much with criticizing traditional medicine as with finding alternative
modes of treatment. One can find a pathography about every conceivable kind of alternative to
traditional medicine (Hawkins, 1999a). This group of pathographies can be invaluable in alerting
doctors to the appeal of alternative medicine and to the specific treatments that attract patients
with particular illnesses.
The fourth type is called ecopathography. This type links personal experience of illness
with larger environmental, political, or cultural problems. Illness is perceived as the product of a
toxic environment. This type of pathography is used to warn us that a person’s illness is a sign
and symptom of much larger problems confronting our culture as a whole. An example of this
type of pathography is Terry Tempest Williams’ narrative Refuge: An Unnatural History of
Family and Place. In Williams’ book, she discussed the death of her mother from cancer at the age
of 44. Williams revealed her concern with the implication of environmental pollution in the
various cancers in the last several generations of women in her family. She revealed that she grew
up in an area that practiced above ground nuclear testing.
The common denominator of all pathographies, whatever the perceived motives of their
authors, is that the act of writing in some way seems to facilitate recovery and the healing of the
whole person. Serious illness is a painful, disorientating, and isolating experience. It is a trauma,
an insult not only to the body, but also to the self. Arthur Frank (1991) has stated, “What
happens to my body happens to my life” (p. 13). Writing about an illness experience is a kind of
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psychic rebuilding that involves finding patterns, imposing order, and discovering meaning
(Lifton, 1967). Pathography is not only a description of how awful it is to be seriously ill, but
also a testimony to the capacity to transform that experience in ways that heal. Audre Lorde
reiterated this sentiment in her book called The Cancer Journals. Her motivation for writing her
pathography is to teach women what she knows about life through her experience with breast
cancer. Lorde (1997) wrote, “…it is necessary to teach by living and speaking those truths which
we believe and know beyond understanding. Because in this way alone we can survive, by taking
part in a process of life that is creative and continuing, that is growth” (p. 21).
The Historical Roots and Traditions of Pathography (Illness Narrative)
The historical advancement and sovereignty of science brought with it a culture that
valued a more rational and detached approach to the world. Science and technology also
introduced a sea of change in the role of medicine and healing, as well as the relationship of healer
and patient. Illness is a time of personal crisis that compels individuals to re-assess and rewrite
their private narrative, in an attempt to create a sense of continuity in the pre and post sickness
identity. Sander Gilman (1988) has stated, “For illness is a real loss of control that results in our
becoming the Other whom we have feared, whom we have projected onto the world” (p. 2). It is
in the state of being the Other that the illness narrative is written. Traditionally, the illness
narrative was a part of the healing process. Prior to the appearance of a more bio-technological
medical model, the importance of the patient’s story was the central feature around which the
healing intervention focused. This was especially true in the seventeenth and eighteenth centuries
before the discovery of antibiotics, when medical interventions primarily centered on procedures
such as bleeding and purging as a way to restore “one’s bodily humors and equilibrium”
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(Lawrence, 1994). As stated by Roy Porter (1997) in his historical overview of medicine, “In the
absence of decisive anatomical or physiological expertise, and without a powerful arsenal of cures
and surgical skills, the ability to diagnose and make prognoses was highly valued, and an intimate
physician-patient relationship was fostered” (pp. 9-10). This relationship was to become greatly
altered with the introduction of modern medicine and its reliance on science and the technological
advances of biochemistry. The healer’s focus shifted from the patient as a key figure in diagnosis
and understanding of disease, to patient as a supplier of biological material that would be
submitted to a laboratory for final analysis and evaluation. David Morris (2000) went as far to
say, “Doctors are authorities on disease, while patients remain the more or less unreliable
narrators of their own unruly illnesses” (p. 38).
The objective of health care evolved from bringing the body to the individual patient’s
healthy “natural state” to curing or repairing. Mike Bury (2001) has stated:
The task of the doctor, increasingly in the 19th and into the 20th century, was to translate
pieces of information into a definitive diagnosis that linked the disease to specific
biological causes and outcomes, rather than to the patient’s circumstances or lifestyle, let
alone to their beliefs or values. (p. 266)
This had political ramifications, impacting the practice of modern medicine and its growing
precedence in the healing arts. According to Christopher Lawrence (1994), “…by 1920 the idea
of disease as individual pathology had become the dominant paradigm and was extricably linked
to the development of a ‘bounded’ medical profession, that exerted almost complete jurisdiction
over illness and its treatment” (p. 27). The acceleration of this process in the 1940s and onward
only seemed to reinforce the tendency to render the patient passive (Bury, 2001). As illness was
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increasingly sequestrated from everyday life by professional medicine, so the patient’s suffering
was effectively silenced, especially under the impact of modern medicine and technological
advancement. Talcott Parsons (1951) further described this in his treatise of the “sick role,”
stating that the patient’s responsibility in illness becomes one of simple compliance as the
physician’s allegiance become connected to the scientific code of medicine rather than the
individual. Arthur Frank (1995), describing the modern experience of illness, stated:
…when the popular experience is overtaken by technical expertise, including complex
organizations of treatment. Folk no longer go to bed and die, cared for by family members
and neighbors who have a talent for healing. Folk now go to paid professionals to
reinterpret their pains as symptoms, using specialized language that is unfamiliar and
overwhelming. (p.5)
And it is the medical narrative, the one told by the physician, which prevails and takes
precedence over all other narratives. As Frank (1995) has asserted, “The story told by
physicians becomes the one against which others are ultimately judged true or false, useful or
not” (p. 5). Is it any wonder that the meaning that we create about our illness, and its impact on
our life, is often the essential but silent element in the patient-doctor interaction? Marla Morris
(2008) has contended, “The narratives that sick people tell – especially stories that women tell –
tend to be discounted by the medical community. It is thought that the sick are unreliable
narrators” (p. 6).
However, spanning a decade or more, various factors have come into play that create
pressure on this technological, bio-medical model of healthcare, shifting the pendulum back
towards a consideration of patient narrative. As stated by Bury (2001) and Kleinman (1989), the
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first of these is the growing impact of degenerative and chronic illness. As the population ages
and health care providers are increasingly focused on management and care, rather than treatment
and cure, the voice of the patient becomes discernable again. As Bury (1998) has described, “The
contingencies of everyday life reassert themselves and the heterogeneous character of the
intersection of the individual’s life worlds become the focus of lay and professional concerns” (p.
25).
Another factor is the expense of providing modern technological healthcare to the ill
population. Greater technological care requires more extensive explanation to both patient and
insurance provider, thus making way for patient and physician to engage in greater dialogue.
Also, as the cost of healthcare rises and coverage shrinks, and as modern medicine continues to
focus on cure, rather than therapeutic treatments, increasingly frustrated patients have to turn
back to the culture of traditional healing (i.e. alternative and complimentary medicine) as a way to
meet their needs. The interest in the other traditions of healing is connected with the expanding
growth of Eastern and other traditions of philosophy, spirituality, and healing in the Western
world. It is also happening at the same time as what Bury (2001) described as a “recent and
powerful democratic impulse leading to a reduction in hierarchical relationships in modern
cultures, including those in the medical field” (p. 268).
Technology has also been a factor in re-establishing the patient voice in the illness
narrative. The expansion of medical information about illness that is now commonly available to
the patient via media coverage and the Internet has resulted in a more equitable footing between
doctor and patient. With access to a plethora of information about the origin, course, outcome,
and treatment of illness, the doctor’s role as “fount of medical knowledge” and over-arching
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expert is weakened. This allows the patient to repossess his or her illness experience and to
connect his or her personal experience with many sources of medical narrative. This evolution
lays the groundwork for patients to progress from passive compliance to a more active
participatory stance, and to reestablish themselves as the primary author of their illness story.
Understanding the Illness Narrative – The Advantages of Pathographical Inquiry
Arthur Kleinman (1989) has suggested, “Illness problems are principal difficulties that
symptoms and disabilities create in our life” (p. 4). How we make sense of those symptoms on
an individual and social level is the beginning of the illness narrative. Our individual and family
biographies create an orientation and explanation towards illness in general. How is illness viewed
in our family? Are we allowed to take time to be ill, or do we continue to attempt our daily
responsibilities, ignoring symptoms until they interfere with our ability to live? In this way, each
person’s illness experience is unique. This uniqueness can form the foundation of a personal
narrative that transcends nonfiction literature and provides the reader with a real story of pain,
suffering, and survival. John Gunther wrote a pathography about his 17-year-old son, Johnny,
who died from a brain tumor. Gunther’s biography of his son’s illness is a testament to how
families cope with a diagnosis, a disease, and the ultimate death of a child. After reading his book,
I learned how vulnerable we are when a family member is ill. One line in Gunther’s book that
shows this vulnerability is when he describes the hospital where his son is being treated. Gunther
(1949) passionately stated, “That building! — it became the citadel of all our hopes and fears for
more than a year, the prison of all our dreams” (p. 28).
Illness has been described as an interruption of trajectory of one’s life. As part of our
conceptualization of self we carry an expectation of our life’s course. Illness interferes with this
49

expectation in a way that demands an explanation. The crisis of illness and suffering raises two
fundamental questions for the sick person and his or her family: “Why me?” and “What can be
done?” Arthur Kleinman explains these as the questions of bafflement and control. Kleinman
(1989) has declared:
Whereas virtually all healing perspectives across cultures, like religious and moral
perspectives, orient sick persons and their circle to the problem of bafflement, the narrow
biomedical model eschews this aspect of suffering much as it turns its back on illness (as
opposed to disease). (p. 29)
As Bury (2001) described it, the illness narrative is the means by which the connections between
the body, self, and society are defined. The illness narrative can provide connections for the ill
person by orienting him or her to a place of unity with other ill people. In this place of unity
they may share their stories of healing, treatments, cures, experience, and education about a
specific disease. For example, Saundra Murray Nettles wrote a pathography, Crazy Visitation, on
her experience with a noncancerous meningioma brain tumor. She chronicles her journey of
misdiagnoses by physicians, memory loss, seizures, and ultimately her recovery. Those with the
same diagnosis can find comfort in her words. They can enter a place of empathy, which may be
the only place an ill person can find support and solace. Nettles (2001) has stated:
I longed for a veteran voice as I sorted through the symptoms and aftermath of the tumor,
but firsthand accounts are rare. I offer my story to those who want a glimpse into the
vulnerability created by an unhealthy brain and the restoration of wholeness in the site of
secrets and dreams, memory and inhibition, and the origin and ending of all the senses. (p.
5)
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Arthur Frank reiterates Nettles’ feelings by comparing the illness narrative to a quest story.
Frank (1995) has stated, “Quest stories meet suffering head on; they accept illness and seek to
use it. What is quested for may never be wholly clear, but the quest is defined by the ill person’s
belief that something is to be gained through the experience” (p. 115). He goes on to say that the
ill person is afforded a voice through the quest narrative to tell his or her story. This voice might
have been silenced if not for the presence of the illness. A.F. Bingley (2008) has stated, “The
telling of one’s illness story proves to be an opportunity to find a politicized voice and raise
public awareness of issues” (p. 654).
Another advantage of the illness narrative is relational; patients tell stories to explain
themselves to others. Teller and listener enter the story space for each other, with the patient’s
story providing a guide or map that others can follow. The storyteller reclaims his or her
suffering, his or her world and relationships, with the creation of the story that can be entered
into by the listener. In this way, his or her isolation is reduced and sense of control heightened.
Marla Morris (2008) has asserted, “Sickness happens in a web of relations. We do not live in a
vacuum. My illness is connected to others’ illnesses. I see my condition, then, in relation to
others who also suffer” (p. 19). Frank (1995) understood this testimony as an act of “moral
action,” which created a sense of connection between the individual, the social order of his or her
life, and the universe, through the development of a narrative that allows patients to think of
themselves as more than just a body, therefore, “disclaiming the vulnerability that all bodies
share” (p. 18). Audre Lorde reveals this sentiment in her pathography called The Cancer
Journals. Her book is about her struggle with breast cancer and what it means to be a woman
with only one breast. Lorde helps women fighting breast cancer realize that the definition of a
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woman is not determined by the number of breasts she has, but what is found in her heart and
soul. Lorde (1997) asserted, “Women have been programmed to view our bodies in terms of how
they look and feel to others, rather than how they feel to ourselves, and how we wish to use
them” (p. 65-66).
An advantage of pathography for physicians is that it can provide a unique “window”
into the experience of their patients, often revealing aspects of patient experience that remain
unarticulated in the medical encounter. Pathography can be medically useful for a number of
reasons. First, they embody the patient’s point of view on a variety of aspects of a medical
experience. Anatole Broyard (1992) wrote his pathography, “When doctors shoved scopes up
my urethral canal, I found it helped a lot when they gave me a narrative of what they were doing.
Their talking humanized the procedure” (p. 20). Second, the pathography can describe common
issues in medical encounters that are often problematic, demonstrating both helpful and harmful
ways in which a physician can deliver bad news. Anatole Broyard (1992) has written, “Not
every patient can be saved, but his illness may be eased by the way the doctor responds to him
(p. 57). Pathographies can also illustrate the patient’s dilemma when confronted with conflicting
advice from different medical experts. Audre Lorde wrote about her dilemma with choosing a
course of treatment for her cancer. She grappled with what course of action to take to fight her
cancer. She contemplates whether to be treated with chemotherapy and radiation, trying
experimental therapies, or having a radical mastectomy. She wrote:
I think now what was most important was not what I chose to do so much as that I was
conscious of being able to choose, and having chosen, was empowered from having made a
decision, done a strike for myself, moved. (1997, p. 32)
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Finally, pathographies can provide information about alternative medical treatments from the
perspectives of the patients who use such treatments. Le Anne Schreiber wrote a pathography
called Midstream about her mother’s battle and death with pancreatic cancer. Schreiber provided
an account when her mother is treated for pain. Schreiber reveals that a medical team decides to
use a nerve block—an elaborate and dangerous procedure—to control her mother’s pain. The
block fails. Her mother was frustrated and desperate so she consulted a Chinese doctor skilled in
acupuncture who used a TENS (transcutaneous electrical nerve stimulator) machine. She
experienced immediate and dramatic positive results. Schreiber (1990) recalled that the most
troubling thing about the whole episode is that the anesthesiologist who performed the nerve
block knew about the TENS method for pain relief. The doctor considered it “very effective” and
yet never offered it as a therapeutic option (Schreiber, 1990, p. 158). Pathographies can be
helpful not only for the people who write them and the patients who read them, but also for
physicians who treat the ill.
The Disadvantages of Pathographical Inquiry
Pathography is a personal narrative about a personal event in one’s life. According to
Bury (1998):
Recent analysts have tended to treat patient narratives as if they represented a form of
unalloyed subjective truth, the authentic voice of the patient ‘underdog’ as opposed to
the voice of dominant medicine or that produced by a more quantitative survey data. (p.
28)
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Illness narratives take many forms, have many uses, and have layers of meaning. This creates a
challenging task for the researcher engaged in deconstructing subtle subjective meanings and
thematic connections. Thus, narrative analysis is always interpretative and somewhat subjective.
With the amount of medical information available to a patient, he or she must be careful
not to self diagnose. Each illness narrative is as unique as the person and disease it describes. The
diagnoses and treatments that work for one ill person might not work for another.
Another problem with the illness narrative is that the “distinction between fact and
fiction is muddled” (Connelly & Clandinin, 2000, p. 179). Lay people usually write illness
narratives. When discussing complicated medical issues a novice might not accurately describe the
procedure, medication, or any other aspect of their treatment.
Having described the intricacies of the illness narrative, I now relate it to my inquiry of
the HPV vaccine. Everyone has some kind of pathography. It took me months to figure out mine.
I had to think hard; I had to search my medical background, my medical biography. I’ve never
had a heart attack, a brain tumor, or been on the brink of death; but I do have a story. My
pathography is a story that many women share, one that is usually pushed under the carpet and
kept silent. I am here to break the silence. Of the four types of pathography, my illness narrative
is a testimonial pathography. I wanted to “project a positive attitude towards medicine,” and I
was “motivated by didactic or altruistic principles” (Hawkins, 1999a, p. 4).
My story is not only one of illness, but a forum to share with girls, mothers, daughters,
partners, whomever will listen about a vaccine that could have prevented my illness if I were
afforded the option 20 years ago. Many women will be able to relate to my story; it is not an
exclusive experience. For those women, particularly the young, I have presented an inquiry of
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information, an inquiry of self-revelation, and an inquiry of empowerment. Through the journey
of medicine and cervical cancer, this inquiry presents a very real picture of how women are
marginalized in all societies of the world. A picture that details a serious debate in this country
about the health of women and a vaccine with both positive and negative implications. After
reading this inquiry, one must decide which side of the fence to stand on – the side of political
mandates or the side of free choice and autonomy. One might already draw a conclusion, but I
must warn the reader that the decision is not an easy one. There are positives and negatives to
both sides. It will be a hard choice. My mantra in writing this inquiry and what has sustained and
inspired me through the wee hours of the night is, “I am my sister’s keeper.”
My Illness Story
-Each person is as unique and individual in dying as in living.
Larry Churchill
About 5 years ago I got the dreaded phone call from the gynecologist, or actually his
nurse. She was quite terse as she told me that she had my results from my annual Pap exam, and
pathologists found irregular cells. My heart sank, and I immediately thought I had cervical
cancer. I asked her, as my heart raced, “What does this mean? What do I need to do? How did
this happen to me? What is this going to do to the chances of me having a baby?” She did not
want to hear my litany of questions; her job was just to inform me. She told me to schedule a
follow-up appointment with the doctor, and he would explain everything to me. I made the first
available appointment possible. It would be 7 days from receiving the news. I had 7 days to fret,
to do Internet research, to plan what felt like the rest of my short life, or as Broyard (1992) wrote,
“I thought that time had tapped me on the shoulder, that I had been given a real deadline at last”
(p. 3). Yes, I look back now and think that I was being overly dramatic. However, at the time my
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mother-in-law was battling breast cancer, and my best friend’s mom was battling ovarian cancer.
How could I not think I would be another victim of the cancer plight? One of my greatest hopes
for writing my dissertation is to take my difficult experience and use it to inform girls and
women of their medical health options. Robin Sharma (2002), an international author, reflected,
“I often wonder why we, as human beings, spend so much of our lives focusing on the negative
aspects of our most difficult experiences rather than seeing them for what they truly are: our
greatest teachers” (p. 47). Sharing my experience with cervical dysplasia allows the reader to
understand my personal journey with illness and to provide validity to my inquiry. My
pathography was a personal affair, and I chose to expose myself in a very vulnerable way. I hope
the reader will appreciate my honesty and acknowledge that HPV is a very real disease that does
not discriminate.
The Doctor’s Phone Call
It started out like any annual Pap smear exam – an hour in the waiting room reading year
old magazines, a vinyl table covered in what feels like sandpaper, a gown that only covers half of
the female body, and a cold speculum (an instrument that if carefully examined looks like a
medieval torture device). I find the whole Pap smear procedure, which entails “microscopic
scrapings taken from a women’s cervix” (Gawande, 2002, p. 44), completely humiliating. Thank
goodness it only lasts about 50 seconds. On this particular occasion, when the procedure was
over I changed clothes, paid my deductible, and quickly ran to my car in hopes of forgetting the
last hour and 50 seconds. A week later I expected to receive the postcard that tells everyone who
handles the mail that my annual Pap exam was normal and to call in a year to schedule another
appointment. The postcard never came.
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I was finishing up a long day of teaching by cleaning my middle school science
classroom and straightening the chairs when I heard my cell phone vibrating on my desk. It was
a call from my gynecologist’s office. I thought to myself that something must be wrong; they
never call me. Maybe I did not pay the right amount for my deductible, or my insurance was not
going to cover the bill. Never did I think my test results were irregular. I was young, healthy,
athletic; I was not promiscuous; I did not smoke, drink, or do drugs. Yes, I am the “poster child”
for good clean living, or so I thought. I answered the phone and received the dreadful news about
the irregular cervical cells. I first called my husband, an emergency room physician, hoping he
would tell me everything was okay, it is common, don’t worry, life is good. He did not. He told
me I would have to have a colposcopy. “A what?” I asked with trepidation. He started to explain
the procedure to me when a fellow colleague walked in my classroom and wanted to discuss the
next day’s carpool agenda. I told my husband I had to go and that we would talk later. My
colleague could tell something was wrong. I told her the news I had just received and how it felt
like a death sentence. She did not know what to say. I could see the pity in her face. She could
not get out of my room fast enough. Did she think it was casually contagious?
I went home that night and immediately jumped on the Internet to weed through the
mounds of medical information available in cyberspace. I had to educate myself about my
illness. This was an illness that a few Tylenol was not going to cure. That was the surreal part of
this whole experience. Before, popping a few pills could cure all my ailments. Headaches,
backaches, and menstrual cramps were the extremes of my health complaints. I was fortunate,
until now. Rita Charon (2002) stated, “Illness and its counterpart, health, are by definition timebound” (p. 61). This was my time, my good health was now confronted by my evil illness and
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“…the two [would] suffer together…” (Buber, 2002, p. 7). Which would be victorious? Only
time would tell.
After doing some research I learned more than I ever wanted to know about my cervix, a
colposcope, and a little germ called human papillomavirus (HPV). I was diagnosed with
moderate cervical dysplasia (CIN II). There are various levels describing the severity of cervical
dysplasia. Dysplasia is a word that means “abnormal or disordered growth” and therefore can be
mild (I), moderate (II), or severe (III). CIN, pronounced “sin” (supposedly not meant to reflect
the woman being examined) is short for “cervical intra-epithelial neoplasia,” basically a longer
way of saying dysplasia. From my research, I learned that if a Pap smear shows one of these
levels of dysplasia of the cervix it is not cancer but rather changes in normal cell growth (precancer) that if left alone might – over months or years – develop into cancer (Moore & de Costa,
2004). The HPV vaccine has been shown to “offer 98-100 % protection in preventing CIN II and
CIN III caused by HPV types 16 and 18. This may mean fewer cases of abnormal Pap tests in the
future” (Krishnan, 2008, p. 155).
At this point I started to feel a little better, albeit the term pre-cancerous was not much
comfort. As Arthur Kleinman (1989) acknowledged, “Cancer is an unsettling reminder of the
obdurate grain of unpredictability and uncertainty and injustice in the human condition. Cancer
forces us to confront our lack of control over our own or others’ death” (p. 20). As a person
always in control, this betrayal in my body was new territory for me. Cancer is caused by the
uncontrollable growth of cells. I found it ironic that this was one situation that I could not
control. My own body’s cells had taken over, they were making the decisions, and there was
nothing my mind, soul, or spirit could do about it. Lesley Sharp (2007) has stated, “Our bodies
are typically absent from our consciousness when we are healthy. When the body fails us, we
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suddenly become acutely – and painfully aware of its presence and our dependence on it” (p. 8).
A healthy body is taken advantage of on a daily basis; one uses it, one abuses it not giving a
second thought to its care. When our bodies fail us we realize the importance of health, and we
become consumed with making it better. The goal becomes returning to the pre-ill body so that
life can return to normal.
The Procedure
Seven days finally passed, and at 10:15 in the morning I was scheduled to meet with my
gynecologist to have a colposcopy and cyrotherapy. A colposcopy is a way a gynecologist can
examine the vagina, vulva (vagina opening) and cervix closely. A colposcope is an instrument
that shines a light on the cervix and magnifies the view for the doctor (Welch, 2004). At the
beginning of the exam, I had to lie on the sandpaper table and place my feet in the stirrups as I
had for the Pap smear. My doctor inserted a speculum and opened it slightly so he could see my
cervix. He then applied a vinegar solution to my cervix with a cotton ball or swab. The vinegar
makes abnormal tissue turn white so my doctor could identify areas that might need further
evaluation. As all of this was happening, Dr. Peterman was trying to converse with me about
trivial matters such as my job and if I had any plans for the winter break. I knew he was only
trying to put me at ease, but at this point I had no interest in talking. I was actually counting the
number of ceiling tiles in the box of a room I was in with the doctor and nurse. There were
roughly 19. How did I remember that? I do not know; maybe mild trauma does strange things to
my memory.
When the colposcopy portion of the procedure was over, Dr. Peterman started with the
cyrotherapy. Cyrotherapy, or freezing, is done by placing a probe against the cervix, which cools
the cervix to sub-zero temperatures. The cells damaged by freezing are shed over the next week
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or so. Wherever Dr. Peterman saw a white tint to my cervix he froze it with the probe. He told
me that I might experience cramping or a slight uncomfortable feeling during the procedure. I
thought, okay, I can handle cramping or slight discomfort. Obviously, Dr. Peterman did not have
a cervix nor had he never experienced cyrotherapy because slight discomfort is not the
appropriate description of what I experienced. I felt like someone was jabbing me with a hot
poker. I had to do everything not to scream. Thank goodness the procedure was over within a
few seconds. He told me everything went great, and I might experience some cramping the rest
of the day. I could take Motrin™ for the pain. I asked him what my prognosis was now that I had
had these two procedures. Dr. Peterman told me that he felt confident that he froze all the
suspicious areas and that I would need another Pap smear in 6 months.
As I recovered from this procedure, I began to wonder what caused cervical dysplasia? I
have always been interested in the science of disease and cure ever since I learned about Edward
Jenner, the scientist who discovered the smallpox vaccine. In 1796 he scraped pus from the sore
of a dairymaid infected with cowpox into an incision on a healthy boy’s arm. This event marked
the birth of the smallpox vaccine, and the beginning of vaccinology. In 1806, Thomas Jefferson
declared in a letter to Jenner:
You have erased from the calendar of human afflictions one of its greatest. Yours is the
comfortable reflection that mankind can never forget that you have lived. Future nations
will know by history that the loathsome smallpox has existed. (Baron, 1838, p.2)
The story of Edward Jenner is an important one to me. Even though his risky procedure helped to
eradicate smallpox, he was criticized for the lack of ethical judgment in endangering a young,
healthy boy. Vaccinators like Jenner who used cowpox experienced both hostility and derision.
David Koplow has stated, “Jenner’s proposals … stimulated strong reactions: both profound
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celebrations for salvation from smallpox, and intense, sporadic opposition for promoting an
allegedly unnatural and dangerous deviation from established medical practice” (2003, p. 54).
From my research and personal experience with cervical dysplasia, I became interested
in the national debate that surrounds the HPV vaccine. It is a vaccine that could drastically
reduce the number of women who are diagnosed with cervical dysplasia or who die from
cervical cancer each year.
Significance of the Study for Curriculum Studies
My dissertation is important for the curriculum studies field because medicine, illness,
and science are scarcely represented. In today’s ever advancing technological world, why do we
not see more of an emphasis on science, biotechnology, mathematics, and medicine within the
curriculum theory literature? Francis Connelly, in the forward of Delese Wear’s book on the
Medical Academy, has stated, “Science reigns” (1997, p. ix). But when reviewing the curriculum
studies literature, science is scant. Jacob Heller (2008) has asserted, “We simultaneously
understand vaccines as a shield against disease, a right of passage for children and parents, and
an expression of our science, civilization, modernity, and morality” (p. 1). In describing vaccines
this way, curriculum studies is remiss not to include such an important part of our health and
well-being into its literature. Marla Morris (2008) has stated, “Medicine is a torture chamber.
Medicine is sadism. And yet – without doctors and medicines many of us would be dead. A debt
is owed” (p. 65). Despite vaccines widespread use and their predominant role in medicine,
health, and in the reduction of infectious diseases, they are under-studied and under-theorized.
My inquiry pertaining to the HPV vaccine was an investigation into its nature and origin that
helps us understand it as a cultural as opposed to strictly medical or scientific phenomenon.
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It is time to find a place for vaccines in the curriculum discourse, and a dialogue of the
social construction of the HPV vaccine controversy in our American culture be discussed. Delese
Wear and Lois LaCivita Nixon (1994) have written, “The ‘unknown’ where we venture into
women’s bodies and medical/health-related experiences can be explored in multiple, conflicting,
overlapping, sometimes uncharted spheres of meaning” (p. 2). When discussing the HPV vaccine
controversy “multiple spheres” emerge. These spheres make up the framework for my
dissertation – the political sphere, the social sphere, and the bioethical sphere. My inquiry
deconstructs each of these spheres in order to understand the complexity of the HPV vaccine
controversy.
Pinar, Reynolds, Slattery, and Taubman (2004) have opined, “Many curriculum
specialists are so caught up in their individual perspectives that they feel little obligation to
present the perspectives of others with whom they might disagree. That breakdown in the sense
of collective effort is a major problem facing the field today” (p. 5). One of my intentions in
writing this work was to embed science, medicine, and illness into the field of curriculum theory.
Marla Morris recently wrote a book about teaching and illness. Morris (2008) has contended,
“To educate about illness is key. Learning about illness and the course the illness might take are
necessary steps along the difficult path of life’s way” (p. 1). In sharing my story of illness I hope
to educate women and adolescent girls on one of the most widespread sexually transmitted
diseases in the United States. We must begin the “complicated conversation” about sex and
disease. Adina Nack (2008) has stated, “A recent study pointed out, ‘while these diseases [HPV
and HSV] are of epidemic proportion, we actually see surprising little about them in the media,
and we talk about them even less” (p. 3).
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My inquiry was the “complicated conversation” that represents the heart and soul of
curriculum theory (Pinar, 2000, p. 30). Pinar (2000) has stated, “Curriculum understood as
currere [is] a form of social pychoanalysis, a complicated conversation with myself and others,
the point of which is movement: autobiographic, political, cultural” (p. 30). With a thorough
discussion of the HPV vaccine controversy, my story is the autobiographic portion, the
government’s mandate is the political portion, and the backlash from parents, religious leaders,
and conservatives is the cultural portion.
William Schubert makes a similar point that curriculum is so much more than what is
presented in a textbook. Schubert (1986) has asserted, “Curriculum thoughts, decisions, and
practices are socially, politically, and culturally constructed. They are powerfully governed by
economic and legal contexts in which they exist. Moreover, the values of the day exert profound
influence on curriculum” (p. 93). What values are we teaching children in today’s political
climate? Are we teaching them to think critically about the world around them? Can we expect
an 11- or 12-year-old girl to understand her options when presented with choice of receiving the
HPV vaccine? What if the choice becomes a mandate? Will she be able to make a critical
decision about her health and well-being? Nel Noddings (2006), stated, “Possibly no goal of
education is more important – or more neglected – than self-understanding” (p. 10). Curriculum
must be about the whole person, not just reading, writing, and arithmetic. Understanding the
mind and body connection will allow students to have a more holistic academic experience.
If we compare the critical gaze of vaccines to the sociological inquiry that curriculum
theorists continually discuss, we see a correlation of traditional themes that run deep within the
field of curriculum like social class, capitalism, power, gender roles, medical institutions, racial
categories, sexual behaviors, and emotions. These themes become evident when the HPV
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vaccine controversy is analyzed. Discussing class, gender, and race within the context of
vaccines and curriculum studies seems to threaten our comfort level. In order to prepare students
to participate intelligently and democratically in a pluralistic society, teachers need to create
environments and curricula where students can actively engage with other people to overcome
social obstacles (Dewey, 1997). This would happen in environments that allow the individual to
inquire, imagine, act, feel, talk, develop a sense of community, think critically about their world,
develop his or her own voice, make choices (and suffer their consequence), share ideas, use a
wide range of tools and materials, construct knowledge with others, and participate in learning
activities that are connected to his or her life.
Pinar, Reynolds, Slattery, & Taubman (2004) have stated that the aim of curriculum studies
“is to present a mosaic, even if, at times, it will sound (to change momentarily from a visual to an
auditory image) like a cacophony of individuals’ voices so that the beginning student might see
this quilt, might hear the complicated symphony, that is the contemporary curriculum field” (p.
5). Discussing science, illness, and medicine in the realm of curriculum studies allowed me to
present an important educational issue in a field that is otherwise devoid of such topics. This
inquiry added a missing piece of the curriculum studies quilt.
Methodology
My dissertation has educated the reader on the causes of cervical dysplasia, the incidence
of cervical cancer, the science behind the first vaccine ever developed to prevent cancer,
specifically cervical cancer, and the political and social ramifications of inoculating adolescent
girls. My work was grounded in bioethical feminist theory, which included the work of
Rosemarie Tong and Susan Sherwin.
Current literature tends to pit parents, social conservatives, and religious leaders against
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the government and pharmaceutical companies. By dissecting the political, social, and bioethical
controversy that surrounds the HPV vaccine I hope to convey a transparent representation of the
benefits of the vaccine, the greed of the pharmaceutical industry, the mandating motives of the
politicians, and the legitimate concerns of parents and bioethical feminists.
The roots of my inquiry lie in the fact that I have experienced cervical disease. It is too
late for me to receive the vaccine, but through my inquiry I educate other women and girls of the
harmful effects of HPV exposure. My form of inquiry was pathography. My pathography is a
story that many women share, one that is usually pushed under the carpet and kept silent. I am
here to break the silence. I am here to tell my story; and as Anatole Broyard says, this will be my
“literary aspirin” (1992, p.18). My story is not only one of illness, but a forum to share with girls,
mothers, daughters, partners, or whoever will read about a vaccine that possibly could have
prevented my illness. My narrative was a testimonial pathography. I “project a positive attitude
towards medicine,” and I was “motivated by didactic or altruistic principles” (Hawkins, 1999a,
p. 4).
My research focused on publicly available resources of information such as medical
journals, government reports (federal and state), non-governmental organization (NGO) reports,
newspapers, and books. I began with a background discussion of HPV, cervical cancer, and
vaccines. I then discussed the history, definition, and application of bioethical feminist theory as
a theoretical framework. I then examined the controversy surrounding the HPV vaccine. I
discussed political, social, and ethical ramifications surrounding the controversy behind the
government’s push to mandate the HPV vaccine for school enrollment. In the final section of this
dissertation, I focused on the future of vaccine with a discussion of ways to reduce the opposition
to vaccine mandates.
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Limitations of Study
Because this is a theoretical dissertation, there is no direct data collected from physicians,
pharmaceutical representatives, politicians, or parents. All data obtained for this inquiry were
retrieved via the Internet, journals, and books.
Definition of Terms
Bioethical Feminist Theory – examines the history and current issues of harm, inequality, and
disadvantage based on gender in the healthcare industry.
Vaccine – A substance that introduces a whole or partial version of a pathogenic microorganism
into the body in order to train the immune system to defend itself when the organism
threatens to cause an infection through natural means” (Allen, A., 2007, p. 14).
Mandate – a government order to do something.
Cervical cancer – Cervical cancer is cancer of the cervix. The cervix is the lower, narrow portion
of the uterus.
Human papillomavirus (HPV) – a species- and tissue-specific DNA virus that infects surface
cells that cover the skin, mouth, esophagus, upper airways, urethra, anus, vagina, and the
cervix (Fiander & Tristram, 2007, Henderson & Yasgur, 2002).
Centers for Disease Control (CDC) – part of the U.S. Department of Health and Human
Services. The CDC’s purpose is to protect public health and safety by providing current
information, statistics, research data, and educational materials.
Gardasil– the HPV vaccine produced by Merck & Co.
Summary
Although he would recommend that girls receive the HPV vaccine, physician Louis
Cooper, a past president of the American Academy of Pediatrics, believes now is not the right
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time to push for a mandatory immunization law. The public, he said, is increasingly wary of new
vaccines and of medicine in general (cited in Hendricks, 2007). “Public trust is at the heart of all
public health measures” noted Cooper; pushing for mandatory HPV vaccination now could
further erode that trust (cited in Hendricks, 2007, ¶22). Cooper said there has been a backlash
among some groups of parents as the number of required vaccinations has grown. He believes
the public has grown increasingly skeptical of new vaccines for all sorts of reasons—medical,
religious, political (Hendricks, 2007). So in the current climate, Cooper favors waiting awhile
before advocating the proposed laws, to afford the public the time to learn about the vaccine and
to give health professionals a chance to gather more data on the vaccine’s risks and benefits,
which could build a compelling case for mandatory vaccination. For now, Cooper advocates
parents to be the ones to decide whether their daughters get vaccinated.
Before government officials decide whether the HPV vaccine should be mandated,
ethical concerns must be alleviated. There are three complementary steps that can help calm
parental fears and promote the purpose of this vaccine: which is to save the lives of women.
First, the public must realize that the HPV vaccine has the potential for decreasing the number of
women who contract cervical cancer. Second, public health officials need to stress that the
reason it must be given early in life is that inoculation at that point provides that best chance of
lifetime protection. Last and most important, there must be a complete separation of the medical
matter of preventing cancer from the moral matter regarding premarital sex. Health officials must
make serious attempts to reach out to the religious community, which has moral qualms. Perhaps
Merck can circumvent this controversy. While promoting the inclusion of Gardasil as a standard
or required form of vaccination, the company might also work with family-focused groups who
oppose sex outside of marriage to co-develop educational tools for discouraging premature
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sexual relationships citing medical, emotional, and practical reasons for doing so. If these three
issues are addressed, the government will not have to mandate Gardasil, because parents will
understand that they are protecting their daughters against the second leading cause of cancer
death in women (Krishnan, 2008).
My dissertation embedded the vaccine controversy within the curriculum studies field.
Curriculum studies involves the political, social, cultural, and religious issues of the schooling
process. The same can be said about vaccines and their place in society. The ironic twist is that
before a student can even encounter the curriculum process, he or she must be vaccinated.
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CHAPTER 2
THEORETICAL FRAMEWORK
My approach to researching the HPV vaccine controversy is framed around bioethical
feminist theory. This chapter provides a complete exploration of bioethical feminist theory. The
next few sections of this chapter provide a breakdown of bioethical feminist theory into its
different perspectives. I have begun by providing a brief overview of bioethics as a field of study
followed by a summation of the field of feminist theory.
The Bioethical Perspective – An Overview of Bioethics
The bioethics movement was triggered by protest against gross abuses of medical
authority such as Nazi doctors’ experiments on nonconsenting concentration camp inmates and
the Tuskegee Syphilis Study, a 40-year “experiment” on poor black men who were misled into
believing they were receiving medical treatment. At the beginning of this millennium
advancements in genetic and reproductive technologies presented society with many new ethical
dilemmas. Should we be allowed to select the sex of a child? Should we clone embryos for spare
parts? Does an embryo have rights? Should we allow DNA fingerprinting of all citizens? Should
a terminally ill patient have the right to take his or her own life with the help of assisted suicide?
These dilemmas have led to a field called “bioethics.” Mary Mahowald (2006) has asserted, “The
majority of questions addressed in contemporary bioethics involve the beginning and end of life”
(p. 50).
The word bioethics literally means the ethics of life. We have understood that ethics is
the branch of philosophy concerned with how we should decide what is morally wrong and what
is morally right (Reiss, 2002). Sometimes the words “ethics” and “morals” are used
interchangeably. We all have to make moral decisions daily on matters great or more often small
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about what is the right thing to do: Should I have an abortion? Should I obey the law and drive
the speed limit? Should I lie to get out of an uncomfortable situation? We may give much
thought, little thought, or practically no thought at all to such questions. Ethics, though, is a
specific discipline that tries to probe the reasoning behind a moral life, particularly by critically
analyzing the thinking, which is or could be used to justify our moral choices and actions in
particular situations. Bioethics is a field that tries to answer the moral decisions involving life
and death such as choices about dying, reproduction, genetics, disability, and disease. Susan
Wolf (1997) has defined bioethics as, “The study and formulation of the ethics of health care and
the biological sciences. I do not dwell on the distinction between ethics and morals; bioethics
usually is used to encompass both” (p. 7).
Modern bioethics is a collaboration of several disciplines, with their relative importance
shifting over time. Philosophers, lawyers, physicians, and scientists have played major roles from
the beginning. Theologians were significant players early, but more recently have worried about
a loss of influence (McCormick, 1989). Meanwhile, nurses, medical sociologists, and
anthropologists have begun to play a larger role in the bioethical field.
Modern bioethics began in the late 1960s and early 1970s. It has focused on the
passionate plea for patients’ and research subjects’ moral and legal rights. It grew up alongside
other rights movements such as the civil and women’s rights movements. Bioethics has
concerned itself with the protection of vulnerable patients and research subjects, the relationship
between medical and scientific fact and social meaning, and the ethics that should guide
physicians and scientists (Wolf, 1997).
Bioethics in Relation to Other Academic Fields
Bioethics has been scantly represented in other major academic developments like

70

feminism, critical race theory, and postmodernism. One might conclude that bioethics has
managed a sort of isolation from major trends in the academic field. Wolf (1997) has argued that
bioethics is more selective than isolating saying, “The upsurge of academic interest in narrative
and narrative ethics has spawned attention to narrative and narrative ethics in bioethics” (p. 20).
The appeal for narrative ethics is probably based on the traditional importance of cases in
medicine and the scientific study of human beings. Cases, after all, are mini-narratives.
Bioethicists intrigued with narrative and narrative ethics have called for richer and more
complete case narratives. Dena Davis (1991) has asserted, “When cases are described thinly to
protect patient confidentiality, they teach us only what we put into them. Thick description, like
myth, allows a fuller moral response” (p. 12). Thus the enthusiasm for narrative among
bioethicists meshes nicely with a long tradition in medicine and science. Mary Mahowald (2006)
has stated, “The contribution of narrative theory [to ethics] is mainly epistemological because it
stresses the need for attention to different ‘stories’ told by different authors from different
standpoints about specific cases. Attention to these stories is crucial to the knowledge base
required for ethical decision-making” (p. 11). The idea of narrative being an important aspect of
bioethical theory complements my form of inquiry, which is illness narrative. Illness narrative is
a form of inquiry in which a person shares his or her story of illness.
Critical race theory and postmodernism have no obvious correlation to the practices of
medicine and science (Wolf, 1997). There is an association though. Analysis of the role of race
in medicine can teach us a great deal. In the United States, health disparities have been framed
by categories of race. Racial health disparities have been documented for cervical cancer,
cardiovascular disease, cancer, diabetes, HIV/AIDS, and numerous other diseases and measures
of health status. Although such disparities can be read as symptoms of disparities in healthcare
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access, pervasive social and economic inequities, and discrimination, some have suggested that
the disparities might be due, at least in part, to biological differences based on race (Yu, Goering,
& Fullerton, 2009).
In the case of postmodernism, Michel Foucault’s early Birth of the Clinic could have
forged the way for a rich deconstructive and postmodern look at medical and scientific practices
and texts. Foucault’s idea of the “Gaze” reiterates the importance of ethical narrative in
medicine. The “Gaze” was a term used by Foucault to denote the dehumanizing medical
separation of the patient's body from the patient's person. He stresses the need for a reconnection
in the patient-physician relationship. Foucault (1973) has written, “There is boundary, form, and
meaning only if interrogation and examination are connected with each other, defining at the
level of fundamental structures the meeting place of doctor and patient” (p. 111). Foucault’s idea
of “interrogation and examination” makes a strong argument for case narrative within the
medical field and bioethics.
Bioethics and Politics
The field of bioethics speaks to a broad range of human inquiry, ranging from debates
over the boundaries of life, the allocation of healthcare resources, and the right to turn down
medical care for religious or cultural reasons. There is a debate among bioethicists about the
precise limits of their discipline. Should the field of bioethics concern itself with the ethical
evaluation of all questions involving medicine, human research, and biology? Some bioethicists
would narrow ethical evaluation to medical treatments and technological advancements
pertaining to only humans. Others might broaden their scope to cover any organism capable of
feeling fear and pain.
In recent years bioethics has gone from the philosophical lens to the political lens. Take
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any number of recent examples – from the right-to-die Terri Schiavo case, to human embryonic
stem cell research, to, most recently, the California women implanted with six embryos and then
giving birth to octuplets – that place bioethics squarely in the middle of the Culture Wars. These
few examples have sparked public interest and emotion. It seems everyone has an opinion about
the ethics of some of the recent medical and scientific stories that have flooded the media. There
seems to be a liberal stance and a conservative stance when it comes to issues like euthanasia,
abortion, stem cell research, and reproductive technologies, leaving out the important bioethical
stance. The mingling of bioethics and politics is here to stay, and bioethicists can and ought to
play a role in pressing societal issues. Bioethics as scholarship should be able to coexist with
bioethics as politics without being subsumed under it (Kahn, 2006). One way to assure this
outcome is to treat the two as distinct areas much as political science is distinct from political
consulting. A healthy bioethics should expect and welcome struggles between opposing
viewpoints. The issues are difficult, contentious, and complex; disagreements are bound to occur.
Bioethics as a field should see a lively exposure of those disagreements. But they should take
place within bioethics, not the political arena.
The Epistemology of Bioethics
According to Susan Wolf (1996), it is not clear whether bioethics has an explicit
epistemology, a theory of how bioethical knowledge is produced. One widely held, although not
universal, notion within bioethics is that generating bioethical insight does not require agreement
at the level of fundamental theory. Wolf (1996) has stated, “[Bioethicists] reject the notion that
one must choose a single theory from among the competitors” (p. 24). Bioethicists tend to draw
on the societal norms and principles to assess a particular situation or issue. Beauchamp and
Childress (2001) have asserted, “Far more social consensus exists about principles and rules
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drawn from the common morality… than about theories” (p. 102). If the generation of bioethics
knowledge begins with “common morality” or is usually approached as a matter of achieving
reasoned agreement, the relevant community and rules of agreement are rarely stated. Having
provided an overview of bioethics, I will now turn to the feminist aspect of my theoretical
framework.
The Feminist Perspective – An Overview of Feminist Theory
It seems that the majority of current bioethical issues reported in the media have to do
with the woman and her body. For example, the California woman who gave birth to octuplets
has generated a firestorm of controversy involving the ethics of assisted reproduction. Another
example, especially popular in last year’s presidential election, is a woman’s right to have an
abortion. Abortion is an issue that deeply divides American society. Generally, the bioethical
argument centers between the right-to-life and the pro-choice ideologies. Against this
background, it becomes truly perplexing why modern bioethics has paid so little attention to
gender and feminist work.
The term "feminism" may bring to mind stereotypical images of Gloria Steinem, Betty
Friedan, and the "bra-burners" of the 1970s marching through the streets with signs reading
“Equal Pay for Equal Work,” “No More Miss America,” “The Personal Is Political,” and “Pass
the ERA (Equal Rights Amendment).” Whereas these images do convey some of the key events
and leaders of the so-called second wave of feminism in the United States, they do not do justice
to the complexities of the feminist social movement. Although the activism of the 1970s has
tempered, feminism, as an academic focus, has thrived throughout the 1980s and 1990s and
continues to thrive today. A primary task of feminist scholarship has been clarifying the meaning
of feminism and how it can influence research in the humanities and social sciences. The
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clarification of feminism is “a central problem within feminist discourse” (hooks, 2000, p. 18).
bell hooks has argued that feminists cannot “arrive at a consensus of opinion about what
feminism is or accept definition(s) that could serve as points of unification” (2000, p. 18). The
idea that feminism represents a fight for social, economic, and political equality with men is
distressing to hooks. She has stated, “Since men are not equal in white supremacist, capitalist,
patriarchal class structure, which men do women want to be equal to?” (hooks, 2000, p. 19).
Defining feminism in terms of equality is a difficult task for the very reason hooks contends.
Susan Sherwin has defined feminism in terms of oppression instead of inequality. Sherwin
(1992), in a consistent and more epistemological manner, defines feminism as “the name given
to various theories that help reveal the multiple, gender-specific patterns of harm that constitute
women’s oppression. It is also the term used to characterize the complex, diverse political
movement to eliminate all such forms of oppression” (p. 1). When a woman is oppressed she is
held back from reaching her full potential due to social, cultural, political, or economic
injustices. The primary goal of the feminist movement is to end sexist oppression in all its forms.
hooks (2000) has stated, “Its [feminism] aim is not to benefit solely any specific group of
women, any particular race or class of women. It does not privilege women over men” (p. 28).
Feminism has also been defined as the political movement to end women’s subordination
(Jaggar, 1989). Feminist work takes gender and sex as centrally important analytic categories,
seeks to understand their operation in the world, and strives to change the distribution and use of
power to stop the oppression of women (Wolf, 1996).
From my research, I have found that no one theory or perspective constitutes “feminism”;
there are a number of feminisms, which some feminist writers have classified. Rosemarie Tong
(2009) has stated, “Feminist thought is old enough to have a history complete with a set of
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labels: liberal, radical, Marxist/socialist, psychoanalytic, care-focused,
multicultural/global/colonial, ecofeminist, and postmodern/third wave” (p. 1). Nonetheless,
feminist inquiry provides a wide range of perspectives on social, cultural, and political
phenomena.
Common Themes within Feminism
The assemblage of scholars who consider themselves feminists is large and diverse,
representing a broad range of different opinions and perspectives (Pellegrino, 1993). Despite this
array of views, it is possible to identify some common themes. First, feminists have shared the
recognition that women are oppressed in society and an understanding that their oppression takes
many different forms, compounded often by other forms of oppression based on characteristics
such as race, ethnicity, sexual orientation, and economic class. Susan Sherwin (1992) has stated,
“Because feminists believe that oppression is objectionable on both moral and political grounds,
most are committed to transforming society in ways that will ensure the elimination of
oppression in all its forms” (p. 47). Second, much of the harm of sexism has been obvious and
thus can be readily challenged. For example, women are disproportionately subjected to
domestic violence and sexual assault, which can result in a sense of insecurity and vulnerability
in them. Third, women are subjected to economic disadvantage in the work place. Women earn
considerably less then men in the same position. Fourth, the predominance of men, especially
White, middle-class men, in positions of influence in virtually all segments of society (legal,
political, financial, cultural, medical, and military) is dominant. Susan Sherwin (1992) has
pointed out, “Feminists have shown that male standards have been consistently taken as the norm
from which theories are developed and against which they are tested; this has left women in the
position of being either ignored altogether or treated as deviant” (p. 1). Finally, the implicit male
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bias in our language is subtle, but also creates a form of sexism. The tendency to confuse genderspecific male forms of expression with supposedly neutral generic forms of expression
perpetuates culturally embedded notion of male-defined norms and assumptions of female
deviance (Sherwin, 1992). For example, words like chairman, manpower, and mankind exude a
strong male bias and undermine the influence of women in society. These examples illustrate
major themes that feminists strive to eradicate within the various institutions that shape society.
The Epistemology of Feminism
Just as there is no single feminist perspective or theory, there is no single feminist
epistemology. In general, feminist epistemologies investigate the relationship of power, gender,
and the means of generating authoritative knowledge. Their general goal is “the expansion of
democracy in the production of knowledge” (Tong, 2009, p. 217). Feminism has identified ways
in which dominant conceptions and practices of knowledge attribution, acquisitions, and
justification systematically disadvantage women and other subordinate groups, and has strived to
reform these conceptions and practices so that they serve the interests of these oppressed groups.
Dominant knowledge practices disadvantage women by excluding them from inquiry, denying
them epistemic authority, and producing theories of women that represent them as inferior,
deviant, or significant only in the ways they serve male interests. Feminist epistemologists trace
these failures to flawed conceptions of knowledge, knowers, objectivity, and scientific
methodology.
There are three main feminist epistemologies that have become popular over the last
quarter-century. They are rational-empirical epistemology, standpoint epistemology, and
postmodern anti-epistemology. Rational-empirical epistemology is the view that experience
provides the sole, or at least the primary, justification for all knowledge. Feminist empiricists are
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concerned with the impact on inquiry of social practices relating to gender, race, class, and other
bases of inequality.
Standpoint theories claim to represent the world from a particular socially situated
perspective that can lay a claim to epistemic privilege or authority. The defining characteristic of
the standpoint feminist approach is to “give voice” to oppressed people in social situations (Bui,
2007). The idea of giving a voice to the less powerful members of the social order stems from
the belief that they encounter a different reality as a result of their societal oppression. Sandra
Harding has pointed out, “Whatever the kind of difference identified, the point … is that
women’s [or any oppressed person’s]‘difference’ is only difference, not a sign of inferiority”
(1991, p. 122). Feminist standpoint theory has begun with the idea that the standpoint or position
in society of women provides a vantage point from which to view women’s social reality
(Swigonski, 1994). Nancy Hartsock, in her classic study of feminist standpoint epistemology,
argued that women’s intuition provides a standpoint from which she can envision possibilities
for overcoming oppression and building a better society. It was Hartsock’s belief that such a
vision is superior to a masculine focus on hierarchy, dominance, and oppositional thinking. Ways
of knowing informed by motive of caring for everyone’s needs will produce more valuable
representations than ways of knowing informed by the interests of domination. A feminist
standpoint allows us to “go beneath” patriarchal structures and understand them as “perverse
inversions of more humane social relations” (Hartsock, 1998, p. 107).
Postmodern anti-epistemology dictates no “true” facts exist for anyone to discover,
regardless of their standpoint. Rosemarie Tong (1997) has stated, “Postmodern feminists rebuke
feminists who formulate general theories about women’s subordinate status in society” (p. 89).
All three approaches to feminist epistemology embrace pluralism and reject totalizing
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theories. No matter how the knowledge is formed, feminism is a philosophy that “urges us to
revise the values, perceptions, and concerns that shape how we look at human interactions, so
that we may take account of the place of those interactions in the broader set of human
relationships” (Sherwin, 1992, p. 5).
The Melding of Bioethics and Feminism: An Overview of the History and the Strengths of
Bioethical Feminist Theory
Up to this point in my dissertation I have provided a synopsis of bioethics and feminism.
This section will provide an overview of bioethical feminist theory. I discuss the role of
bioethical feminist theory as the theoretical framework for my dissertation.
What might a bioethics attentive to gender and feminist analysis look like? Bioethical
feminist theory recognizes that moral and ethical analysis requires attention to gender. There is a
long history of harm, inequality, and disadvantage based on gender in the healthcare industry that
has been ignored completely, which is ironic because according to Barbara Ehrenreich and
Deirdre English (1973), “Women have always been healers” (p. 3). Wolf (1996) asserts,
“Ignoring it merely helps to keep such oppression invisible and alive” (p. 21). A principal
characteristic of bioethical feminist theory is the critical interest it takes in oppressive aspects of
medical organization and practice.
Bioethical feminist theory began to emerge as a new area of academic interest when
feminist scholars turned their attention to the field of bioethics and the field of medicine and
science. Both bioethics and “Second Wave” feminism gathered momentum in the 1960s, a
pivotal era for social turmoil. Sandra Harding (1991) has written:
It is at this moment that feminism and other liberatory social movements appear on the
scene with agendas that include generating new science. Women need sciences and
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technologies that are for women and that are for women in every class, race, and culture.
(p. 5)
In this second wave, feminists pushed beyond the early quest for political rights to the fight for
greater equality in education, the workplace, and at home.
The long history of women’s interest in health care issues extends prior to the seizure of
practices of midwifery and nursing by the medical profession. Ehrenreich and English (1973)
have asserted, “The women’s health movement of today has ancient roots in the medieval
covens, and its opponents have as their ancestors those who ruthlessly forced the elimination of
witches” (p. 6). It was those historic influences that fed into protest movements of the 1960s
resurgence of feminism. That revival reinvigorated and extended longstanding concerns and
directed attention to areas of health care where women’s interests were neglected, such as access
to birth control, abortion, pregnancy, and representations of female sexuality (Wolf, 1996). The
vigilance of the women’s movement in the 1960s and early 1970s called attention to sexist biases
in medical research and practice. Susan Wolf (1996) has stated:
Our societal definitions of what constitutes illness and thus merits medical attention have
been influenced by gender. Historians have argued those defining women’s psychological
reactions as madness and women’s usual physical functioning as pathological have
reflected the biases and misogyny of the day. (p. 12)
Protest against the widespread exclusion of women from clinical trials, particularly in the United
States, swelled momentum even further. Feminists campaigned for increased breast cancer
research, more convenient and cheaper contraceptive methods, research on the physiology of
menopause, and elimination of unnecessary surgical interventions, particularly hysterectomies,
Caesarean sections, and radical mastectomies (Tong, 1997). Advocacy groups have struggled to
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raise public awareness of women’s health issues, influence health policy, and act as a
counterforce to organized medicine and the pharmaceutical industry.
Feminist scholars began to complement the agenda of health care activists. They
documented the erosion of abortion access following the 1973 Roe v. Wade Supreme Court
decision, and critiqued childbirth practices that sacrifice the interests of the birthing woman to
the convenience of her obstetrician. By the 1980s, feminist bioethics scholarship was being
widely circulated in feminist publications, and a small portion of this effort was surfacing in
bioethics journals. Unfortunately, most of the feminist literature published was often mistakenly
assumed to address “women’s concerns” – also known as a special ethics for women. Feminist
contributions to texts were included, but they were confined to topics relating to reproductive
issues.
One of the turning points in feminist bioethics was the publishing of Susan Sherwin’s
book called No Longer Patient: Feminist Ethics and Health Care (1992). This was the first fulllength book dedicated to bioethical feminist theory. In this groundbreaking work, Sherwin
expanded feminist bioethics in a new direction that circumvented the prevalent theoretical
approaches of the dominant bioethics framework and demonstrated its shortcomings. Sherwin
(1992) has asserted, “Feminism expands the scope of bioethics, for it proposes that additional
considerations be raised in the ethical evaluation of specific practices: it demands that we
consider the role of each action or practice with respect to the general structures of oppression in
society” (p. 4-5).
The field of medicine and medical research can at times be mechanizing and
dehumanizing, especially towards women. There is an underlying power of those in the
patriarchal medical authority to define illness (Sherwin, 1992). Women have been especially
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harmed by this power. It has evolved into the bizarre conclusion that women are never quite
healthy: premenstrual or not premenstrual; hysterical or not hysterical; pregnant or not pregnant;
menstruating or not menstruating; menopausal or not menopausal. Susan Sherwin (1992) has
asserted, “The decision to view as diseases such elements of women’s lives as menstruation,
pregnancy, menopause, body size, and feminine behavior forms an integral part of women’s
general oppression” (p. 179). Bioethical feminists are understandably critical of the
indiscriminate classification of common female experience as illness.
The concept of the either/or dichotomy can be extended to HPV vaccine argument. A
parent that decides to vaccinate his or her daughter against an STD may be ridiculed for
condoning adolescent sex; and a parent who decides not to vaccinate his or her daughter may be
ridiculed for not protecting her against an STD that has the potential of causing cancer. Both
sides are polarized for doing something wrong. Will there ever be a right answer when it comes
to vaccinating adolescent girls against an STD?
More recent bioethical feminist work has sought to bring increased attention to obstacles
surrounding policy reforms that could alleviate burdens imposed predominantly on women. Both
Jennifer Park’s No Place Like Home: Feminist Ethics and Home Health Care (2003) and
Rosalind Ladd’s anthology, Ethical Issues in Home Health Care (2002) address the growing
problem of caring for the elderly, homebound, and those who risk their own economic security to
care for them. They both discuss topics relating to care and justice. Several other bioethical
feminists have joined the growing discourse with disability scholars who adapt features of care
ethics with issues of justice. One feminist who has argued persuasively for a necessary
connection between care and justice is Marilyn Friedman. According to Friedman, the
care/justice dichotomy overlap, and if care is morally adequate it involves justice in personal as
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well as professional relationships (Friedman, 1987). Similarly, if justice means giving people
their due (treating people appropriately), it demands determination of what constitutes due care
for each. The application of this concept to health care is obvious: the health practitioner must
recognize and respond to the different health needs of each patient (Friedman, 1987).
Two other feminists who have developed discourse in care ethics are Carol Gilligan and
Nel Noddings. Both derive their understanding of care from an analysis of women’s experience.
Gilligan (1982) has stated, “The ideal of care is thus an activity of relationship, of seeing and
responding to need, taking care of the world by sustaining the web of connection so that no one
is left alone” (p. 62). The idea that care is responding to one’s needs is the backbone of bioethical
theory. Building relationships of trust also goes along with care and bioethics. The physicianpatient relationship must be one of trust in order for treatment to be successful. If the patient does
not feel that the physician cares about him or her and there is not a relationship of trust then the
healing process will suffer.
Rosemarie Tong (1997) has made a forceful case for incorporating features of a care ethic
into bioethical theory to challenge the structures and systems that perpetuate women’s
disempowerment. She notes that justice and care are closely intertwined on a practical level.
Though far greater prestige attaches to high-tech medicine than the mundane tasks of providing
quality care to the sick, caring values count heavily in providing high caliber healthcare. Tong
(1996) has stated, “Caring can and has served as a trap for women – as a “virtue” that turns
women into masochists, living only to serve other people’s interests (particularly, men’s and
children’s) while steadfastly neglecting or ignoring their own” (p. 72). Virginia Warren (1992)
made a good point that caring tasks of medicine have been stigmatized as “housekeeping tasks”
that garner little interest and even less remuneration while “crisis issues” dominate attention and
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reward their practitioners handsomely (p. 32). This inequality in the healthcare system is of
special concern for bioethical feminists. The majority of health caregivers are women, but they
occupy primarily low status, low paying positions. As a result, women’s voices are rarely heard
in debates over the public and institutional health care policies and practices that shape our
medical experiences (Dresser, 1996). In my opinion, nurses, the majority being women who care
for the sick, are given very little appreciation. Doctors, the majority being men who care for the
sick, are revered as Gods (Warren, 1992). Often when one reads illness narratives, the doctor is
thanked for saving the patient’s life, and there is no mention of the “Other” people in the healing
process. The Other in the medical field is often a woman whose caring, trusting, sympathetic,
and compassionate nature contributed to the healing process just as much as the doctor that
ordered the medicine (Warren, 1992). Sherwin (1992) has stated, “Speaking with the authority of
a discipline devoted to improving the human condition, medical practitioners have been granted
the status of the new priesthood within secularized Western culture” (p. 5).
The greatest strength of bioethical feminist theory as a framework is the vast array of
discourse among its scholars. There are differing perspectives among bioethical feminists
depending on the particular topic of interest. Each bioethical feminist must be sensitive to the
possibility that her perspective is offensive or hurtful to others. For example, my view that
abortion should only be used in cases of rape, incest, or harm to the mother’s life distresses many
pro-life women. The fact that I have to be sensitive to other, differing perspectives on abortion
does not mean I have to abandon my own perspective. Katharine Bartlett (1990) has made a
similar point:
Although I must consider other points of view from the positional stance, I need not
accept their truths as my own. Positionality is not a strategy of process and compromise
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that seeks to reconcile all competing interests. Rather, it imposes a twin obligation to
make commitments based on the current truths and values that have emerged from
methods of feminism, and to be open to previously unseen perspectives that might come
to alter these commitments. Positionality, however, sets an ideal of self-critical
commitment whereby I act, but consider the truths upon which I act subject to further
refinement, amendment, and correction. (p. 389)
Rosemarie Tong believes that bioethical feminists need to “develop a feminist
methodology in ways that may increase their ability to forge mutually agreeable public policies
that actually reduce gender oppression in the world of biomedicine” (1997, p. 96). Bioethical
feminist theory can empower women to achieve consensus on issues that have divided them in
the past. The eclectic mix of perspectives within bioethical feminist theory can be used to
recommend proactive policies that will permit the widest variety as well as the greatest number
of women to control their “interconnected reproductive and genetic destinies” (Tong, 1997, p.
98).
Bioethical Feminist Theory as a Theoretical Framework
As the medical field continues to grow and technological advancement pushes the
boundaries of the ethical and the unethical, bioethical feminist theory will have its place in
scholarly discourse. My intention was to help bioethical feminist theory find its place in
curriculum studies.
Bioethical feminist theory is committed to developing analyses that can offer meaningful
guidance in the morally troubling situations of real life. Bioethical feminist theory will provide a
solid framework for my discussion as I lay out the conflict-ridden story that surrounds the HPV
vaccine.
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There are several bioethical feminist issues pertaining to this particular vaccine. The
vaccine is wrapped in controversy that pits the government and pharmaceutical companies
against religious leaders and parents of adolescence girls. It is a fight between the validity of
science and the moral and religious views of a society. The HPV vaccine has put a wedge
between the ethicality of medicine and the morality of society.
Proponents of the vaccine claim that it will provide unequivocal safeguards against a
sexually transmitted virus that causes cervical cancer, but the vaccine has to be administered to
girls between the ages of 11 and 12. The Centers for Disease Control and Prevention (CDC)
picked this age range because the vaccine has to be given before a girl becomes sexually active.
The decision whether to inoculate girls this young poses a moral dilemma to parents, religious
leaders, and even some medical professionals. They find themselves asking the following
question, “Should preteen girls be vaccinated against a potentially cancer-causing sexually
transmitted disease, or will the benefits of vaccinating our girls be outweighed by increased
promiscuity and risky sexual behavior?” Although these perceived risks of the vaccine may seem
completely unfounded by the scientific community, many parents wonder whether the vaccine is
just a “quick fix” to address the consequences of behavioral choices.
In spite of the widespread opposition to the vaccine from parents and religious leaders,
many states such as Texas proposed legislation mandating the vaccine be administered to all
preteen girls attending public school. Under current proposals, mandates would force adolescent
girls to undergo drug therapy (vaccination), when they have no disease, under the presumption
that they might get a disease based on future behavior. One might argue that we do have, as
public policy, mandatory vaccinations for some infectious diseases like mumps, measles, and
rubella (MMR). The difference is that MMR are contagious diseases that can be caught by sitting
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next to an infected person in a classroom. HPV is not spread by casual contact. James Colgrove,
a professor of sociomedical sciences in the Center for the History and Ethics of Public Health at
Columbia University’s Mailman School of Public Health, has stated “In general, you use
coercion in public health to prevent imminent harm to others. It’s the classic jurisdiction in the
USA. You don’t pass a law requiring something unless it causes imminent harm” (cited in
Udesky, 207, p. 980). Physician Jon Abramson, the chairman of the Advisory Committee on
Immunization Practices of the CDC, has explained that protecting children against a virus that is
spread by sexual activity is different from preventing the spread of measles (cited in O’Beirne,
2007). Abramson believes that mandating the HPV vaccine “is a much harder case to make,
because you’re not going to spread it in school unless you are doing something you’re not
supposed to be doing in school” (cited in O’Beirne, 2007, p. 20). Non-vaccinated students would
pose no risk to others while in school. So, does the government have a right to mandate the HPV
vaccine? Susan Sherwin (1992) has asserted, “That the trend in medical ethics has been to
examine moral issues in context and to avoid dependence on general, abstract rules and rights.
The theme of seeking a practical, context-specific approach to ethics is widely stressed” (p. 79).
In this case, examining the moral and ethical issue of mandating the HPV vaccine is easy.
Bioethical feminist theory would support the parents and religious leaders. One has to wonder
why the government would mandate a vaccine for an illness that is not caught by airborne or
casual contact. Further investigation into the state of Texas revealed that the governor had
financial and political ties to the pharmaceutical company that produces the HPV vaccine.
Currently, the vaccine is gender-specific, recommended for girls only. The American
Academy of Pediatrics does not support a school-linked mandate because “there are people who
are concerned about gender discrimination because it’s a policy that would keep girls out of
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school and not boys, because it’s a vaccine for girls” (Udesky, 2007, p, 980). From the bioethical
feminist theory standpoint, research on vaccinating boys must be further investigated. In the
majority of cases, HPV is spread to women through sexual contact with men. Therefore, an
understanding of HPV infections in men is critical in reducing the risk of transmission to women.
The Global Perspective of HPV – A Lack of Screening
In the U.S., nearly 3,700 women who will die of cervical cancer will have something in
common – no screening (Pap smear) or no treatment follow-up after screening. These facts speak
to access to healthcare, and the conclusion is clear – cervical cancer is a disease of disparity
(Outterson, 2009). While this technology is widely available and has reduced cervical cancer
incidence in industrialized nations, it is not readily available in third world nations in which
cervical cancer incidence and mortality is high (Brinkman, Caffrey, Muderspach, Roman, &
Kast, 2005). In many developing countries it is the leading cause of cancer death among women
(Siddiqui & Perry, 2006). Cervical screening has reduced the incidence of cervical cancer deaths
by 70% over the last 50 years. In the U.S., approximately 60 million women receive a Pap smear
each year, which results in the diagnosis of 1.25 million women with pre-cancers (Siddiqui &
Perry, 2006). However, Nicoletti & Tonelli (2006) have stated, “On average, there are about
9,710 new cases of cervical cancer in the United States each year and 3,700 deaths are attributed
to it” (p. 423). The lethality of cervical cancer is even greater worldwide, causing over 470,000
new cases each year and 233,000 deaths (Nicoletti & Tonelli, 205). The discrepancy is largely
due to the decreased availability of affordable screening and treatment in many countries.
According to Franco and Harper (2005), Eastern and Southern Africa have the highest incidence
and mortality from HPV in the world.
Few countries have the resources and infrastructure necessary to run organized screening
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programs, so the poorest regions of the world bear the brunt of the disease. Most women in lowincome countries do not have access to routine screening: only 5% have undergone a Pap smear
in the past 5 years (Katz & Wright, 2006). In parts of Latin America and the Caribbean, more
women die from cervical cancer than from complications of childbirth (Population Reference
Bureau, 2006).
Currently, the HPV vaccine is extremely expensive compared to the other mandated
vaccines. Bioethically speaking, this in itself produces the marginalization of women in terms of
healthcare. If minority women and women living in developing countries are not receiving the
proper screening for cervical cancer, then the vaccine would be a great treatment to protect them.
Unfortunately, at a cost of $320 for the complete treatment with the HPV vaccine not all women
have financial access to it. The marginalization of women’s needs in biomedicine and research
continues to be one of the greatest struggles in the field of bioethical feminism. The last section
of this chapter outlines the criticisms that are waged against bioethical feminist theory.
Criticisms of Bioethical Feminist Theory
Throughout its short historical span, bioethical feminist theory has been marked by
criticism regarding its conceptual framework, methodology, multidisciplinary composition and
dynamics, agenda of gender moral issues, and relationships with social institutions and culture of
American society. The conceptual framework of bioethical feminist theory is based on societal
norms and moral teachings of one’s religion. So, bioethical feminist theory has been criticized
for not being properly theoretical.
Critics believe feminists’ concerns lack mooring in a bona fide ethical theory (Tong,
1996). Feminists themselves hotly contest ideas such as Carol Gilligan’s or Nel Noddings’ ethics
of care. Some object to what they see as its valorization of negative traits born of subordination
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and the need to please. A further complaint is that the ethics of care offers too little analytic rigor
in facing moral problems. Carol Gilligan’s response to such a criticism might have been, “To
admit the truth of the women’s perspective to the conception of moral development is to
recognize for both sexes the importance throughout life of the connection between self and other,
the universality of the need for compassion and care” (1982, p. 98).
In contrast, other critics fault feminist approaches to bioethics for being too theoretical;
that is, for clinging to the category of gender as the ultimate reference point or foundation for
women’s diverse experiences, as if gender always mattered to each woman more than her own
race or class, for example (Nicholson, 1990). Feminist bioethicists might have responded that so
long as gender inequities remain, there will be a need for feminist approaches to bioethics that
emphasize women’s ways of perceiving, thinking, and acting.
Bioethical feminist theory has also been criticized for being biased and highly personal.
Rosemarie Tong (2007) has stated:
An unfortunate, but common effect of realizing that ethical theories are plural rather than
singular in number is the feeling that, when all is said and done, ethics is a very relative
and highly subjective practice in all realms of human activity. (p. 6)
When bioethical feminists try to invoke major moral theories, most find it difficult to fit the
theories’ criteria to the problems before them, a restriction that clearly limits their practical
usefulness (Tong, 2000). Moreover, many find that a single comprehensive moral theory is
inadequate to capture all of their moral intuitions; in such cases they may sometimes find
themselves tempted by the attractions of alternative theoretical approaches for addressing
different sorts of issues. It has even been argued that there are “no universal moral standards, that
ethics is without foundations, and that moral differences cannot be resolved” (Tong, 2007, p. 7).
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The response to this criticism is easy. Ethics and morality are not sciences. Answers to ethical
issues are not always black and white. Scholarly discourse within the field of ethics provides a
vast range of opinions, insights, commonalities, and differences. This richness of views only
strengthens our moral judgments to the tough bioethical problems and injustices that are found in
the world of medicine and research. Rosemarie Tong (2007) states, “[Ethics] is an art that
requires every ounce of moral imagination, emotion, and thought we can muster” (p. 9).
Summary
Bioethical feminist theory is a rapidly developing area of philosophical specialization.
This is a field that tries to offer concrete practical advice that might not be readily inferred from
abstract theories. Women are more often patients in the United States and have more physician
contact than men (Horton, 1992). Even when women are not seeking medical advice for
themselves, they are often the ones that must make medical decisions for others. They have made
those medical decisions as mothers, wives, sisters, partners, and daughters. Bioethical feminist
theory provides a voice for those women. The bioethical feminist voice not only analyzes a
paternalistic medical system, but also offers medical counsel and moral reasoning with women as
the central participants.
The most controversial issues of the twenty-first century are related to women and their
bodies. Assisted reproduction, surrogacy, abortion, birth control methods, the increasing number
of Caesarean sections, consumption of cosmetic surgery, fetal screening, and female genital
circumcision are only a few of the pressing issues that are hotly contested but widely practiced.
Ethical and legal rules on all of these issues will affect women first and foremost, and analysis of
such rules must attend to the gender inequalities they may reinforce or create. This is the
objective of bioethical feminist theory.
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Susan Wolf (1996) has stated, “Bioethics cannot afford to overlook half the world, to
ignore the pervasive effects of gender, and to avoid the feminist literature transforming the
disciplines that make up this field” (p. 32). Modern bioethics is committed to protecting the
health and interests of the patient and the research subject from harm by the physician and the
medical researcher. Modern bioethical feminist theory has extended this commitment to
alleviating the oppression and inequalities of oppressed women and children in the medical field.
Rosemarie Tong has written, “Just because an approach to bioethics is gendered does not mean it
is sexist” (1996, p. 83).
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CHAPTER 3
REVIEW OF LITERATURE
Since the approval of the HPV vaccine by the FDA in June of 2006, there has been a
plethora of journal and newspaper articles outlining the arguments for and against a government
mandate and the efficacy of the new immunization. Currently, only two books have been written
specifically discussing the HPV vaccine.
When one looks at the current literature regarding the HPV vaccine, several themes are
evident. The first theme has dealt with the political controversy that commenced as soon as the
state governments insisted on mandating the HPV vaccine for adolescent girls. The second theme
has focused on the rebuttal to the government by parents, religious leaders, and bioethical
feminists, which causes a social/ethical controversy to occur. A third theme that has surfaced in
the literature is the worry about increased sexual promiscuity among adolescent girls if they
receive this vaccine. This theme has both social and ethical underpinnings. Parents are afraid that
they are sending the wrong message to their daughters if they have them vaccinated against an
STD.
The purpose of this literature review was to provide an overview of these three themes
and how these themes align with my investigation of mandating the HPV vaccine for adolescent
girls. When the literature was reviewed, it was evident that authors came from a political,
medical, social, or ethical stance. There currently is no piece of literature that incorporates the
four stances and melds them into one body of literature. My theoretical inquiry was an attempt at
melding the four stances to come to a decisive conclusion about why there has been such a huge
controversy over mandating the first vaccine ever produced to prevent cancer.
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Scope of Literature Review
The literature review for this theoretical inquiry surveyed significant literature published
about the HPV vaccine. The literature for this review included works acquired from the Georgia
Southern University Library, books used during my doctoral coursework, scholarly journals,
newspapers, GALILEO database, and the websites for the Centers for Disease Control and
Prevention and the United States Department of Health and Human Services. The majority of
sources used were published within the last 5 years given the recent development of the HPV
vaccine. A wide variety of sources were necessary in order to gain a complete picture of the
political, social, medical, moral, legal, and bioethical dilemmas involved with the vaccination of
adolescent girls against HPV.
Efficacy of the HPV Vaccine
Before discussing the three themes that have emerged when reviewing the HPV vaccine
literature, I feel a review of the literature that discussed the HPV vaccine’s efficacy was
important to include in this section of the inquiry.
HPV is the underlying cause of virtually all cervical cancer diagnoses in women (Cutts,
Franceshi, Goldie, Castellsague, de Sanjose, et.al, 2007). Each year in the US, cervical cancer is
newly diagnosed in approximately 10,000 to 11,000 women, and over 3,000 women die from the
malignancy (Krishnan, 2008). Even more staggering is the total number of HPV-associated
conditions in both males and females. A total of 2.3 to 2.8 million cases each year are related to
an infection with HPV (Krishnan, 2008). These cases range from mouth and throat cancers,
penile cancer, vaginal cancer, vulvar cancer, anal cancer, cervical cancer, recurrent respiratory
papillomas, cervical dysplasia, and genital warts (Krishnan, 2008). Dr. Shobha Krishnan has
asserted, “The medical costs associated with treating HPV-related diseases in the United States
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are second only to the costs created by HIV/AIDS” (2008, p. 49).
The World Health Organization (WHO) reported that cervical cancer is the most common
cancer affecting women in developing countries (2007). It has been estimated that in 2005,
cervical cancer killed 260,000 women, of whom 80% occurred in developing countries (WHO,
2007).
Recently, a vaccine that has the potential to prevent certain HPV infections, and hence
reduce the incidence of cervical cancer and other anogenital cancers, has been licensed. The
FDA approved Merck’s HPV vaccine, Gardasil, in June 2006. Another HPV vaccine called
Cervarix (produced by the drug company GlaxoSmithKline) is in advanced clinical testing.
Gardasil, historic in that it is “the first vaccine explicitly designed to prevent cancer induced by
a virus,” provides hope that the burden of HPV-related illness may be reduced (Baden, Curfman,
Morrissey, & Drazen, 2007, ¶ 2). Clinical trials have shown the HPV vaccine to be safe and
effective at preventing HPV infections that are commonly associated with the development of
cervical cancer, as well as other HPV-related cancers and warts (Cutts et al., 2007). Physician
Angie Goeser of the Creighton University School of Pharmacy and Health Professions wrote an
article in American Family Physician outlining the HPV vaccines effectiveness. Dr. Goeser
(2007) has stated:
Four studies enrolling more than 20,000 females 16 to 26 years of age who were free of
HPV infection showed that only 2 of 7,858 patients who received all three doses of the
HPV vaccine developed cervical intraepithelial neoplasia (CIN) grades I, II, or III
because of one of the 2 strains of HPV; this was compared with 83 of 7,861 patients
receiving the placebo (0.05 percent versus 1.1 percent, respectively). (p. 573)
These trials have demonstrated at least 95% efficacy in preventing disease related to four types
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of HPV: types 6 and 11, which cause genital warts, and types 16 and 18, responsible for 70% of
cervical cancers (Atkinson, Hamborsky, McIntyre, & Wolfe, 2008).
The very high clinical efficacy in women without prior HPV infection, and the lower
efficacy among those already exposed to HPV, shows that vaccinating girls before they are
exposed to HPV would have the greatest impact (WHO, 2007). The vaccine is most effective
when administered in childhood, before initial exposure to HPV, which typically occurs shortly
after the onset of sexual activity (Krishnan, 2008). Accordingly, the CDC’s Advisory Committee
on Immunization Practices (ACIP) has recommended routine vaccination of adolescent girls
aged 11 or 12 years old, although the vaccine may be given as early as 9 years of age (CDC,
2009a). ACIP consists of 15 experts in fields associated with immunization who have been
selected by the Secretary of the U. S. Department of Health and Human Services to provide
advice and guidance to the Secretary, the Assistant Secretary for Health, and the CDC on the
control of vaccine-preventable diseases.
The duration of the vaccine’s protective effect is unknown, although studies have found
no evidence of waning immunity or decline in efficacy for prevention even 4 to 5 years after
administration of the vaccine series (Cutts et al., 2007). Once the initial vaccine series has been
completed, booster doses are not currently recommended by ACIP. As studies progress and
continuing research data is collected, this recommendation could be altered and booster shots
may be required to enhance immunity.
Dr. Goeser (2007) has asserted, “Clinical trials have not yet identified serious safety
issues with the HPV vaccine” (p. 573). Adverse reaction to the HPV vaccine administration has
been limited to local reactions at the site of injection such as pain, swelling, or redness and to
minor symptoms common to most any vaccine administration as syncope, nausea, dizziness,
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malaise, and muscle aches. According to Atkinson et al., “These symptoms occurred with equal
frequency among both vaccine and placebo recipients” (2008, p. 121).
The medical community has raised several major concerns regarding the HPV vaccine.
Physicians George Sawaya and Karen Smith McCune, associate professors in residence in the
Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of
California, San Francisco, wrote an article in the New England Journal of Medicine expressing
their concern. They believe there are several unanswered questions regarding the HPV vaccine.
First, the studies involving the HPV vaccine have, out of necessity, used pre-invasive cervical
lesions (specifically CIN II and III) as surrogates for the primary result of interest – cervical
cancer (Sawaya & Smith-McClune, 2007). Because of the low incidence of cervical cancer, the
FDA considers CIN II and III to be acceptable outcomes for cervical cancer. A study using
cervical cancer as the primary outcome would take years to complete because of the delay
between HPV infection and cervical cancer. Furthermore, a study allowing CIN lesions, detected
through Pap screening, to progress to malignancy would be unethical. Due to the practical
necessity of using substitute outcomes, the ultimate question of whether HPV vaccination
prevents cervical cancer is still in question and will require long-term observation of a large
number of vaccinated women.
A second concern involves the potential unintended consequence of vaccination.
Currently, the vaccine protects against only two of the several HPV types known to cause
cervical cancer. With widespread vaccination, other cancer-inducing HPV types may emerge as
significant causes of cervical cancer (Sawaya & Smith-McClune, 2007). Continued analyses of
data from ongoing clinical trials “will be important to determine the effect of vaccination on
rates of pre-invasive lesions caused by non-vaccine HPV types” (Sawaya & Smith-McClune,
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2007, p. 1993).
A third concern is that the vaccine is not licensed for use in males although data on
immune response and safety in males aged 9-15 years are available, efficacy studies have not
been completed (Markowitz, 2007). Males, of course, are not susceptible to the most significant
adverse consequences of HPV infection – cervical disease – but they are susceptible to genital
warts and cancers of the penis, anus, and oropharynx. Each of these cancers has been associated
with HPV infection and may be preventable with vaccination (Cutts et al., 2007). In addition,
vaccination of males could enhance “herd immunity” and reduce the number of cervical
infections in women, since males are frequent carriers of HPV infection. On the other hand,
“mathematical modeling has shown that, if vaccine coverage [of females] is high, vaccination of
males in addition to females will offer little additive benefit in preventing HPV-related cervical
disease” (Saslow, 2007 p. ). Bioethically speaking, I found Saslow’s deduction using
mathematical modeling unfounded and discriminatory especially when our history with the
rubella vaccine was reviewed and the possible benefits of the HPV vaccine for men.
We can learn from our experience with rubella vaccination. When effective rubella
vaccine became available in the 1970s, some public health authorities chose to vaccinate only the
girls, in some cases not until their early teens (Allen, A., 2007). This seemed reasonable because
the main deleterious consequence of rubella infection was fetal rubella syndrome, a major cause
of devastating birth defects. Vaccinating women of childbearing age should have been sufficient
(Allen, A., 2007). However, experience, best documented in Sweden, showed that sex-specific
vaccination was not an effective policy. Only when boys and girls were vaccinated in the first
years of life did rubella and fetal rubella syndrome essentially vanish (Boettinger & Forsgren,
1997).
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Clinical trials to date have focused on females because women suffer most from the
pathology of HPV infection. Males, however, are the carriers of HPV and are responsible for
infecting their female partners. With the notable exception of genital warts and some cases of
penile and anal cancer, there is little pathology associated with HPV in heterosexual males
(Jansen & Shaw, 2004). HPV is very difficult to detect in this population. This is partly because
of the lack (until recently) of an acceptable method of sampling. Men having sex with men do
show an increased risk of anal cancer (Krishnan, 2008). The cells that line the anal canal have
similar features to the cells that form the cervix. These cells, in both the anus and cervix, are the
most frequent site of HPV infection. Since vaccines work best when given to large proportions of
the population (provide herd immunity), vaccination trials to show some efficacy in men are
currently being reviewed by the FDA. An FDA advisory panel recently voted in favor of the
safety and efficacy of Gardasil to inhibit genital warts in boys and men ages 9 to 26 (Singer,
2009). The FDA typically follows the recommendations of the advisory panels on drug
approvals, but a determination on the marketing of the vaccine for boys and men has yet been
made.
Dr. Goeser (2007) has concluded, “The HPV vaccine is safe and effective in preventing
genital warts and cervical changes that may lead to cervical cancer” (p. 574). Vaccines that
protect against HPV types 16 and 18 have the potential to reduce, but not eliminate, the risk of
cervical cancer (WHO, 2007). Women will still be at risk from other high-risk types of HPV, and
other interventions, including cervical screening, will be required.
The Political Theme
The vast majority of literature written about the HPV vaccine relates to the current
controversy surrounding the government’s attempt at mandating the vaccine for preteen girls.
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Given the controversial nature of the HPV vaccine and the infection it is designed to prevent,
there are several different cultural and political elements involved with the widespread
administration and promotion of the product. One major political issue is the possible mandating
of HPV vaccination around the country. This possibility has completely overshadowed the
purpose of the vaccination, which is preventing cervical cancer. Several different areas in the
United States have or have tried to create legislation regarding the required administration of this
vaccine. R. Alta Charo, a professor of law and bioethics at the University of Wisconsin, wrote an
article describing the current feeling as it relates to politics and the HPV vaccine. Professor
Charo (2007) has stated:
Cancer prevention has fallen victim to the culture wars. Throughout the United States,
state legislatures are scrambling to respond to the availability of Merck’s human
papillomavirus vaccine, which has been shown to be effective in preventing infection
with HPV strains that cause about 70% of cases of cervical cancer. (p. 1905)
This statement has implied the success or failure of this vaccine was not only based on medical
facts but also on impressions and behaviors of different cultures. Professor Charo believes that
access to the vaccine has become more of a political issue than a public health issue. She has
asserted, “…concern has focused on a purported interference in family life and sexual mores.
This concern has resulted in a variety of political efforts to forestall the creation of a mandated
vaccination program” (2007, p. 1905). Numerous pieces of legislation regarding the HPV
vaccine are being created and considered all over the United States. Only 3 months after the
vaccine received approval from the FDA, the Michigan Senate became the first state governing
body to propose legislation (Senate Bill 1416) that the HPV vaccine be compulsory for young
girls entering middle school (Colgrove, 2006). The bill has not been enacted.
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The first US state to enact a mandate was Texas. Texas governor, Rick Perry, issued an
executive order in February 2007 requiring that all adolescent girls be vaccinated against HPV.
The Texas House and Senate unanimously overturned the order in April 2007 due to the
backlash of fellow politicians, civil rights groups, and Texas parents.
The most recent literature suggests states are still in the process of mandating this
vaccine. According to National Conference of State Legislatures (2009), legislators in at least 42
states and Washington, D.C. have proposed HPV related legislation or resolutions. Some states
are experiencing high approval for such legislation. Currently, 20 states have enacted legislation
that would either require, fund, or educate the public about the HPV vaccine: Alaska, Colorado,
Indiana, Iowa, Maine, Maryland, Michigan, Minnesota, Nevada, New Hampshire, New Mexico,
New York, North Carolina, North Dakota, Rhode Island, South Dakota, Texas, Utah, Virginia,
and Washington (National Conference of State Legislatures, 2009; see Appendix A). Some states
are still facing strong opposition for a school mandate. For example, New Mexico was able to
successfully pass a bill (Senate Bill 244) through their state legislatures, but the mandate was
vetoed once it reached the governor. Currently, New Mexico requires insurance plans in the state
to cover the vaccine for girls between the ages of 9 and 14 (National Conference of State
Legislatures, 2009).
Professor Charo has contended that states have the right to require people to be
vaccinated. She has asserted (2007), “…both federal and state court decisions have consistently
upheld vaccination mandates for children, even to the extent of denying unvaccinated children
access to the public schools” (p. 1906). The literature supports that HPV vaccination mandates,
which are aimed more at protecting the recipient than at achieving herd immunity have been
attacked as an unwarranted intrusion on individual and parental rights (Charo, 2007; see also
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Colgrove 2006; Daley & McDermott, 2007; Krishnan, 2008; Savage, 2007; Thomas, 2008). This
has placed parents and lawmakers in a very complicated state of affairs. They can both deny
sexual activity of teenagers and not promote vaccination, or they can promote vaccination that
will spare lives while possibly giving teenagers a sense that their sexual activity is expected and
in some way approved by adults. Many legislatures and family members seem more focused on
the possible implications this vaccine could have on the sexual activity of adolescent girls.
According to Professor Charo (2007), “Opposition seems based on the concern that to recognize
the reality of teenage sexual activity is implicitly to endorse it” (p. 1907). Opponents have
claimed that the HPV vaccine will change the onset and frequency of sexual activity in girls.
However, this claim is not supported by empirical evidence and may be based on misconceptions
and moral convictions (Monk & Wiley, 2006). The CDC has reported that it is unlikely that
sexual activity will increase among teenagers as a result of the HPV vaccine (Kaiser Family
Foundation, 2006). Moreover, fear of an STD has not been the primary reason for adolescents
not to engage in sexual activity (Krishnan, 2008). Specifically, empirical research has found that
distributing condoms in schools and increasing the availability of the morning-after pill are not
associated with younger sexual debut or an increase in sexual frequency (Kirby, Brener, Brown,
Person, & Harrist, 1999).
Legislative efforts to pass a mandate for adolescent girls are in line with the Advisory
Committee on Immunization Practices (ACIP) of the CDC’s recommendations. The
recommendations have stated that the HPV vaccine should be administered on a routine basis to
all healthy 11- and 12- year-old girls, although the vaccine is approved for use as early as 9years- old (Colgrove, 2006). Individual state requirements for childhood and adolescent
vaccination varies as to the range of communicable diseases but are often based on ACIP
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recommendations. Professor Charo (2007) has written, “School-based immunization
requirements represent a key impetus for widespread vaccination of children and adolescents and
are enforceable even when they allegedly conflict with personal or religious beliefs” (p. 1906).
This statement brought up the question as to whether mandating the HPV vaccine has violated a
girl’s constitutional right to autonomy. Beuchamp and Childress have stated, “Personal
autonomy is, at a minimum, self-rule that is free from both controlling interference by others and
from limitations, such as inadequate understanding, that prevent meaningful choice” (2001, p.
58).
Tracy Solomon Dowling (2008), a JD candidate from Boston University School of Law,
investigated the constitutionality of mandating the HPV vaccine, Gardasil. She began her
discussion summarizing the current HPV vaccine climate. Dowling has stated, “Because this
medical advancement has the potential to improve public health and decrease the number of
cervical cancer victims, many want to mandate vaccination for all women through a major public
health initiative” (2008, p. 66). But do states have the constitutional right to require such a
mandate for a disease that is not spread through casual contact? Dowling (2008) has asserted:
States have the constitutional right through their police powers to mandate vaccines in
specific circumstances: if a public health necessity exists, if a reasonable relationship
between the intervention and a public health objective exists, and if the intervention is
proportional to the risk. (p. 66)
I disagree with Dowling; I do not believe individual governing states have a constitutional right
to mandate the HPV vaccine. I have discussed my reasoning in chapter 6.
Even though Dowling believes the HPV vaccine mandate is constitutional, she asserted,
“state legislatures should not require it” (2008, p. 66). Her reasoning is based on the fact that
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cervical cancer impacts only a small portion of the population. My question to Dowling is,
“What would constitute a large portion?” According to the CDC, in 2005, 11,999 women in the
U.S. were diagnosed with cervical cancer, and 3,924 women died from the disease (2009b).
Cervical cancer is the second leading cause of cancer deaths in women; the first being breast
cancer (Krishnan, 2008). Globally, cervical cancer is the leading cause of cancer deaths in
women (WHO, 2007). Dowling believes that it is unnecessary to mandate the vaccine when it
“benefits only a limited number of individuals” (2008, p. 66). Would her opinion change if she
were one of those “ 11,999 individuals?” She only justifies a mandate if the “collective benefits
of mandatory vaccination outweigh the costs” (2008, p. 66). Mandating the vaccine would come
at high costs because it is the most expensive vaccine available. Dowling (2008) has written,
“The drug itself is extremely expensive, imposing a high financial burden on an already costinflated health care system” (p. 66). A projected cost effectiveness study was performed using a
computer-based model and published in the Journal of the National Cancer Institute in 2004.
Goldie et al. (2004) have stated, “Our results indicate that the addition of an HPV 16/18 vaccine
to current cervical cancer screening in the United States has the potential to be a cost-effective
use of health care resources” (p. 612). According to Jonathan Temte of the University of
Wisconsin School of Medicine and Public Health, “HPV infection accounts for expenditures of
more than $2 billion per year and significantly affects patient privacy and comfort” (2007, p.
117). Dowling cannot determine if the cost of vaccinating adolescent girls outweighs the cost of
treating HPV induced cancers. Cutts et al. (2007) has asserted:
The estimated costs of and benefits from HPV vaccine need to be compared to those of
other interventions. The magnitude of benefit in a specific country will depend on the
incidence, mortality and treatment costs of disease attributable to the HPV types against
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which the vaccines protect, as well as on the vaccine efficacy, achievable coverage and
duration of protection. (p. 722)
The administration of the HPV vaccine is only 3 years old; long-term data on the vaccine’s
efficacy and duration of protection are unavailable so a true cost analysis is not currently
available.
The last point Dowling discusses in terms of not mandating the HPV vaccine is the fact
that it would violate one’s autonomy. Dowling (2008) has stated, “Mandatory vaccinations
restrict privacy rights and ownership of one’s body, adding non-monetary costs that are critical
to any evaluation of mandatory legislation” (p. 66). I agree with Dowling on this point. HPV is
contracted almost exclusively by sexual contact. HPV does not fall into the same category as
pertussis or measles, which are contracted by coughing and sneezing.
Since the landmark 1905 decision by the United States Supreme Court in Jacobson v
Massachusetts upholding the state’s compulsory vaccination law during the Boston smallpox
epidemic that began in 1901, the federal and state courts have consistently supported vaccine
mandates for both adults and children (Gostin, 2005). In the conflict between individual liberty
and the common good, the law tends to favor the common good, at least in terms of protecting
public health (other examples include laws mandating sanitation, animal control, and
quarantines). Although the law does not allow for an individual to be vaccinated against his or
her will, it does allow for punishment of those who refuse to comply. In the case of childhood
vaccines, the typical punishment is denying access to public schools.
The constitutionality of mandating the HPV vaccine is based on the threat HPV-related
illness poses to the general public, and “to the extent that required HPV vaccination is an
example of state paternalism rather than community protection” (Charo, 2007, p. 1906). While
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vaccines are designed to protect the individual, the development of herd immunity that results
from large numbers of individual vaccinations serves an even more important role in protecting
the population as a whole from infection. This is the “so-called” basis for the political drive to
mandate the vaccine – protect the public. If this is the basis for mandating the vaccine then why
are boys not vaccinated? Why only girls? In the critical analysis section I dissect this reasoning
by answering this question. I also take a look at the link between the politicians who have pushed
hard for the mandate and their relationship to the drug company, Merck, which produces the
immunization. Another question that is addressed in the critical analysis section is the fact that
the brunt of HPV-related illness is carried by the less influential members of society – those of
ethnic minorities or low socioeconomic status. If we have the statistics that prove that Hispanic
and African American women have higher rates of cervical cancer, then why is the drug so
expensive? How can Merck, in good faith, market a drug for a disease of disparity and charge
over $350 for its administration. How can the HPV vaccine be made more affordable so that the
girls who really need to be immunized not only have access to the drug, but are educated about
their reproductive health?
The Social/Ethical Theme
Mandating Gardasil also raises social/bioethical issues. Under current proposals,
mandates would force people to undergo drug therapy (vaccination), when they have no disease,
under the presumption that they might get a disease based on future behavior. One might argue
that we do have, as public policy, mandatory vaccinations for some infectious diseases like
mumps, measles, and rubella (MMR). The difference is that MMR are contagious diseases that
can be caught by sitting next to an infected person in a classroom. HPV is not spread by casual
contact. Jon Abramson, the chairman of the ACIP of the CDC, explains that protecting children
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against a virus that is spread by sexual activity is different from preventing the spread of measles
(cited in O’Beiren, 2007). Abramson believes that mandating the HPV vaccine “is a much harder
case to make, because you’re not going to spread it in school unless you are doing something
you’re not supposed to be doing in school” (cited in O’Beirne, 2007, p. 20). Non-vaccinated
students would pose no risk to others while in school.
In addition to specific parental concerns regarding the HPV vaccine as it pertains to
adolescent sexuality, HPV vaccine mandates also face opposition from an increasing number of
parents who resist vaccination efforts in general. Arthur Allen, a former Associated Press foreign
correspondent and author, wrote a book entitled Vaccine: The Controversial Story of Medicine’s
Greatest Lifesaver. In his book he has discussed the inflammatory history of vaccines. Arthur
Allen (2007) has asserted, “There was a time not so long ago when nearly all Americans, grateful
for the defeat of polio by Jonas Salk’s famous shots, eagerly embraced vaccination” (p. 14).
Today, however, vaccine-preventable disease has become less common than adverse reactions
from vaccination itself, leading many parents to believe that the cure is worse than the disease:
the fainting spell or sore arm that their child experienced as a result of vaccination is fresh on
their minds, while the scourge of paralysis from polio is a distant memory (if that). In addition,
many individuals fall prey to the tendency to attribute any number of ailments to a vaccine
received days (or weeks) prior. Perhaps the most prominent example is the commonly stated
belief that an individual contracted his or her flu from the influenza vaccine, despite there being
vast numbers of noninfluenza respiratory infections that circulate during cold and flu season and
no real basis for the notion that the inactivated viral particles in the influenza vaccine can cause
the flu.
More troublesome, is the trend to attribute blame for diseases that have no known
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cause, to vaccination. Some advocacy groups are now implicating vaccines as the cause of a
wide range of illnesses—including, among others, asthma, attention deficit disorder, chronic
fatigue syndrome, diabetes, inflammatory bowel disease, and sudden infant death syndrome
(Infectious Diseases in Children, 1999). Perhaps the most controversial of these implications
is the link between vaccination and autism. Thimerosal, a mercury-containing preservative,
is used in several vaccine formulations. Although the assertion is not supported by scientific
research, many parents and various anti-vaccine advocacy groups implicate thimerosal as a
cause of autism. Although the HPV vaccine does not contain thimerosal, an emerging mistrust of
scientific claims of safety could play a role in the public’s slow acceptance of new vaccines,
regardless of their thimerosal content.
Bioethical feminists have brought up another ethical issue at the forefront of the debate.
Currently, the vaccine is gender-specific, recommended for girls only. Even though cervical
dysplasia and cervical cancer are the most widely recognized disease caused by HPV, the virus
does not just present a risk in women. HPV can cause significant health risks in men, too.
Krishnan, a board certified gynecologist and family practice physician, has stated, “HPV is
responsible for causing genital warts and penile, anal, mouth, and throat cancers in men” (2008,
p. 117). Furthermore, in the majority of cases, HPV is spread to women through sexual contact
with men. Therefore, an understanding of HPV infections in men is critical in reducing the risk
of transmission to women (Krishnan, 2008). So the bioethical question has become, “Why are
men not being targeted equally by the HPV prevention program and Merck’s ‘One Less’
campaign when they play such an integral role in transmission of the disease?” According to
Krishnan (2008), “The answer might lie in the sheer lack of information. While a wealth of
information about HPV in women is available, research in men has so far only scratched the
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surface” (p. 118). Clinical trials looking at the vaccine’s efficacy in adolescent boys are
underway (Udesky, 2007). The vaccine is currently not recommended for boys because the
safety and effectiveness has not been proven.
There is also a concern from the medical community, that there will be a drop in the
number of women getting annual Pap smears if the HPV vaccine is mandated. Ian Anderson
(2002) from the University of Leeds has stated:
If just women are vaccinated against HPV, there will be a negative effect on smear
attendance. Many women already find cervical smear testing unpleasant and if they think
that they are immune from cervical cancer, they may be disinclined to continue with
them, despite the fact that routine gynecological examination allow the medical
profession the opportunity to inspect for other problems and to educate women about
pregnancy and sexually transmitted diseases. (p. 2)
Education will be a vital part of a successful immunization program. Women need to understand
that just because they have been immunized, they are not immune to cervical cancer. Gardasil
only protects women from two of the 30 types of HPV that cause cancer. Yes, those two types
cause 70% of all cervical cancers, but there is still a 30% chance of getting the disease. An
annual Pap smear is still recommended to detect for abnormal cervical cells that could lead to
cancer.
The swiftness that pro-vaccine advocates are pushing for a mandate is alarming some,
especially parents who do not want their daughters used as guinea pigs. Merck cannot guarantee
there will be any long-term health consequences, as have occurred with other vaccines. They also
cannot guarantee long-term protection. Although the side effects of the vaccine are quite low,
thus far subjects have been followed for only 4 years. Merck has agreed to continue to conduct
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several studies following licensure to further evaluate general safety and long-term effectiveness
(Nicoletti & Tonelli, 2006). Barbara Loe Fisher, co-founder of the National Vaccine Information
Center, is very concerned. She recently has stated, “[There is] a thin base of testing upon which
to make this vaccine mandatory” (cited in Houppert, 2007). William Schaffner, a chair of the
Department of Preventative Medicine at the Vanderbilt School of Medicine, has pointed out,
“There is merit in not immediately mandating the vaccine. Let’s do some surveillance first, let’s
be a little prudent” (cited in Udesky, 2007, p. 980). The best line of reasoning for a delayed
approach is the history behind the first vaccine against rotavirus, a virus that causes severe
diarrhea in children. After widespread use of the vaccine, an unsuspected side effect occurred;
intussusception, a life-threatening bowel disorder, occurred in some children and the vaccine was
removed from the market (Udesky, 2007).
In January of this year, The American Academy of Pediatrics and the Association of
American Physicians and Surgeons voiced concerns over patchy reimbursement. Dr. Goodman, a
pediatrician, had stated, “So far I have not seen any reimbursement from insurance companies
for the vaccines I have administered, but I guess time will tell” (personal communication, July 3,
2007). This attitude may seem cavalier to some, but doctor offices must purchase vaccines and
wait for reimbursement from either the government or private insurance companies. Some
physicians have argued that the rising costs of vaccines and the rising number of new mandatory
vaccines make it increasingly difficult for them to purchase vaccinations initially and that they
net a loss due to insufficient reimbursement from insurers (Javitt, Berkowitz, & Gostin, 2008).
Another concern was the absence of safety data in the target population and the
knowledge of immunizing girls against a disease that is now less prevalent in the U.S. and that,
in any case, does not develop until later in life. This had prompted the question – “Will immunity
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last?” Preteens are the preferred demographic for vaccination, but only 1,184 (5%) of the 25,000
people participating in Gardasil’s clinical trials were from this group (Flogging Gardasil,
2007). Critics could, therefore, claim that an “untested” product was being foisted onto
America’s children, and Merck did not have a strong enough data based case to allay parents’
fears concerning vaccine safety. Merck’s quest for compulsory immunization so soon after
approval also broke with precedent for vaccines, which are usually in use for years before being
mandated.
Barbara Fisher insists that making the HPV vaccine compulsory violates parents’ rights.
“We are not against vaccine availability, just vaccine mandates” (cited in Houppert, 2007, p. 18).
While she concedes that every governing state but two has some kind of opt-out clause for
parents who object to the vaccine for health, religious, moral, or ethical reasons, she believes
parents who refuse immunization are harassed (Houppert, 2007). Texas state senator Glenn
Hegar introduced legislation to reverse Governor Perry’s order on the grounds that research trials
are still underway and “such mandates take away parents’ rights to make medical decisions for
their children and usurp parental authority” (O’Beirne, 2007, p. 20).
Neal Halsey, a professor in the department of International Health and Pediatrics at John
Hopkins’s Bloomberg School of Public Health, worries about the logistics of mandating
Gardasil. He has asserted, “I think it’s premature to require this for school entry, because we
don’t have good systems in place to make sure we can deliver this to all girls” (cited in
Houppert, 2007, p. 20). If the government is going to mandate this vaccine, then public health
officials need to make sure the supply can be maintained, and that there are mechanisms in place
to insure that the drug will make it to all those in need. According to Halsey, the U.S.
Health Department does a great job of getting babies and little children immunized in this
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country because well-baby visits insure regular contact with doctors and because the government
has a system in place to make sure all young children, even those without insurance, can get the
required shots. “But we are doing a terrible job delivering vaccines to adolescents, due to the
lack of infrastructure at the CDC and state health departments” (cited in Houppert, 2007, p. 20).
He worries those rushing school immunization requirements for the HPV vaccine will just
overwhelm an already stretched system. Halsey’s sentiment is one of efficiency not
effectiveness; this devalues the lives of girls. If the government mandates the HPV vaccine, a
strategy of dispersal will need to be set in place. Why not allow the vaccine to be administered in
the school’s nurse’s office? It seems reasonable that if the vaccine is mandated for school
entrance, why not kill two birds with one stone?
Will the HPV Vaccine Promote Adolescent Sex?
Mandating Gardasil has also been criticized by family organizations, like Focus on the
Family, abstinence-only hardliners, evangelical groups, and right-wing conservatives. They are
touting the familiar argument: Safe sex leads to more sex. Krishnan (2008) has asserted, “Many
parents and religious leaders wonder whether the vaccine is just a ‘quick fix’ to address the
consequences of behavioral choices” (p. xi). Is giving a vaccine for a sexually transmitted
disease tantamount to promoting sexual activity? This argument has been raised before
concerning comprehensive sex education (as opposed to abstinence only education) and the
distribution of condoms to adolescents in an attempt to reduce the risk of more immediate and
threatening adverse health outcomes such as AIDS or pregnancy. But research suggests that just
the opposite is true: Comprehensive sex education strategies may actually “delay initiation of
sexual intercourse, reduce frequency of sex, reduce frequency of unprotected sex, and reduce the
number of sexual partners” (Bleakley, Hennessy, & Fishbein, 2006, p. 1153).
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Similar to the debate surrounding the distribution of condoms to prevent unwanted teen
pregnancies or HIV and other sexually transmitted diseases, the use of the HPV vaccine to
prevent cervical cancer has passed from the public health arena into the political arena. This is
particularly true given the need to vaccinate children. If the HPV vaccine were equally effective
before or after HPV exposure, then it could be equally efficacious as an adult immunization, and
perhaps much of the controversy would subside. As it is, however, HPV vaccine mandates have
been attacked as “an intrusion on parental discretion and an invitation to teenage promiscuity”
(Charo, 2007, p. 1907).
Proponents of the current political push for an abstinence-only approach to STD
prevention argue that abstinence offers a practical and safe alternative that “undermines the
argument for a state initiative that encourages vaccination” (Charo, 2007, 1907). But experience
shows that abstinence-only approaches to sex education do not delay the age of sexual initiation,
nor do they decrease the number of sexual encounters (Charo, 2007). A research study
commissioned by the U.S. Department of Health and Human Services in order to evaluate the
effectiveness of the $50 million annual federal funding of abstinence education programs found
that “youth in the [abstinence education] program group were no more likely than the control
group youth to have abstained from sex, and among those who reported having sex, they had
similar numbers of sexual partners and had initiated sex at the same mean age (Trenholm et al.,
2007). According to the CDC, though only 13% of American girls are sexually experienced by
15 years of age, by 17 the proportion grows to 43%, and by 19 to 70% (Dailard, 2006). Professor
Charo has pointed out that any sex education curriculum needs to begin before children begin to
drop out where rates begin to increase during the middle school years. Charo (2007) has stated:
School-based programs are crucial for reaching those at highest risk of contracting
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sexually transmitted diseases, and despite the relatively low rate of sexual activity before
age 15, the programs need to begin with children as young as 12 years: the rates at which
adolescents drop out of school begin to increase at 13 years of age, and younger dropouts
have been shown to be especially likely to engage in earlier or riskier sexual activity (p.
1907).
Further evidence suggesting that current approaches to adolescent STD prevention are
ineffective is a recent CDC study of 838 female adolescents participating in the 2003-2004
National Health and Nutrition Examination Survey (NHANES). This study revealed that
approximately one in four females age 14-19 years is infected with one of four common STDs:
HPV, Chlamydia, herpes simplex virus 2, or trichomoniasis (Hampton, 2008). The most
prevalent STD found among the girls was HPV at a rate of 18.3% (Hampton, 2008).
Summary
A review of the HPV vaccine literature demonstrates the need for critical discourse when
discussing the role of vaccines and healthcare. The debate seems to be more about politics than
the health of our children. In my critical analysis chapter I sort out this debate to come up with a
conclusion about what is the solution to this controversy.
In chapter 4, I have provided a synopsis for the politics behind vaccine mandates. I
discuss the role of the CDC, how vaccines are approved, and how the FDA ensures vaccine
safety.
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CHAPTER 4
VACCINE POLICY: A BIOETHICAL SHOT AT YOUR RIGHTS
Vaccination is the single most cost-effective health intervention known to modern
science and public policy (Russell, 1995). The United States, known for its commitment to one’s
individual freedom and rights, has taken an unusually aggressive stance with regard to
vaccination. Since the Constitution did not grant to the federal government the power to enact
health regulations, the individual states control compulsory vaccination programs. In some states
the Department of Health and Human Services (HHS) decides vaccine policy; in other states,
policy is legislated. In both instances, however, there is tremendous pressure to follow federal
guidelines. State health departments depend heavily on federal dollars, which may be withdrawn
if the state does not meet federal quotas. The power and prestige of the CDC and the FDA easily
intimidate state legislators and even health care professionals who might otherwise deviate from
the official path of the mandated vaccine schedule (Link, 2005).
When I have my daughter vaccinated against tetanus, which grows in soil and on rusty
nails, and does not spread from child to child, I am protecting my child alone. But I also
vaccinate her against measles, mumps, polio, pertussis, hepatitis, diphtheria, and pneumonia. In
doing so I not only protect my own child, but also help eliminate the safe haven from which
these organisms might launch an attack on somebody else’s child, on a teenager whose immunity
has waned, or an adult who has never been immunized. Public health policy recognizes that
complete personal responsibility is unattainable. Within limits, we must all help look after one
another – that is our social duty as fellow human beings.
Public health policy has played a large role in the health and welfare of each person in
society. Public health policy has encompassed everything from clean water and air quality to the
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mandating of bike helmets and immunizing our children. Health policy has helped increase the
life expectancy from 47.8 years in 1900 to 78.1 years today (Kohrs, 2002). Many people have
been saved from the horrendous cough of pertussis, the crippling effects of polio, and the
devastating birth defects caused by rubella.
While many laws infringe on a person’s rights under the Constitution, most governing
states allow exemptions to the mandated vaccines. For example, 48 states allow exemptions for
religious beliefs (Mississippi and West Virginia do not), 17 exempt for philosophical beliefs, and
all states allow medical exemptions (Kohrs, 2002). Those claiming religious exemptions base
their arguments on the right to free exercise of religion encompassed in the First Amendment.
However, the U.S. Supreme Court has not recognized the First Amendment exemption to
mandatory vaccination programs for dangerous diseases (Kohrs, 2002). The U.S. Supreme Court
states, “We have never held that an individual’s religious beliefs excuse him from compliance
with an otherwise valid law prohibiting conduct that the State is free to regulate” (Kohrs, 2002,
p. 241). Philosophical exemption is based on an individual’s objection to vaccines for personal,
philosophical, moral, or other beliefs. The medical exemption requires a written declaration by a
licensed physician stating the vaccination is dangerous to the individual’s health. The final
verdict for these three types of exemptions is left in the hands of the courts. Throughout history,
the courts have, in matters of health, consistently put the common good before individual rights.
There is no question the compulsory vaccination policy is a violation of a person’s right
to autonomy and privacy as stated by the Fourteenth Amendment, but we can thank this policy
for the complete eradication of smallpox, with polio not far behind. It has also significantly
reduced the incidence of several of the most devastating communicable diseases. We, as
Americans, must realize that that the good of the many outweighs the interest of the few.
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The Crossroads – Vaccine Compliance, Politics, and Controversy
Every man is entitled to his own opinions, but not to his own facts.
- Daniel Patrick Moynihan
Last month I took my 2-month-old daughter to the pediatrician for her check-up. She was
due for her first set of vaccinations. The first government mandated vaccines are administered at
the age of 2 months. There are six vaccines required: Hepatitis B, Rotavirus, DTaP (Diphtheria,
Tetanus, & Pertussis), Haemophilus influenza, Pneumococcal, and Polio. Arthur Allen (2007)
states, “In America, vaccination is the first act the state requires of a person” (p. 15).
Knowing I was writing this dissertation, I asked the pediatrician if she thought there was
any harm to giving a 2-month-old so many vaccines at one time (six total would be given). I
already knew the answer the pediatrician would politely tell me. She proceeded to explain that
there is always a risk in administering any medicine, and each child reacts differently to drugs.
Some have absolutely no side effects from the drug, some get a slight fever, and a few get
violently ill or die. “A few get violently ill or die,” rolled off her tongue as if she were telling me
a bedtime story. I thought to myself, “Boy, that was a textbook answer.” She had to tell me there
is some risk to vaccinating children.
I then began to think about my Aunt Patricia. She was a wonderful woman with a really
bad cough. In 1931, when Pat was only one-year-old, she caught whooping cough from an
infected cousin. Although the vaccine was developed in 1914, Pat had not been immunized.
From the day she was exposed to Bordetella pertussis, the bacteria that causes whooping cough,
she was never the same. She spent her life coughing up blood and eventually had 2/3 of her lungs
removed. Towards the end of her life she was on oxygen. I thought to myself, as I was standing
in the pediatrician’s office, what would Pat’s life have been like if she had been vaccinated?
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Would she still be with us? It was my relationship with Pat that taught me how important
vaccines are to individuals and society as a whole. I then signed the vaccination waiver, took the
CDC vaccine information hand-outs, and held my daughter’s arms as the nurse injected her legs
with possibly life-saving drugs.
According to the CDC’s National Immunization Survey (NIS), childhood immunization
rates remain at or near record levels, with more than 77% of children being fully vaccinated with
all vaccines in the series of recommended immunizations (CDC, 2008b). Julie Gerberding, the
CDC director, has stated, “The ongoing success of our nation’s immunization program is largely
dependent on the trust that parents put in the safety of vaccines and in those caregivers who
administer them” (CDC, 2008b, ¶4). The issue of vaccine administration is more than a trust
relationship between parents and the end of the needle. It is also a relationship of coercion.
The government and technocracies deploy three strategies to ensure compliance with
vaccination mandates from the general public. The first strategy uses force and compulsion.
Many of the early smallpox vaccination campaigns relied on real force often orchestrated by the
military (Leach & Fairhead, 2007). On March 15, 1902 Reverend Henning Jacobson refused to
be vaccinated against smallpox and he was convicted and fined $5. In 1905, in the ruling in
Jacobson vs. Massachusetts, the Supreme Court upheld the right of the city of Cambridge,
Massachusetts to mandate vaccination against smallpox (Parmet, Goodman, & Farber, 2005).
The high court rejected the contention that mandatory vaccination violated an individual’s rights
to due process and equal protection as guaranteed by the Fourteenth Amendment of the
Constitution (Parmet et al., 2005). The court held that states may limit individual liberty in the
service of well-established public health interventions. The court also ruled that the risk of injury
from vaccination was small when compared to the substantial social benefits. I expound further
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on this ruling by the Supreme Court in Chapter 6 when I discuss the constitutionality of
mandating the HPV vaccine.
The second strategy links vaccination to rules of material benefits. For example, in the
U.S., students are not allowed to enter public school without proof of vaccination. In France,
immunization is a requirement for access to certain welfare and tax benefits.
The third strategy aims at instilling vaccination as a habit, and inculcating a desire for it.
Leach and Fairhead (2007) has asserted, “The incorporation of vaccination into parents’ normal
routines and practices is the goal of mandating immunizations, so that it becomes an
unproblematic matter of unthinking and passive acceptance of community practices (social
demand)” (p. 9).
These compliance strategies have not eliminated the antivaccination movement that seeks
to stop vaccination, and its arguments cover the spectrum from reasonable discourse to hysterical
paranoia. The antivaccination argument begins with vaccination being counterintuitive.
Bioethically speaking, what sense does it make to inject a well baby with a potent, biologically
active vaccine that contains elements of the very disease it is supposed to prevent? The
vaccination is literally an infection with a variant of the disease-causing agent. It is also feared
that vaccines contain poisons and chemicals, including mercury, formaldehyde, antibiotics, and
aluminum salts (Link, 2005). Vaccines also contain material derived from animals, including
cattle, horse, chicken, monkey, and duck. Some vaccines have been recalled or discontinued
because they were toxic or ineffective. The rotavirus and Lyme disease vaccines are two recent
examples. Some vaccines have serious side effects. Vaccines have been known to cause
convulsions, fever, rashes, nerve and brain damage, and even death (Link, 2005).
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The antivaccinationists also argue that the number of cases of common childhood
diseases had dropped dramatically from the pre-vaccine era, and, on the other hand, even some
vaccinated children get infected. More sophisticated critics are concerned about the age shift
caused by vaccines. Natural infection often causes lifelong immunity, whereas vaccine-induced
immunity tends to wear off. This results in a population of nonimmune adults, and many mild
childhood diseases are more severe in adults. For example, they argue that the chickenpox
vaccine is unnecessary and may cause an epidemic of adult shingles in years to come.
Politics and financial profits are entwined with medical policymaking. Those against
mandatory vaccination argue that the medical establishment, the pharmaceutical industry, and
political interest groups influence vaccine policies to favor their interests. This whiff of
corruption further energizes the antivaccination group, reinforcing their resentment of the policy
of mandatory vaccination. I provide some examples of this corruption later in the paper.
So why vaccinate? Vaccination saves millions of lives and prevents a world of suffering.
We know that vaccines work. Epidemiological studies, clinical trials, antibody titers, and
recurrence of disease when vaccination is discontinued all prove that vaccines work (Allen, A.,
2007). None of them work 100 percent of the time; none of them are 100 percent safe. Each
vaccine has unique problems and benefits. The reduction in the number of cases before the
vaccine era was probably due to better hygiene, antibiotics, and better nutrition (Link, 2005).
However, in all cases the common infections persisted at lower but significant levels until a
vaccine became available. No disease has been known to disappear spontaneously (Allen, A.,
2007). Now smallpox is gone; polio is not far behind.
Developing longer-lasting vaccines or developing boosters for adults can address the
problem of age shift. The concern about autism and the many other unproven toxicities is usually
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due to confusion about causality and coincidence. Autism typically starts at the age when
immunizations are routinely administered so of course the two appear to be related, but are not
(Link, 2005). The mercury story is complicated but moot in the United States because there is no
longer mercury in the routine vaccines. The other chemicals and animal products are in trace
amounts and harmless (Link, 2005).
Sometimes a vaccine is a victim of its own success. As the disease disappears, the side
effects alone remain. Today’s parents have never seen the horror of whooping cough or the grisly
death of tetanus so their tolerance of vaccine side effects, like fever and soreness at the injection
site, approaches zero. The controversy gets really heated when the issue is vaccine injury. How
many infections or deaths prevented justify a death from a vaccine? Some would say it is never
justified; better a thousand cases of measles than the life of one healthy child. Peggy O’Mara
(1997) even goes so far as to have written, “It is immoral to risk the health of even one child in
order to save the lives of many” (p. 3). To the medical scientist such a position is illogical,
inhibits further medical advances, and denies children the freedom to grow up healthy. The pro
and con sides of the vaccine debate, having staked opposing positions based on mutually
exclusive premises, will likely span across another hundred years of controversy.
The Vaccine Machine – How Drug Companies Can Influence Vaccine Policy
As I stated previously, the CDC dictates the United States immunization policy. It
appoints members of the Advisory Committee on Immunization Practices (ACIP), which then
makes a schedule of vaccine recommendations and publishes it in the CDC Morbidity and
Mortality Weekly Report (Schlafly, 1999). The “advice” of ACIP is what trickles down to a
doctor’s office or clinic. Members who serve on the advisory committees are made up of experts
outside the government. On June 15, 2000 Republican congressman Dan Burton of Indiana
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presided over the Government Reform Committee hearings on conflicts of interest in the vaccine
approval process. Burton (2000) has affirmed:
The FDA and CDC rely on advisory committees to help them make vaccine policies that
affect every child in this country. We’ve looked carefully at conflicts of interest. We’ve
taken a good hard look at whether the pharmaceutical industry has too much influence
over these committees. From the evidence we found, I think they do. (p. 4)
Rep. Burton learned that many advisory panel members had received research grants from drug
companies, either for themselves or their academic institutions; others received money for
speaking honoraria, travel funds or other benefits (Kirby, 2005). Some were found to even share
patents on certain vaccines. Even though they were required to recuse themselves from voting on
products in which they held a direct financial stake, the advisors could lobby colleagues in
closed-door meetings (Kirby, 2005).
Pharmaceutical companies are big campaign finance contributors, having given $44
million over the last ten years (Angell, 2005). FDA scientists who approve drugs or decide upon
regulations are also current, past, or future employees of the drug industry (Allen, A., 2007).
They are inextricably tied to the industry that they are supposed to be policing. What this means
is that the FDA is effectively financed and staffed by the pharmaceutical industry. The agencies
“work for” the industry, not for consumers, because consumers are not making campaign
contributions nor are they arbiters of job security.
Burton believed the conflicts might have played a role in why so many new vaccines
were added in quick succession to the immunization schedule, including the ill-fated Rotashield.
Rotashield was a vaccine given to children against rotavirus, a diarrhea-causing colonist of the
gut (Allen, A., 2007). ACIP placed Rotashield on the list of recommended vaccines on June 25,
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1998. Rotashield was then pulled from the market on July 16, 1999 because it was found to
cause intussusceptions, an inversion of the intestine within itself that sometimes required surgery
and could even be fatal (Rennels, 2000). It was later disclosed that members of the FDA and
CDC advisory committees who made decisions about what immunizations should be mandated
owned stock in drug companies that made the vaccines (Kirby, 2005). Three out of five of the
members of the FDA’s advisory committee who voted for the rotavirus vaccine (Rotashield) had
conflicts of interest that were waived (Kirby 2005). Rep. Burton (2000) has charged:
The entire process has been polluted and the public trust has been violated. No individual
who stands to gain financially from the decisions regarding vaccines that may be
mandated for use should be participating in the discussion or policy making for vaccines.
(p. 6)
Marcia Angell (2005) has contended, “The heavy hand of Big Pharma is felt at all levels of
government” (p. 193). The “heavy hand” unfortunately includes the FDA and CDC. Even with
corruption in the system it only behooves all involved to make sure vaccines are safe to
administer to children.
How the FDA Ensures Vaccines Safety
First, do no harm.
-Hippocrates
The highest standards of safety must be required of vaccine manufacturers because the
majority of vaccines are administered to healthy infants and children. The Public Health Service
Act provides the federal government with authority to regulate biological products such as
vaccines (Hargan, O’Brien, Sherman, & Benjamin, 2007). Vaccines are evaluated by the FDA-
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specifically the Center for Biologics Evaluation and Research (CBER). The CBER requires drug
companies to supply data on vaccine safety and effectiveness.
The first step to licensing a new vaccine is safety testing on animals. This step is called
the safety trials. Animal safety tests usually come at the end of a long process of safety data
collection that may include testing the product “in vitro” (i.e. in a test-tube) and using a computer
program to simulate what might happen to the drug inside the body. The regulations on what
safety data are required for a new product varies from country to country (and also from drug to
drug). The FDA requires all new drugs, including vaccines, to be tested on animals before human
trials may start. Generally, two or more species (one rodent, one non-rodent) are tested because a
drug may affect one species differently from another. Only after successful animal testing has
been done does testing in people begin.
A drug company that wants to begin clinical trials of a new vaccine must submit an
Investigational New Drug (IND) application to the FDA. The IND describes the vaccine, the
method of manufacture, and the quality control testing (safety trials) done prior to administering
the vaccine to humans (CDC, 2001). The IND must also include the vaccine’s safety and ability
to elicit an immune response in animals. Pre-marketing clinical trials usually occur in three
phases.
Initial human studies, referred to as Phase I trials, evaluate basic safety and identify
serious adverse effects, and immunogenicity or the ability to produce an immune response.
These trials are small, between 20 and 100 patients, and last just several months. Phase II trials
enroll up to hundreds of subjects and include dose-ranging studies. This phase can take up to 2
years to complete. Phase III includes several hundred to several thousand people and provides
the critical documentation of effectiveness and important safety data required for licensing. But
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until a vaccine is given to the general population, all potential adverse events cannot be
anticipated. Thus, many vaccines undergo Phase 4 studies – formal studies on a vaccine once it is
on the market. The government also relies on the Vaccine Adverse Event Reporting System
(VAERS) to identify problems after marketing begins.
The FDA and CDC manage VAERS, a system the two agencies developed in response to
the National Vaccine Injury Act of 1986. Anyone – physicians, nurses, vaccine manufacturers,
patients, and parents – can report to VAERS an adverse event that may be associated with any
vaccine. Susan Ellenberg, director of CBER’s division of biostatistics and epidemiology, has
stated, “What we’re most interested in with VAERS is identifying any new problem, particularly
serious problems, that might be so rare that it wasn’t noticed or detected during clinical trials”
(cited in Stehlin, 1995). The Vaccine Datalink is another tighter program, administered by the
CDC, with seven million HMOs that report vaccine events (Hargan et al., 2007).
On the surface, it may seem that approaching vaccine safety as a continuous process,
always looking into problems and potential problems, implies that vaccines are unsafe. Jesse
Goodman, deputy director for medicine at CBER, has stated, "It's actually a reflection of our
ongoing commitment to safety, and to assuring the prevention of potentially lethal infectious
diseases. It's also the nature of science to seek and implement improvements which make for
safer and more effective medical products" (cited in Meadows, 2001, p. 18).
Since 1996, for example, CBER has licensed several acellular pertussis vaccines.
Acellular pertussis vaccines use only parts of the disease-causing bacteria and are associated
with fewer side effects than the whole cell pertussis vaccines that had been in use. In 1997, the
ACIP recommended a switch from using the whole cell pertussis component of the diphtheria,
tetanus, pertussis (DTP) vaccine to using acellular pertussis vaccines for all five doses in the
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childhood schedule (Meadows, 2001, p. 18).
The National Institute of Allergy and Infectious Diseases (NIAID) sponsored clinical
trials for some of the experimental acellular vaccines. "We set out to develop an improved
vaccine that would be as effective as the standard whole cell vaccine but cause less extended
crying, fevers, and other side effects," said Carole Heilman, director of NIAID's division of
microbiology and infectious diseases (cited in Meadows, 2001 p. 18). CBER scientists also
played a critical role by developing methods to evaluate the acellular vaccines, which helped
them get to clinical trials faster.
There have been other recent policy changes to improve vaccine safety, including ACIP's
1999 recommendation to change from the use of oral polio vaccine (OPV) to the inactivated
polio virus (IPV). OPV had been highly effective in controlling naturally occurring polio
outbreaks, preventing thousands of cases of paralysis a year. But as a live virus, it mutated in
extremely rare cases to cause polio itself. Continued use of OPV resulted in about 10 cases of
paralytic polio each year among millions vaccinated and their contacts, according to William
Egan, deputy director of CBER's Office of Vaccine Research and Review (Brotherton & Gold,
2008). Switching to the use of IPV eliminated this risk and was appropriate once epidemic polio
was controlled.
"There are times when we also take action even when there is just the theoretical
potential for harm," Goodman says (cited in Meadows, 2001, p. 18). Thimerosal, a mercurycontaining compound, had been the most widely used preservative in vaccines. Its use in minute
amounts helped to prevent bacteria from contaminating multi-dose vials of vaccines and other
medicines, protecting against potentially serious infections. But thimerosal has been nearly
eliminated from vaccines because of legitimate and growing scientific concerns about the

126

possible effects of mercury on the human nervous system (Link, 2005).
Even though there are no convincing data that show harm because of thimerosal in
vaccines, the U.S. Public Health Service recommended moving rapidly to vaccines that are
thimerosal-free. The FDA encouraged manufacturers to comply and set the highest priority for
its reviews of such products. As a result, all recommended pediatric vaccines available are now
thimerosal free or have greatly reduced thimerosal contents. In March 2001, the FDA approved a
newly formulated version of Tripedia, a diphtheria, tetanus toxoids, and acellular pertussis
(DTaP) vaccine, with only a trace amount of thimerosal (Link, 2005). Like any medicine,
vaccines carry a small risk of serious harm such as severe allergic reaction. But experts point out
that the risk of being harmed by a vaccine is much lower than the risk, which comes with
infectious diseases (Allen, A., 2007).
Compensating for the Side Effects of Vaccines
Concerns over vaccine safety have the potential to derail immunization programs. This
may, in turn, cause considerable harm through resurgence of disease as vaccination coverage
falls (Brotherton & Gold, 2008). For example, fears the measles-mumps-rubella (MMR) vaccine
might have caused autism resulted in the recent resurgence of measles in the United Kingdom
(McIntyre & Leask, 2008). Thus, monitoring and ensuring vaccine safety is critical to the
success of any immunization program.
There are two critical questions about a vaccine or any other medical intervention: 1) Is it
effective? 2) What are the adverse side effects? (Angell, 2005). The scientific answer to these
questions comes from clinical trials. When a new vaccine is first licensed, the majority of
vaccine safety data is derived from Phase I, II, and III clinical trials. Marcia Angell (2005) has
stated, “The clinical stage of drug development is regulated by the Food and Drug
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Administration (FDA)” (p. 27). Specifically, the FDA’s Center for Biologics Evaluation and
Research (CBER) is responsible for regulating vaccines in the United States. Vaccine clinical
development follows the same general pathway as drugs and other biologics.
The CBER was developed to help keep tabs on the side effects that vaccines cause.
Vaccine regulation was once in the control of the National Institutes of Health (NIH). A
reorganization of vaccine regulation took place after the Cutter incident in 1955. The Cutter
incident was one of the worst pharmaceutical disasters in U.S. history causing several thousand
children to be exposed to live poliovirus after being immunized (Allen, A., 2007). This
watershed event in medical history, a disaster that could have “wrecked the polio eradication
campaign and all vaccination programs, in fact inspired major reforms in the public health
service, bolstering new structures that would serve the country well over the next five decades”
(Allen, A., 2007, p. 199). Paul Offit (2005b) has stated, “The Cutter incident resulted in the first
coordinated national response to a medical emergency and in the creation of a better system of
regulating vaccines” (p. 1411).
The CDC has set up active disease surveillance units; investigations by the CDC’s new
Epidemic Intelligence Service established the credibility of that group which would become the
crown jewel of the agency. Seeing the need for better vaccine regulation, the government
replaced the Laboratory of Biologics Control with the much larger Division of Biologic
Standards and expanded the scientific staff from 10 to 110 (Allen, A., 2007).
In the early 1980s, following reports of harmful side effects after the administration of
the DTP vaccine, numerous lawsuits were filed against vaccine manufacturers. Parents of
children with severe vaccine-related injuries had few options to cope with random tragedy.
Health insurance rarely covered long-term care. Thus, parents resorted to the courts, suing the
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vaccine manufacturers for producing or distributing a defective vaccine or for failing to warn of
the risks. The difficulty in predicting adverse reactions made it equally difficult to prove that the
vaccine caused an injury. Vaccine manufacturers found these lawsuits oppressive. The
possibility of losing even one expensive lawsuit made manufactures nervous, given vaccines’
relatively low profit margins. The number of domestic vaccine producers had been declining
since the 1960s (Mariner, 1992). Public health officials worried that if manufacturers abandoned
the vaccine market, the country might be left without an adequate vaccine supply. This litigation
led to concerns about the continued viability of the U.S. vaccine industry.
In response, Congress created the National Vaccine Injury Act of 1986 as a compromise
solution to 2 decades of controversy over whether and how adverse reactions to vaccines should
be compensated. Among its provisions, the act established the National Vaccine injury
Compensation Program (VICP). Those injured by vaccines can make claims against a special
government fund. Congress fashioned this no-fault system to benefit people who suffer vaccinerelated injuries (Vernick, Rutkow, & Salmon, 2007). “No-fault” means that compensation is
provided without the need to show that a wrong was committed. To be eligible for compensation,
a vaccine-related injury or death ordinarily must occur after the administration of a vaccine listed
on a Vaccine Injury Table created by the law (Vernick et al., 2007). In addition, the petitioner
must have suffered an injury listed on the table within a prescribed time frame. For example, to
qualify for compensation following a tetanus vaccination, the injury must be recognized in the
table and have occurred within 4 hours after the vaccine’s administration (Vernick et al., 2007).
Under the VICP, several types of compensation are available. Compensation can include medical
expenses, loss of earning capacity, up to $250,000 for pain and suffering, and attorney’s fees
(Mariner, 1992). Congress has established a federal $0.75 excise tax per covered vaccine that
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funds the VICP (Hargan et al., 2007). The VICP remains the model method for ensuring that all
persons harmed by vaccines are compensated quickly and generously, while protecting
companies that make lifesaving products from abuses of the tort system.
Summary – Our Best Shot
Does U.S. vaccine policy infringe on individual rights? Yes. Is there corruption in the
organizations that regulate vaccine policy? Yes. Are vaccines 100% safe? No. Is there a
bioethical concern with giving a perfectly healthy baby a drug to prevent a disease that he or she
may come into contact in the future? Maybe. All these concerns being voiced do not alter the
undisputed fact that vaccines are still considered the greatest medical achievement known to man
(Allen, A., 2007).
In this time of great uncertainty, especially with an impending threat of bioterrorism, the
public and politicians need to understand the danger that thoughtless actions pose to the great
immunological commons we have built by decades of vaccinating children. If the vaccination
program is to remain successful in eliminating disease, all interested parties need to continue the
discourse of vaccines true risks and importantly its benefits. Elected officials must play their part
by providing subsidies for vaccines when called for, by providing legal protection from lawsuits
for pharmaceutical companies that are doing their honest best to create safe vaccines, and by
assuring that those who are accidentally damaged by vaccination will be properly compensated.
Only then will vaccination fulfill its promise as our collective commitment to protect children
and our population as a whole from infectious disease.
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CHAPTER 5
CRITICAL ANAYLSIS – THE POLITICAL DEBATE
The purpose of this theoretical inquiry was to elucidate the political, social, and
bioethical controversy surrounding the HPV vaccine mandate. The research was inspired by
bioethical feminist theory as a theoretical framework. This chapter provides the underlying
origins of the political controversy surrounding the HPV vaccine. Jacob Heller, a sociology
professor at SUNY Old Westbury, has stated:
Public and heated controversies like those surrounding the HPV vaccine, however, rarely
concern the vaccine itself, which typically receives high and hopeful praise once it has
passed scientific muster. Instead, conflicts seem to arise around context: the laws
regarding vaccine use, the role of corporate lobbying, or the politics of a vaccine
designed to protect against a controversial disease. (2008, p. 2)
This chapter focused on the political context of the HPV vaccine controversy in an attempt to
understand how we have viewed and understood the role of vaccines in our society.
Let the Debate Commence
Every controversy or debate has two or more points of view. The HPV vaccine is no
different; there are several dichotomous distinctions that can be applied to the discussion:
political versus social, government versus parents, mandate versus autonomy, rich versus poor,
and girls versus boys. Each of these debates are found somewhere within the HPV vaccine
literature. The question is, “Why has the HPV vaccine evoked such a storm of controversy?” We
have a drug that has been tested safe, effective, and cancer-preventing. So why, since June of
2006, has a shroud of controversy surrounded this vaccine?
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According to Anne Donchin and Laura Purdy (1999), bioethical feminist theory “requires
us to take nothing for granted, and to question everything” (p. 3). In laying out this debate, both
sides are scrutinized for their validity and contribution to the problem at hand – “Should the HPV
vaccine be mandated for adolescent girls in order to attend school?” The discussion begins with
the rationale for a government mandate of the HPV vaccine. I then discuss what happened when
the Texas state government tried to invoke a school-linked mandate for girls. I end the political
discussion with the tumultuous story of Merck’s lobbying campaign and heavy marketing of the
Gardasil vaccine.
Reasons for Mandating the HPV Vaccine
Before I explore the reasons for requiring the HPV vaccine for school enrollment it is
important to define the term “mandate” as it applies to vaccines. The word mandate comes from
the Latin terms manus, for hand, and dare, for give. A mandate is generally considered to be a
command, handed down from a superior to subordinate (Wynia, 2007a). In public health,
mandates must fit two criteria. First, opting out of the mandate requires some action beyond
simply saying no (Wynia, 2007a). Second, there is an enforcement mechanism that encourages
compliance (Wynia, 2007a). Wynia (2007a) has written, “In short, a mandate is not the same as a
mere recommendation” (p. 2).
Those that feel that the HPV vaccine should be mandated provide the framework for the
political side of the debate. State and federal policy makers, physicians, public health workers,
the professional medical and public bureaucracies, and pharmaceutical companies are at the
forefront of the political discussion. Jacob Heller (2008) has stated, “Their unanimity about
vaccines as beneficent and necessary, coupled with almost no tolerance for dissent about
vaccines’ continued use, quickly marginalizes any opposition to vaccines” (p. 23). This section
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laid out the reasoning behind the push to mandate the vaccine for adolescent girls.
HPV Vaccine is Effective at Preventing Cervical Cancer
The HPV vaccine represents an important medical accomplishment and a major public
health achievement. This vaccine has been tested worldwide with more than 11,000 females
between the ages of 9 and 26 years and has been proven to be 100% effective in preventing the
four HPV strains that are responsible for 70% of cervical cancers and 90% of genital warts
(Vamos, McDermott, & Daley, 2008). In addition to the efficacy, the vaccine has no serious side
effects (Krishnan, 2008). A successful vaccination campaign can significantly reduce cervical
disease and the burden of invasive procedures, similar to what I experienced, that remove
detected precancerous and cancerous lesions of the cervix. By combining routine Pap smear
exams and HPV vaccination can drastically reduce cervical disease (Vamos et al., 2008).
Pharmaceutical companies have lobbied for the mandating of the HPV vaccine as a way of
eradicating cervical cancer (Vamos et al., 2008). This lobbying campaign is misleading because
the HPV vaccine protects against the two types of HPV that are responsible for 70% of cervical
cancers and not against the types that cause the other 30% of cervical cancers (Krishnan, 2008).
A more accurate description would be that the HPV vaccine has the potential to “reduce” the
incidence of cervical cancer, but not “eradicate” it. The only clear way of completely eradicating
cervical cancer is to make sure that all women, in every country, have access to the HPV
vaccine, regular Pap smear exams, and follow-up treatments. An unfortunate consequence of the
hierarchal structure of any society is that nondominant, powerless groups are, by definition,
always marginalized; when persons of these groups become sick, they are doubly marginalized
(Holmes, 1999). So is a worldwide campaign to vaccinate and provide Pap smear exams to every
woman unattainable?
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Vaccinate Before Onset of Sexual Activity
To be most effective in preventing HPV infection, the HPV vaccine will need to be
administered before the onset of sexual activity. The vaccine is only effective at preventing not
treating an HPV infection. Public health experts say that the majority teenagers have sex by the
time they finish high school (Hendricks, 2007). The CDC’s National Survey of Family Growth,
conducted in 2002, shows that 69% of 18- to 19-year-old women, and 64% of men in that age
group, have had sex (Hendricks, 2007). Before high school graduation, 14% of sexually active
teenagers have had four or more sexual partners (Krishnan, 2008). Targeting adolescent girls
before they reach high school is imperative in protecting them from being infected from HPV.
Heller (2008) has asserted, “Vaccines by themselves do not prevent disease, they need to be
delivered to the susceptible population” (p. 6). A school-linked mandate for HPV would be an
effective and efficient way to protect the public from a widespread sexually transmitted disease.
The decision to recommend girls between the ages 11 and 12 to receive the vaccine is sound,
based upon the science of vaccine development and bolstered by the practicalities of decades of
successful vaccination programs. John Niederhuber, Acting Director of the National Cancer
Institutes, has stated:
The entire cancer community should be elated and proud. This [HPV vaccine] approval is
a watershed moment that highlights the very best of biomedical research: the translation
of basic and population science into an intervention that will save hundreds of thousands
of lives. (2006, p. 3)
For those parents who do not want to vaccinate their daughters with the HPV vaccine, all 50
states allow them to eschew required vaccines for medical reasons, 48 states allow exemptions
for religious beliefs, and 20 states allow exclusion for philosophical reasons (Vamos et al., 2008)
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Mandates Force People to Vaccinate
In California, State Assembly member Edward Hernandez has said he will introduce a
mandatory measure despite protest from parents. “There’s a great amount of data that shows that
people don’t get vaccinations unless they’re mandated. Disease rates don’t start to decline unless
it’s mandated”, says Tim Valderrama, Hernandez’s legislative director (cited in Udesky, 2007, p.
979). In the 1970s in Sweden, after reports that pertussis (whooping cough) was no longer a
serious disease and was not mandated, vaccine coverage fell from 90% in 1974 to 12% in 1979
(Jacob, Bradley, & Barone, 2005). Disease rates subsequently multiplied 30-fold (Jacob et al.,
2005). “Mandates provide a reminder,” said Dr. Louis Cooper, a past president of the American
Academy of Pediatrics (cited in Hendricks, 2007, ¶22). Cooper has stated, “When several new
vaccines came online in the 1950s and 60s, including polio, measles, mumps and rubella, disease
rates did not decline significantly until states started requiring vaccination for school enrollment”
(Hendricks, 2007, ¶21). California Assembly woman Sally Lieber also supports the HPV vaccine
mandate. She has stated, “Requiring vaccinations against a number of diseases for school
enrollment gives us the best chance of controlling preventable diseases in society” (Hendricks,
2007, ¶22). Vaccination is part of our public health and well-being; therefore, it is tied to our
public policy. Bradley Monk, a professor of gynecologic oncology at the University of
California-Irvine Medical Center, has stated, “Everyday 10 women die of cervical cancer in the
United States, and to delay mandating this vaccine because of some uncertainty is like not using
penicillin because you’re waiting for a better antibiotic” (Savage, 2007, p. 666).
Adolescence is the Last Opportunity
Another argument for mandating the HPV vaccine is based on the fact that adolescent
children and their parents rarely visit family physicians, and would not have the opportunity to
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learn about the HPV vaccine. By the time children reach the age of six, all of the major
mandatory vaccines have been given. The onset of adolescence often is a time when patients
generally are in relatively good health and do not visit their physicians; the majority of
adolescent visits are for acute illness and injury (Temte, 2007). Making the HPV vaccine
compulsory for adolescent girls, ages 11 and 12, would ensure that they do not miss the best
opportunity for receiving the immunization. Daley and McDermott have stated:
This age group is one that is still easily assessable as a cohort to receive widespread
protection through school entry programs. Implementing the vaccine in this way
guarantees that few adolescents will miss out on this protection, and those who do will
benefit from herd immunity. (2007, p. 178)
Cost Effectiveness
As with all medical interventions, the HPV vaccine will come at a cost, although there is
little evidence to suggest what that cost will be. One study by Sanders and Tiara (2003)
evaluated the cost-effectiveness of giving the HPV vaccine to adolescent girls. The study (target
population: all girls living in the United States) concluded that a vaccine that afforded 75% of
those immunized would result in a 2.8 days gain in life expectancy. The study hypothesized that
if all 12-year-old girls in the U.S. were vaccinated, it would prevent more than 1,300 cervical
cancer-related deaths in their lifetimes, similar to the benefits of existing vaccination programs
for other diseases (Sanders & Tiara, 2003). Another argument that may be used to justify a
mandate for the HPV vaccine is that it is more cost effective to immunize and also cheaper than
increasing the frequency of current pap screening tests (Kulasingam & Myers, 2003). Dr. Darrin
Strickland, an obstetrician and gynecologist, charges $135 plus $90 for lab fees for an annual pap
smear, between $200-$400 to treat genital warts, between $700-$1300 to treat pre-cancerous
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cervical lesions, and between $3500-$5000 for a hysterectomy due to cervical cancer (personal
communication, July 5, 2007). The cost of the hysterectomy does not include pathology costs,
radiation or chemotherapy, or treatment by an oncologist. Ralph Insinga (2003) suggests the cost
for treating cervical cancer can run as much as $26,000. The high price tag of the HPV vaccine
has been criticized, but in light of the cost of treating genital warts, pre-cancerous lesions, or
cervical cancer, the immunization seems to be the cheaper alternative.
About 75% of the 4.7 million abnormal Pap smear screenings that require costly followup every year are related to HPV (Merck, 2006). Some authorities have estimated that five
billion healthcare dollars are spent in the United States annually on HPV-related disease (Vamos
et al., 2008). In addition to expenses, high stress levels associated with repeated testing and everpresent threat of cervical cancer may be eliminated with the HPV vaccine (Biedrzycki, 2007).
Protecting Women Who Do Not Get Annual Exams
Mandating the HPV vaccine would also help protect women who do not receive regular
Pap smear screenings. In the U.S., nearly 3,700 women who will die of cervical cancer will have
something in common – no screening or no treatment follow-up after screening. These facts
speak to access to healthcare, and the conclusion is clear – cervical cancer is a disease of
disparity. Women who are able to afford screening by Pap tests and HPV tests will not likely die
of the disease (Daley & McDermott, 2007). Rather, the women who lack access to screening and
treatment become victims of an otherwise largely preventable disease and cause of death.
Implementation of a mandatory school entry vaccine program guarantees that few adolescents
will miss out on this protection, and those who do will benefit from herd immunity. Deborah
Arrindell, Vice President of health policy at the American Social Health Association, has stated,
“Middle school may be the last public health gate we all walk through together, before children
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start dropping out of schools, or getting a crummy job without health insurance, or entering the
workforce in general with its fragmented healthcare system” (Houppert, 2007, p. 20).
Arrindell also has contended, “It is vital to mandate the shots. That’s because leaving the
shots voluntary means some girls will get them, but a lot won’t. And those who won’t get the
shots are those that can’t afford them” (cited in Houppert, 2007, p. 20). If the HPV vaccine is a
mandated immunization, then insurance companies are more likely to cover the cost of the
injections, and Medicaid will pay for federally funded vaccine programs that offer free vaccines
for uninsured children (Houppert, 2007).
Protects Against Genital Warts
Mandating the HPV vaccine not only has the potential of protecting against cervical
cancer, it also protects the recipient against the types of HPV that cause 90% of the cases of
genital warts (Harvard Women’s Health Watch, 2007). There are nearly 1 million cases of
genital warts per year in the United States, with both men and women equally affected
(Krishnan, 2008). Gardasil is the only vaccine that is almost 100% effective against HPV types
6 and 11, which account for the majority of genital warts cases (Sharma, 2008). There may also
be protection from HPV-induced oral and anal cancers, and recurrent respiratory papillomas
(Krishnan, 2008).
Lesson Learned from the Hepatitis B Vaccine
Merck’s prior experience with its hepatitis B virus (HBV) vaccine helped frame its
strategy for its HPV vaccine. HBV means inflammation of the liver. HBV can lead to liver
failure, jaundice, and in severe cases, death (Link, 2005). Infections with HBV occur by
transmission from mother to fetus or from mother to newborn; by blood transfusion; or by
contact with sexual secretions, including semen and vaginal secretions (Link, 2005).

138

Both Merck and federal agencies initially targeted the HBV vaccine for a limited market.
ACIP defined the target population for the HBV vaccine narrowly: health care workers who may
have contact with blood and other bodily fluids, men who have sex with men, intravenous drug
users, prisoners and staff in custodial institutions, and pregnant women in high-risk groups
(CDC, 1982). Merck did not suggest that because hepatitis B infections may lead to cirrhosis and
liver cancer, the vaccine should be universal. Nor did it challenge the ACIP’s presumption that
most Americans were at low risk of contracting or dying from HBV-related liver diseases, which
in 1982 amounted to approximately 4000 cases (Rothman & Rothman, 2009). Although 800
individuals died annually from hepatitis B-related liver cancer, Merck did not promote the
vaccine as an anticancer product (CDC, 1982).
Targeting high-risks groups was not working because the groups where the virus was
circulating were hard to reach, and the activities known to spread it were stigmatizing (Allen, A.,
2007). So as a result, hepatitis B rates did not decline (Sharfstein, 2000). One reason was an
absence of government reimbursement programs. Arthur Allen has stated, “services for junkies
and gay men were not a popular line item” (2007. p.311). ACIP, disappointed by the results, in
1991 proposed universal infant vaccination, “before humans who carried it had a chance to make
the behavioral choices that spread it” (Allen, A., 2007, p. 311). Nevertheless, use of the HBV
vaccine lagged. Link has written:
On its first introduction into the medical community and the general public, there was
considerable resistance to the use of the vaccine. The association of hepatitis B with gays,
whores, and addicts did not make the vaccine especially popular, and many parents (and
doctors) considered themselves and their children at low risk. (2005, p. 115)
A 1992 Merck-funded study reported that two-thirds of pediatricians and one-third of family

139

physicians thought universal vaccination desirable; however, only half the pediatricians and onequarter the family physicians made HBV vaccination standard practice (Freed, Bordley, Clark, &
Konrad, 1994). Solo practitioners were unwilling to stock the vaccine or await insurance
company reimbursement, and many parents objected to adding another injection to the
immunization schedule (Freed et al., 1994).
Despite initial doubts, states moved quickly to include HBV vaccination to their
mandatory programs (Allen, A., 2007). In 1994, to reduce the number of unvaccinated children,
Congress enacted the Vaccines for Children program, covering uninsured and Medicaid-eligible
children. Administered by the CDC, the program purchases ACIP-recommended vaccines and
supplies them to state and local health departments, who in turn distribute the vaccines to
participating clinicians (Orenstein, Douglas, Rodewald, & Hinman, 2005). Once funding was
available and universal vaccination recommended, use of the HBV vaccine soared. By 2002,
90% of children younger than 3 years had received it (CDC, 2002). The CDC estimated that in
2002 there were 79,000 new HBV infections, compared to 200,000 to 300,000 in 1982 (CDC,
2002). The vaccine was working. Allen has written:
Part of the credit went to safe-sex behavior in the age of AIDS. But vaccination was
having a major impact on infections in babies. There was less hepatitis B among
teenagers who’d been vaccinated as children and among adults vaccinated as teenagers.
(2007, p. 312)
Interestingly, HBV is the very first vaccine administered to infants. Newborns get the first of
three doses before they leave the hospital (CDC, 2009d).
I included the story of HBV because its tumultuous beginning parallels that of the HPV
vaccine – both viruses are associated with sexually transmitted diseases; both of the vaccines
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faced criticism because contracting the disease was based on a behavioral choice – promiscuous
behavior; both require three doses and are two of the most expensive vaccines; both vaccines
faced the question if immunity would last into adulthood when people started engaging in the
behaviors that put them at risk; both vaccines were developed to target a specific group (HBV –
drug abusers, gay men and HPV – sexually inactive girls); and both vaccines have shown great
success in reducing the number of infected people for their specific diseases (Allen, A., 2007).
The manufacturing and marketing strategies for the HPV vaccine sought to overcome the
obstacles that the HBV had encountered: avoid limiting the vaccine to high-risk populations,
promote it for all women, and secure government reimbursement and mandates (Rothman, S. &
Rothman, D., 2009). Even in deploying these strategies, Merck encountered problems that it is
still trying to overcome. It will be interesting to see if Gardasil proves to provide lasting
immunity will it be mandated for infant girls before they leave the hospital too?
I have discussed the reasoning and logic behind the government’s push to mandate the
HPV vaccine. There are certainly valid justifications for a school-linked mandate. Some of these
justifications have fueled the public’s skepticism about the government playing “big brother” in
terms of dictating health care policy. The next section discusses the reasons that a political
debate over the HPV vaccine has ensued.
Causes of the Political Skepticism in Mandating the HPV Vaccine
Success in public health relies on public trust.
-Matthew K. Wynia (2007)
Vaccinations are widely viewed as among the most cost effective and widely used public
health interventions. Yet, since Dr. Jenner’s time, vaccination has provoked popular and vocal
resistance. Although the population of colonial America generally accepted vaccination, minority
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opposition arose in many quarters. Some opponents expressed valid scientific objections about
effectiveness; some worried that vaccination transmitted other diseases (like syphilis) or caused
harmful effects; and others objected on grounds of religious or philosophical principles.
Compulsory vaccination laws were once viewed as an unwarranted governmental interference
with one’s autonomy and liberty to make his or her personal health care decisions. This latter
view is attributable in part to overly assertive public health practices and general public distrust
of the public health objectives and policies. A close inspection of the relationship between an
aggressive pharmaceutical company and the government gives a citizen good reason to distrust
public health policies especially when the pharmaceutical company’s marketing practices are
reviewed.
Since the approval of Gardasil in 2006 worldwide sales have been estimated in the
billions (Merck, 2008). In the United States, 25% of girls aged 13 to 17 have received at least 1
of 3 recommended doses (CDC, 2008a). To achieve these statistics and profit, the marketing of
this vaccine broke with traditional practices. Up until this time, vaccines have been identified by
the disease they were preventing (polio, rubella, or measles) or by their creators (Salk, Pasteur,
or Sabin) (Allen, A., 2007). This HPV vaccine followed a different model. It was identified by a
trade name, Gardasil, and promoted primarily to “guard” not against HPV viruses or sexually
transmitted diseases but against cervical cancer. The marketing campaign that follows, according
to Merck’s chief executive officer, proceeded “flawlessly” (Herskovits, 2007, p. 60). In 2006,
Gardasil was named the pharmaceutical “brand of the year” for building a market “out of thin
air” (Herskovits, 2007, p. 60).
Within weeks following the FDA’a approval of Gardasil, Merck started an
unprecedented lobbying blitz, securing 23 states’ legislation that would mandate vaccination of
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pre-teen girls. Unusually, Merck also targeted adolescents directly through television ads in
which free-spirited young girls jump rope, pummel punching bags, or skateboard, declaiming
“one less” cervical cancer case, never actually mentioning that HPV is a sexually transmitted
disease; while mothers gently admonish, “Gardasil may not fully protect everyone” and
tenderly list the side effects. This all seemed to be working nicely—by the end of 2007 the
company had already sold $1.5 billion worth of the vaccine worldwide (Merck, 2008; see
Appendix B). But this marketing sensation soon began to unravel when talk of mandating the
vaccine for school entrance started to hit the airwaves.
The debate against mandating Gardasil comes from many different positions, and
arguments are touted by conservative politicians, civil rights groups, evangelical groups, ethical
groups, abstinence-only groups, anti-big pharmaceutical groups, and concerned parents. The
debate against the HPV vaccine started with the impulsive actions of the governor of Texas. This
incident raised many eyebrows and skepticism about the ulterior motives behind the hasty
decision to mandate Gardasil in Texas.
On February 2, 2007, Gov. Rick Perry issued an executive order that required schoolgirls
to be immunized against HPV. By employing an executive order, Perry sidestepped opposition in
the Legislature from conservatives and parents’ right groups who fear such a requirement would
condone premarital sex and interfere with the way Texans raise their children. The executive
order would require that girls entering the sixth grade receive Gardasil. Governor Perry also
directed state health officials to make the vaccine available free for girls 9 to 18 who are
uninsured or whose insurance does not cover vaccines. In addition, he ordered the Medicaid offer
Gardasil to women ages 19 to 21. Governor Perry stated, “The HPV vaccine provided us with
an incredible opportunity to effectively target and prevent cervical cancer” (Peterson, 2007, ¶13).
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On April 25th, Texas lawmakers blocked Gov. Perry’s effort to make Texas the first state
to require sixth-grade girls to be vaccinated with Gardasil. In a 135-to-2 vote the Texas House
gave final passage to a Senate bill that bars the state from ordering the shots until at least 2011
(Blumenthal et al., 2007). Even many supporters of the governor resented Mr. Perry’s proposal
an abuse of executive authority (Blumenthal et al., 2007). Texas Senator Glenn Hegar Jr., who
sponsored the bill to overturn the executive order, stated, “There was no public testimony- why
were we jumping so fast into a vaccine that was not for a true communicable disease”
(Blumenthal et al., 2007).
This incident has not been good for Merck’s heavy lobbying and public relations. To
compound the problem, Governor Perry has been accused of having political ties to Merck.
Before Gov. Perry’s executive order in February, Merck was bankrolling efforts to pass state
laws across the country mandating Gardasil for girls as young as 11 or 12 years of age. It
doubled its lobbying budget in Texas and has funneled money through Women in Government,
an advocacy group made up of female state legislators around the country (Peterson, 2007). Gov.
Perry’s former chief of staff, Mike Toomey, is one of Merck’s three lobbyists in Texas. His
current chief of staff’s mother-in-law, Texas State Representative Dianne White Delisi, is a state
director for Women in Government (Peterson, 2007). The governor also received $6,000 from
Merck’s political action committee during his re-election campaign.
In late February, Merck decided to drop its legislative campaign and stop pushing for a
government mandate due to growing opposition and bad press. Merck’s lobbying of Gardasil
has been criticized as being more self-serving than promoting women’s health (Atkinson, 2007).
On January 8, Business News cited an analyst with T. Rowe Price who estimated that sales of
Merck’s HPV vaccine “will peak at $2 billion per year, but could do as high as $4 billion if the
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states require it” (Jeffrey, 2007, p. 5). Fortune magazine reported that Merck’s and GSK’s HPV
vaccines are together “projected to spawn $8-billion-a-year global market by 2010” (Jeffrey,
2007, p. 5). Merck was hoping for a financial boost from Gardasil because several of its bestselling drugs, like the osteoporosis drug Fosamax, are coming off patent this year (Sturgeon,
2007). Merck is also in a financial quandary and facing litigation over the withdrawal of the
painkiller Vioxx. There are pending civil lawsuits because the drug was found to increase the
chances heart attacks and strokes in patients taking the drug. Vioxx may be responsible for
28,000 deaths (Houppert, 2007).
When it comes to the history of women’s health issues, hindsight has revealed that
economic interests and unfounded medical biases have encouraged women to use dangerous and
unproven treatments. As a result, drug companies and the medical profession have reaped great
financial rewards. Women, however, have suffered and even died as a result. We so easily forget
history as it fades into the mists of time.
The history of treating women with unproven and dangerous drugs and procedures is
rarely remembered these days. However, the wounds remain. For example, the anti-morning
sickness drug, thalidomide, still conjures up images of deformed children (Brown, 2009). The
first synthetic estrogen called diethylstilbestrol (DES) used from 1940-1970 to prevent
miscarriages was used on 10 million women American women without adequate testing (TitusErnstoff et al., 2006). In 1971, the FDA advised physicians to stop prescribing DES because it
was linked to a rare vaginal cancer (Titus-Ernstoff et al., 2006). Sadly, it never prevented
miscarriage (Titus-Ernstoff et al., 2006). Hormone replacement therapy (HRT), the supposed
salvation of menopausal women, is a more recent historical footnote of medical mistakes. We’ll
never know how many women died of HRT-induced breast cancer (Fournier, Berrino, & Clavel-
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Chapelon, 2008). However, the latest report has shown the incidence of breast cancer has fallen
dramatically in the past 4 years. This directly coincides to the decline in HRT use after a major
study, the Women’s Health Initiative in 2002, found direct correlation with breast cancer and
HRT use (Fournier et al., 2008). It seems there is a long history of women becoming unwitting
guinea pigs for medical and pharmaceutical interests. The HPV vaccine has only been on the
market for 3 years. Obviously there is no long-term data available on the safety and efficacy of
the vaccine. Are we adding to the history of using women, or in the case of the HPV vaccine –
girls, as guinea pigs all for the right of Merck to tout it’s vaccine as the first cancer-preventing
immunization?
So as citizens, we must ask ourselves if Merck is more concerned with the health of
adolescent girls or the bottom line of its profit margin? I fear the latter may find some bearing. Is
Merck turning the cervical cancer-free health of 9 to 26 year olds into a commodity? And what a
commodity it is. What consumer would not buy into a product that can improve one’s health or
future well being? Especially when the illness the drug is able to prevent is cancer. According to
the CDC, there were approximately 560,000 cancer deaths in the United States in 2007 (CDC,
2009c). After heart disease, cancer is the second leading cause of death in the United States
(CDC, 2009c). Marketing Gardasil as a cancer preventing vaccine was an ingenious strategy
designed by Merck. I have always equated the word cancer with terms like death, suffering,
radiation, chemotherapy, hair loss, weight loss, and pain. Who would not want to be vaccinated
against a disease associated with such devastation and misery? So Merck is making an enormous
profit by instilling the fear of getting cervical cancer to perfectly healthy adolescent girls and
their parents. According to Krishnan (2008), “It is clear from opinion polls that the vaccine has
considerably higher acceptance (63% approval rating) when marketed as a cancer vaccine versus
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an STD vaccine (43% approval rating)” (p. 156). Merck’s commercial might as well say, “You
could be ‘one less’ to die a horrible death if you are smart and vaccinate yourself with our $360
drug.” Merck needs to be more upfront with the actual function of Gardasil – preventing an
HPV infection. HPV infection can then lead to cervical dysplasia, a precursor to cervical cancer.
Krishnan has written:
Mild dysplasia is more likely to go away without any treatment than severe dyplasias, It
is extremely uncommon for cervical dysplasias to progress to cancer if they are properly
treated and if women obtain their regular Pap test follow-up exams in a timely fashion.
(2008, p. 57)
The high cost of Gardasil poses a genuine obstacle to patients, physicians, and insurers.
According to Marcia Angell (2005), “The United States is the only developed nation that does
not regulate drug prices” (p. 219). So Merck can charge whatever price they want for the
Gardasil vaccine in the United States. Merck gained a financial windfall when the CDC voted
unanimously to recommend that all girls 11 and 12 years of age receive the vaccine, and had it
added to the Vaccines for Children Program, which provides free immunizations to
impoverished or underserved children. Since the Vaccines for Children Program is government
funded, and the government cannot negotiate drug prices; taxpayers are paying for a very
expensive drug, and Merck is cashing in.
Merck has produced a vaccine that is the first of its kind. Gardasil is a vaccine that has
the potential to prevent cancer. This is a scientific breakthrough. It has the ability to save the
lives of millions of women. But the cost of the drug is overwhelming. Can’t Merck be satisfied
with a billion dollar profit instead of a $4 billion profit? Does the drug really need to be so
expensive? I realize we live in a capitalist system and profit is the incentive that motivates for-
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profit corporations like Merck to design pharmaceuticals, satisfy FDA standards, and
manufacture and distribute products to the public. Criticism of Merck for seeking a profit or for
lobbying to encourage its product’s use represents criticism of capitalism itself, not of Merck. So
long as Merck has acted within the letter of the law, critics may wish that we had a system better
equipped to protect consumers of drugs, to limit corporate lobbying, or to produce safer
products. These general criticisms are hardly exclusive to Gardasil; one could apply them
against any product sold by a corporation for profit. In the case of Gardasil, the bioethics of
making billions of dollars profit off of the sexual practices of adolescent girls is unsettling and
slightly disturbing. Bioethics feminists Gwen Anderson, Rita Monsen, and Mary Rorty have
written, “Because social attitudes, legal remedies, and moral standards typically lag behind
scientific and technological developments, it is vital that scientists and technologists consider
how their new products might affect the people who use them, negatively as well as positively”
(2000, pp. 38-39).
Does Merck really need to charge $360 per dose to earn back what it has spent on
developing it? The company estimates its net income for 2006 at nearly $4.5 billion. If it sold
Gardasil for 1/10th its current price, assuming the number of units sold stays relatively steady,
the company would have $36.5 million in sales each quarter, or $146 million each year, from
that product alone. A few more months, and it could recoup its development cost, and start
making up for the funds wasted on researching vaccines that didn't make it to market.
Merck’s marketing campaign has been hypocritical because it has argued to legislators
that Gardasil is an essential tool for public health, and then raised the price to a level that most
women can't afford, especially those outside the United States who are hit the hardest by cervical
cancer. In the first year Gardasil could be marketed in the US, Merck has spent approximately
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$70 million on advertisements and lobbying campaigns touting the vaccine (Edwards, 2007).
They have used celebrity endorsers like MTV’s TRL, Susie Castillo and have sent out 82,000
bead kits that can be assembled into “Make the connection” cervical cancer awareness bracelets
(Edwards, 2007). If the company can afford to spend huge amounts of money convincing
legislators the vaccine is something every woman deserves, it can afford to take its own advice,
and reduce the price. It could be said the Merck is guilty of “The Tragedy of the Commons.”
According to Garrett Hardin, “All commons dependent upon finite material substances, such as
land, would look only to his own interest and not to the community needs” (Waldby & Mitchell,
2006, p. 138). In this case Merck is more interested in the profit that Gardasil will bring it, than
in the stemming of the worldwide epidemic of cervical cancer.
Summary
The HPV vaccine is a significant biomedical and public health achievement. Medical
research has established that HPV is responsible for causing most of the cases of cervical cancer
(Krishnan, 2008). Immunizing adolescent girls with the HPV vaccine is cost effective and
significantly saves health care dollars otherwise spent on treatment and diagnosis of this sexually
transmitted disease. Mandating the vaccine could ensure widespread protection and distribute the
immunization to children regardless of race, ethnicity, or socioeconomic status. History has
proven that mandates force people to vaccinate. If the public health goal is to ensure that every
adolescent girl is protected against cervical cancer, then mandating the HPV vaccine would be
appropriate.
Skepticism towards politicians and state governments who wanted to quickly mandate the
vaccine arose because there was not a consensus among all parties involved. Many state
legislators backed down after parents, advocacy groups, and public-health officials protested the
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proposed mandates. Many blamed Merck’s heavy lobbying efforts for the push to mandate the
vaccine, while others believe overeager pro-vaccine advocacy groups, like Every Child By Two,
were to blame. The politics surrounding the HPV vaccine has brought it into the national
limelight. Alan Hinman, a senior public health scientist at the Taskforce for Child Survival and
Development, has asserted, “This is a marvelous vaccine. And instead of talking about that and
how we can try to bring it to everyone who should get it, the discussion has shifted to be about
the controversy of mandating vaccines” (Savage, 2007, p. 665). In the U.S., for all the childhood
diseases for which there are vaccines and mandates, disparities, for all intents and purposes, have
been eliminated. The mandated vaccination program that is linked to school entrance is the most
color-blind health-delivery program that we have. If HPV were added to this program, all girls
no matter race, color, or socioeconomic status would be afforded the protection from the most
prevalent STD in the world.
The next chapter discussed the social debate surrounding the HPV vaccine and the push
to mandate it. This debate focuses on parental concerns about safety, longevity, and the right to
make medical decisions for their children without being forced to by the government. The
arguments found within the social debate do not support a government mandate and tend to focus
on parental autonomy.
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CHAPTER 6
CRITICAL ANALYSIS – THE SOCIAL DEBATE
For the first time in the history of medicine we have a medical breakthrough that has the
potential of preventing certain cancers in women. This fact has been overshadowed by the
impassioned debate between the government wanting to mandate the HPV vaccine and parents
wanting a choice about making medical decisions for their daughters. In order to have a
successful vaccination campaign there must be a consensus between parents, physicians, and
policy makers about the right course of action to take concerning the health decisions of children.
The social debate presents the reasons not to mandate the HPV vaccine. Those who have
opposed mandating vaccination against HPV as a condition for school entry generally open the
debate with two fundamental questions. First, how can the government interfere in the medical
decisions parents make for their children by compelling immunizations for school entry? Second,
how can the HPV vaccine be a good candidate for school mandates when HPV infection is
transmitted only through intimate contact, not through casual encounters, as with other diseases
that are preventable with vaccines? A portion of the rebuttal to the political debate also consists
of parents, church leaders, and abstinence-only advocates who believe vaccinating adolescent
girls against a sexually transmitted disease will lead to a promiscuous lifestyle.
Reasons Against an HPV Vaccine Mandate
Having laid out the reasoning behind a government mandate of the HPV vaccine in the
previous chapter, I have turned the debate to the other side. The FDA approval of a vaccine
against cancer-causing HPV types is a significant public health advancement. In the face of this
advancement, some may say that opposing a government mandate is foolhardy, if not heretical;
but I am aiming to expose and provide transparency of the political debate as well as the social
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concerns that have ensued over the last 3 years. Earlier in my inquiry I had posed the question,
“If the HPV vaccine has the potential to prevent certain types of cervical cancer, then why not
mandate the immunization for adolescent girls?” Clearly, we have valid reasons for a
government mandate – proven efficacy, best way to protect the public from the spread of HPV,
and increases likelihood that insurance companies will cover the drug. But there are also valid
reasons not to mandate the vaccine for adolescent girls. Presenting both sides of the debate
allows us to step back and focus on the best way to first, stop the spread of HPV and second, find
a non-controversial place for the HPV vaccine in our society as well as developing countries who
need it most.
Let the Debate Continue – Long-Term Safety and Effectiveness of the Vaccine is Unknown
First and foremost the safety of our children is the most important issue in this whole
debate. Heller has asserted:
Americans’ skepticism about vaccination safety has varied over time, depending on the
particular disease, whether there is an ongoing epidemic (or a likely threat of one),
political affiliation, attitudes about the appropriate role of government, religious beliefs,
and the reputation of the health professions. (2008, p. 104)
Although the aim of clinical trials is to generate safety and effectiveness data that can be
presented to the general population, it is widely understood that such trials cannot reveal all
possible adverse events related to a product. Marcia Angell (2005) has written:
Even large, well-designed Phase III trials may not reveal side effects if they are very rare
or no one thought to look for them. They may also miss other effects that show up only in
patients different from those previously studied. (p. 162)
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For this reason, post-market adverse event reporting is required for all manufacturers of FDAapproved products, and post-market surveillance (also called phase IV clinical trials) may be
required in certain circumstances. There have been numerous examples in recent years in which
unforeseen adverse reactions following product approval led manufacturers to withdraw their
product from the market. Some examples are drugs like Rotashield, a vaccine to prevent
rotavirus gastroenteritis, that was found to cause intussusceptions; and Vioxx, a drug used to
reduce arthritic pain, that was found to increase the risk of having a heart attack.
In the case of the HPV vaccine, short-term clinical trials with thousands of young women
did not reveal serious adverse side effects. As of June 30, 2008, the most recent date for which
the CDC has made data available, over 16 million doses of Gardasil have been distributed in the
US and there have been 9,749 VAERS (Vaccine Adverse Event Reporting System) reports of
adverse events following vaccination (CDC, 2008c). Of these, 95% were classified as nonserious, and 6% as serious events (CDC, 2008c). The serious events range from unconfirmed
reports of Guillain-Barre syndrome (GBS), a neurological illness resulting in muscle weakness
and sometimes paralysis, to bronchospasm, gastroenteritis, headache with hypertension, joint
movement impairment near injection site, and vaginal hemorrhage (Javitt et al., 2008). The
adverse events reported since the vaccine’s approval are, at the very least, a sobering reminder
that rare adverse events may surface as the vaccine is administered to millions of girls and young
women. With this being said, we must remember that vaccines aim to protect the entire target
population. There must be a one-size-fits-all drug that works across all races, ages, genetic
backgrounds, and individual medical histories. Heller has written, “Vaccines are an interesting
exception [to drug classifications]: they deal not with individual patients who have specific
complaints, but with statistical rates of immunity in populations, in hope of avoiding the need for
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treatment (2008, p. 25). Vaccines remain one of the safest interventions with very small risks to
the population as a whole (Allen, A., 2007).
The duration or long-term effectiveness of an HPV vaccine-induced immunity is unclear.
The average follow-up period for Gardasil during clinical trials was 15 months after the third
dose of the vaccine (Javitt et al., 2008). There were three phase II trials performed that included
follow-up for 4 to 5 years after the third injection was given. The studies found no evidence of
waning immunity or decreased efficacy for the prevention of an infection (FUTURE II Study
Group, 2007). The vaccine seems to be safe for up to 5 years after it is given, beyond that is
unknown (Harvard Women’s Health Watch, 2007). If ACIP is recommending the vaccine for 11and 12-year old girls then by the time they are 17 or 18 they may need a booster shot. If a 17- or
18-year old girl, who in all likelihood, is sexually active, misses the booster shot she could be at
risk of acquiring an HPV infection due to waning immunity. Not only has she wasted at least
$360, but also her preventive vaccine has failed her miserably.
The minimum protective antibody threshold for disease protection is currently unknown
(Cutts et al., 2007). Follow-up studies are planned to determine antibody levels, side effects, and
long term effectiveness among women through at least 14 years after dose three is given (Cutts et
al., 2007).
The current Advisory Committee on Immunization Practices (ACIP) recommendation is
based on assumptions about duration of immunity and age of the onset of the first sexual
experience (Javitt et al., 2008). As the vaccine is used for a longer time period and long-term
data is collected, it may turn out that the vaccine schedule will need to be revamped or a booster
shot will be required. Another safety concern that is currently lacking data is the effect on co-
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administration of other vaccines. It is unknown whether Gardasil may be administered with
other vaccines.
At present questions remain about the vaccine’s safety and the duration of its immunity,
which call into question the judgment of mandating this immunization for school entrance. Girls
receiving the vaccine face some risk of potential adverse events as well as the risk that the
vaccine will not be completely protective over the long term. Physicians have a responsibility to
inform parents of the risks of the vaccine and decide together if the benefits of the vaccine
outweigh the risks.
Constitutional Justifications for Mandated Vaccine are Not Met
HPV and its vaccine are different in several respects from the immunizations that first led
to state-mandated vaccination. Going back to the opening sentence of my dissertation, it was
1855 when compulsory vaccination laws originated. They were motivated by fears of the
centuries-old pandemic of smallpox and the advent of the vaccine developed by Edward Jenner
in 1796. By the 1900s, the vast majority of states had enacted compulsory smallpox vaccination
laws (Bazin, 2000). While such laws were not immediately tied to school attendance, the
coincidental rise of smallpox outbreaks, growth in the number of public schools, and compulsory
school attendance laws provided a rationale for compulsory vaccination to prevent the spread of
smallpox among school children as well as a means to enforce the requirement by barring
unvaccinated children from school (Duffy, 1978). In 1827, Boston became the first city to
require proof of immunization with the smallpox vaccine before a child could enter public school
(Gostin, 2005). Similar laws were enacted by several states during the latter half of the 19th
century (Gostin, 2005).
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As discussed earlier, the theory of herd immunity was the motivating force behind mass
immunization programs. Herd immunity suggests that, in diseases passed from person to person,
it is difficult to maintain a succession of infection when substantial numbers of the population
are immune. With the increase in number of immune individuals present in the population, the
lower the likelihood that a vulnerable person will come into contact with an infected individual.
As vaccination rates increase, protection from the disease also increases until the infection is
eliminated. This is how smallpox has been completely eradicated from the human population
(Bazin, 2000).
As more governing states had begun to mandate vaccination, courts were called on to
give a ruling on the constitutionality of mandatory vaccination programs (Gostin, 2005). In 1905,
The Supreme Court decided the influential case, Jacobson v. Massachusetts, in which it upheld a
population-wide smallpox vaccination ordinance challenged by Reverend Henning Jacobson
who refused to be vaccinated and was fined $5 (Gostin, 2005). Rev. Jacobson argued that a
compulsory vaccination law was “hostile to the inherent right of every freeman to care for his
own body and health in such a way as to him seems best” (Javitt et al., 2008, p.388). The Court
disagreed with Jacobson and upheld the state’s right to mandate the smallpox vaccine. The Court
adopted a narrower view of individual liberty and emphasized the duties that citizens have
towards each other and to the society as a whole (Gostin 2005). According to the Court, the:
liberty secured by the Constitution of the United States…does not import an absolute
right in each person to be, at all times and in all circumstances, wholly freed from
restraint. There are manifold restraints to which every person is necessarily subject for
the common good. (Jacobson v. Massachusetts, 1905, p. 197)
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With respect to compulsory vaccination, the Court stated, “upon the principle of self-defense, of
paramount necessity, a community has the right to protect itself against an epidemic of disease
which threatens the safety of its members” (Jacobson v. Massachusetts, 1905, p. 197). In the
court’s opinion, compulsory vaccination was consistent with a state’s traditional police powers –
its power to regulate matters affecting the health, safety, and general welfare of the public
(Gostin, 2005).
In reaching its decision, the Court was influenced both by the considerable harm posed
by smallpox – using the words “epidemic” and “danger” repeatedly – as well as the available
scientific evidence demonstrating the efficacy of the vaccine (Javitt et al. 2008). However, the
Court also emphasized that its ruling was valid only to the case before it, and articulated four
principles that must be adhered to for such an exercise of police powers to be constitutional
(Javitt et al., 2008). The principles are: (a) there must be a public health necessity; (b) there must
be a reasonable relationship between the intervention and the public health objective; (c) the
intervention may not be arbitrary or oppressive; and (d) the intervention should not pose a health
risk to its subject (Javitt et al., 2008).
The smallpox rulings of the nineteenth century helped lay the foundation for modern
immunization laws (Gostin, 2005). In 1977, the federal government launched the Childhood
Immunization Initiative, which stressed the importance of strict enforcement of school
immunization laws (Hinman, Orenstein, Williamson, & Darrington, 2002). Currently, all states
have mandated vaccination as a condition for school entry, and in deciding whether to mandate
certain vaccines are guided by ACIP recommendations (Allen, A., 2007). At present, ACIP has
recommended vaccination for diphtheria, tetanus, and acellular pertussis (DTaP), hepatitis B,
polio, measles, mumps, and rubella (MMR), varicella, influenza, rotavirus, haemophilus
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influenza B (HiB), pneumococcus, hepatitis A, meningococcus, and most recently HPV (CDC,
2009d). An interesting point that bioethical feminists have argued is the role of the medical field
on the social authority of our society. Helen Holmes has written, “Medicine’s social authority
ensues because society automatically accepts medicine’s pronouncements, descriptions that then
determine how social institutions (such as courts, schools, insurance companies) control our
lives” (1999, p. 47). ACIP decides which vaccines should be administered to children, places
them on a recommended immunization list, then the state governments, using the
recommendation of ACIP, mandates them for school entrance. We have gone from a
recommendation to a mandate based on the pronouncement of science, which then establishes
the social authority of ACIP.
HPV is different from the vaccines that have previously been mandated by the states. All
of the previous vaccines, with the exception of tetanus, fit comfortably within the “public health
necessity” principle articulated within Jacobson in that the diseases they prevent are highly
contagious and are associated with significant morbidity and mortality occurring shortly after
exposure.
Jacobson’s “reasonable relationship” principle is also clearly met by vaccine mandates
for the other ACIP recommended vaccines. School-aged children are most at risk while in school
because they are more likely to be in close proximity to each other in that setting. All children
who attend school are equally at risk of both transmitting and contracting the diseases. Thus, a
clear relationship exists between conditioning school attendance on vaccination and the
avoidance of the spread of infectious diseases within the school environment.
HPV, in contrast, does not satisfy these two principles. HPV infection presents no public
health necessity. While non-sexual transmission routes are theoretically possible, they are highly
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unlikely (Krishnan, 2008). Like other sexually transmitted diseases which primarily affect adults,
it is not immediately life threatening; as such, cervical cancer, if developed, will not manifest for
years. Furthermore, the majority of those exposed will not go on to develop cervical cancer
(Krishnan, 2008). Thus, conditioning school attendance on HPV vaccination serves only to
coerce compliance in the absence of a public health emergency.
The relationship between the government’s objective of preventing cervical cancer in
women and the means to achieve it – that is, vaccination of all girls as a condition of school
attendance – lacks sufficient rationality. First, given that HPV is transmitted through sexual
contact, exposure to HPV is not directly related to school attendance. Second, not all children
who attend school are at equal risk of exposure to or transmission of the virus. Those who
abstain from sexual conduct are not at risk for transmitting or contracting the virus.
The public health objective that proponents of mandatory HPV vaccination seek to
achieve is compelling and backed by scientific findings. These findings recommend vaccinating
girls before the onset of sexual activity provides the best protection against an adult onset
sexually transmitted disease. This opportunity is lost once sexual activity begins and exposure to
HPV occurs (Krishnan, 2008). However, the HPV vaccination may be both medically justified
and a prudent public health measure, but that is insufficient basis for the state to compel children,
specifically girls, to receive the vaccine as a condition of school attendance.
Risking a Public Backlash
Childhood vaccination rates in the United States are very high; more than half of the
states report meeting the Department of Health and Human Services (HHS) Healthy People 2010
initiative’s goal of ≥95% vaccination coverage for childhood vaccination (Stanwyck, Davila,
Lyons, & Knighton, 2009). However, from its inception, state mandated vaccination has been
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accompanied by a small but vocal anti-vaccination movement. Opposition has historically been
“fueled by general distrust of government, a rugged sense of individualism, and concerns about
the efficacy and safety of vaccines” (Gullion, J., Henry, & Gullion, G., 2008). In recent years,
vaccination programs have been a “victim of there tremendous success, as dreaded diseases such
as measles and polio have largely disappeared in the United States, taking with them the fear that
motivated past generations” (Javitt et al., 2008, p. 390). Activities of today’s antivaccinationists
seem to be having an impact. In recent years, the rates of parents claiming nonmedical
vaccination exemptions for their children have increased (Gullion, J. et al., 2008).
One reason for this increase in anti-vaccination rhetoric is the number of mandated
vaccines we give our children. Vaccine-safety advocates are concerned about adding more
injections to the already full schedule of childhood immunizations. The CDC currently
recommends children receive 48 doses of 14 vaccines by age six and 53 doses of 15 vaccines by
age 12 (CDC, 2009d). With the addition of the HPV vaccine, girls would receive 56 doses of 16
vaccines by age 12 (CDC, 2009d; see Appendix C and D).
The rash decision of state legislators to mandate HPV had led to significant public
concern that the government is overreaching its police power authority. As one conservative
columnist has written, “[F]or the government to mandate the expensive vaccine for children
would be for Big Brother to reach past the parents and into the home” (Hart, 2007, p. B6). Some
might dismiss this statement claiming moral politics, but trivializing this concern is inappropriate
because sexual behavior is involved in transmission and not all children are at equal risk of
contracting the disease (Javitt et al., 2008). Thus, it is reasonable to take the parent’s judgment
into account when considering his or her child’s specific risk of contracting HPV and weigh that
against the risk of vaccination.
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Javitt et al. (2008) have written, “To remove parental autonomy in this case [HPV
vaccination] is not warranted and also risks parental rejection of the vaccine because it is
perceived as coercive” (p. 390). In contrast, educating the public about the value of the vaccine
may be highly effective without risking public backlash. According to one poll, 61% of parents
with daughters under 18 prefer vaccination, 72 % would support the inclusion of information
about the vaccine in school health classes, and just 45 % agreed that the vaccine should be
included as part of the vaccination routine for all children and adolescents (Cummings, 2006).
Parental attitudes are crucial to the acceptance of the HPV vaccine (Krishnan, 2008).
According to Waller et al. (2003) overall parental knowledge about HPV infections and their
relationship to cervical cancer and genital warts is minimal. A study in the Cancer Epidemiology
Biomarkers and Prevention journal showed that only 40% of women had never heard of HPV,
and less than 50% of those women knew that it causes cervical cancer (Savage, 2007). A study
by Brewer and Fazekas (2007) found that only 59% of women knew the purpose of having an
annual Pap smear.
Parents’ acceptance is usually influenced by the attitudes of their peers and their healthcare providers (Krishnan, 2008). Their acceptance is also high when they perceive the disease’s
consequence to be serious, and when they have had some personal experience with the disease
themselves (Dempsey, Zimet, Davis, & Koutsky, 2006). I can attest to this fact seeing that I have
had some experience with the disease that the HPV vaccine prevents. I have two young
daughters who I plan to have vaccinated if the efficacy and safety data remains favorable. In
contrast, acceptance rates are low with parents that lack information or have little concern about
the HPV disease (Krishnan, 2008). Additionally, “parents’ acceptance is low among those who
feel that their child’s personality, behavioral characteristics, and emotional immaturity place
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them at minimal risk for initiating sexual activity and acquiring an STD in the near future”
(Krishnan, 2008, p. 153).
Blumenthal, Hetman, Trocola, and Slomovitz (2008) have asserted that among parents
who were both for and against the vaccine, many of them said that they would be more willing to
accept the vaccine closer to the time of their child’s sexual debut, rather than at age 11 or 12,
which parents believe to be far before the time that their child would consider having sex.
Krishnan (2008) has written, “Parents’ knowledge of their adolescent child’s sexual activity
status is often inaccurate, and so relying on this cue to take action to vaccinate may be unrealistic
and unreliable in relation to the child’s need for protection” (p. 153). In a study by researchers at
the University of Minnesota Adolescent Health Center, half of American mothers of sexually
active teens were unaware of the activity, believing them to be virgins (Moms unaware of teens’
sexual activity, 2002). The key to success for any public health measure is to gain community
support and acceptance. If parents and adolescences feel they have been well versed about HPV
and feel they have a choice about the vaccination then we can hopefully see a decline in the
incidences of HPV.
Unresolved Economic Concerns
Mandated HPV vaccination may have negative unintended economic consequences for
both state and health departments and the federal government, and these consequences should be
thoroughly considered before HPV vaccination is mandated. In recent years, state health
departments have found themselves increasingly financially strapped by the rising number of
mandated vaccines. Some states that once provided free vaccines to all children have abandoned
the practice due to rising costs. For example, Alaska will no longer offer all vaccinations free to
all Alaska schoolchildren; it is cutting funding for the HPV vaccine and the meningococcal
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vaccine (Bryson, 2008). Laurel Wood, manager of the Alaska Immunization Program, has stated,
“Federal funding of the state’s universal immunization program has failed to keep pace with the
increasing cost and rising number of recommended vaccines” (Bryson, 2008, ¶4). Adding HPV
could drive more states to abandon funding for other vaccinations and could divert funding from
other important public health measures. In the case of Alaska, Wood has stated, “The cost of the
HPV vaccine is the budget-buster” (Bryson, 2008, ¶15). At the federal level, spending by the
federal Vaccines for Children program, which pays for immunizations for Medicaid children and
some others, has grown to $2.5 billion, up from $500 million in 2000 (Pollack, 2007). It is
estimated that state and federal governments pay for vaccines for roughly 55% of all U.S.
children, mainly comprised of the poor (Pollack, 2007). Thus, before HPV vaccination is
mandated, a thorough consideration of its economic consequences for existing vaccine programs
and other non-vaccine programs should be undertaken.
Not on Equal Ground with Other Vaccines
Childhood immunizations, such as measles, chicken pox, and polio are mandatory for
school aged children and are required because of their highly contagious nature, especially in a
school setting where people congregate in large numbers and are confined to small spaces
(Allen, A., 2007). The majority of mandated vaccines protect against highly contagious diseases
that cause significant morbidity and mortality and threaten both the individual and the
community (Allen, A., 2007). It is not clear that HPV and the risk of cervical cancer to women
fall into that category. Therefore, the question is whether there is justification for mandating
parents to vaccinate their daughters against a sexually transmitted virus, one that only can be
transmitted through sexual behavior that some people view as being irresponsible. Moreover, the
vaccine only protects against high-risk HPV types for 70% of cervical cancers (Krishnan, 2008).
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This incomplete protection does not reduce susceptibility to the other HPV types that cause the
remaining 30% of cervical cancers and will still require females to undergo yearly cervical
cancer screenings and to practice other preventive measures of reducing STD exposure
(Krishnan, 2008). Regular Pap smears have made cervical cancer a treatable disease,
significantly reducing the number of cervical cancer deaths (Krishnan, 2008). HPV can be
contained through behavioral changes and is not communicable through ordinary daily
interactions. Therefore, mandating the HPV vaccine for girls of school age is an unnecessary
action in response to a promiscuous but preventable behavior. People adopting this position view
a state mandated policy that places HPV on the same playing field with other infectious diseaserelated vaccines as unwarranted.
Giving Children a “License” for Sex
This rationale against mandating the HPV vaccine is the argument that I believe has the
least validity and is completely irrational. I have a hard time understanding why parents actually
believe that inoculating their daughters with a vaccine that prevents a sexually transmitted
disease will cause her to become promiscuous. Having recently taken a Theories of Adolescence
course for my doctoral work, I understand that adolescence is a time when constant hormonal
surges and bodily transformations are occurring. Teens are more likely to take risks and
challenge their parents’ authority and moral values (Krishnan, 2008). Vamos et al. (2008) write,
“Adolescence is a time where concrete and short-term cognitions are common and abstract and
long-term consequences are only just beginning to develop” (p. 303). Even with this being said,
do these hysterical parents, yes I have said it – hysterical – believe a vaccine will lead to sex
have so little trust and confidence in their daughters that they will put her health at risk? Sharpe
(2007) has stated, “Routine technological interventions intended to protect and save human lives
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rapidly dehumanize us as patients” (p. 44). The HPV vaccine was developed to protect us against
an HPV infection with hopes of saving many lives in the process. But the notion of not
vaccinating because it could promote sex is extremely dehumanizing to adolescent girls. It is
inevitable that whether she has sex at 16 or sex at 26, she is going to have sex (unless she joins a
convent). Instead of automatically assuming that parents are giving their daughters permission to
have “vaccinated sex,” why not look at this technological advancement as a way of protecting
them from a possible life threatening disease. Furthermore, such a policy recklessly discounts the
priority of preserving women’s health and inappropriately treats a potentially deadly disease as
something of an affordable cost or a legitimate punishment for women’s unsanctioned sex.
Finally, the “leads to promiscuity” attitude purposefully retains the high-risk types of HPV in the
population. If enough girls, and eventually boys, were vaccinated then there would be a
reduction in types 16 and 18 HPV. The question would become: would one of the other “highrisk” types of HPV fill the niche left by types 16 and 18? Hopefully by then the vaccine could be
extended to cover all high-risk types of HPV.
I should not be so hard on conservative parents, I used to be one of them; but as I have
moved through the process of researching and writing this inquiry I have changed my beliefs
about abstinence-only education – it is unrealistic in today’s society of all-persuasive, sexually
suggestive media.
Conservative parents are not the only ones framing the “license for sex” argument.
Abstinence only groups, religious organizations, and compassionate conservatives are also
worried that a mandatory HPV vaccination order will promote premarital sex and give children
tacit permission to engage in risky sexual behavior. In place of a vaccination program, these
groups advocate abstinence education and better communication between parents and children to
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foster family values that prohibit premarital sexual relationships. I agree that communication
between parents and children in regards to sex is paramount to properly educating adolescence
on safe sexual practices. I disagree with the abstinence only approach to teaching our youth
about sex.
Studies have shown that abstinence only programs do not reduce the sexual activity of
teenagers (Charo, 2007). Promoters that encourage abstinence-only and limit sexual and
reproductive health education have touted that these programs are the cause of a reduction in
teen pregnancy (Thomas, 2008). But a reduction in teen pregnancy does not mean teens are
remaining abstinent. Research from the Vital and Health Statistics of the CDC report that 30%
of females aged 15 to 17 and more than 70% of females aged 18 to 19 engage in sexual
intercourse and for males 31.6% aged 15-17 and 64.7% aged 18-19 engage in sexual intercourse
(CDC, 2009e).
Despite the recent decline, the U.S. teen pregnancy rate still remains very high, even with
abstinence-only programs taught in many schools (Kirby, 2007). In 2002, among all females
aged 15-19, about 75 per 1,000 became pregnant (Guttmacher Institute, 2006). The rates are
higher for African-Americans (134 per 1,000) and Hispanics (132 per 1,000) than non-Hispanic
Whites (48 per 1,000; Guttmacher Institute, 2006). Teen sexually activity also leads to high rates
of STDs (Kirby, 2007). Hillard Weinstock, Stuart Berman, and Willard Cates have written,
“Although young people aged 15-24 represent 25% of the sexually active population, they
account for about half of all new cases of STDs” (2004, p.6). Again, STD rates for minorities are
typically much higher than the rates for Whites (Kirby, 2007). These higher rates reflect greater
poverty, less access to health services, and larger numbers of sexual partners (Kirby 2007).
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A study was performed that evaluated the impact of five abstinence-until-marriage
programs that were implemented in schools; in health, family planning and STD clinics; and in
community organizations working with youth (Trenholm, Devaney, Fortson, Quay, Wheeler, &
Clark, 2007). They employed rigorous experimental design and analysis and tracked youths for 4
to 6 years. They concluded that well-designed intensive abstinence-until-marriage programs are
not effective in changing sexual behavior (Trenholm et al., 2007). They also found that there was
little evidence that any particular abstinence program delays the initiation of sex and did not
reduce the risk of getting pregnant or contracting an STD (Trenholm at al., 2007).
In another study, a comprehensive-based sex program was also evaluated for its impact of
the sexual behavior of teens (Coyle, Kirby, Marin, Gomez, & Gregorich, 2004). Comprehensive
programs may emphasize abstinence but also support condom or contraceptive use. The focus of
most comprehensive programs is to prevent pregnancy and STDs (Kirby, 2007). The study
showed that there was a decrease in sexual activity, reduction in the number of cases of
unprotected sex, and a delay in sexual initiation (Coyle et al., 2004). We know teens are having
sex, not all of them, but a good portion. Abstinence-only programs are not as effective as
comprehensive based programs at educating our youth about sex, pregnancy, and STDs. Parents,
educators, abstinence-only groups, and the federal government (who spends $170 million each
year on abstinence-only programs) (Robin, 2006) need to be more realistic and open-minded
about what should be presented to our adolescent children when it comes to discussing taboo
issues like sex, teen pregnancy, and STDs.
With this data in hand, what can we conclude about the notion that administering the
HPV vaccine will increase teenage promiscuity? Will a teenage girl who just received the
Gardasil vaccine become more promiscuous because she thinks she is safe from contracting
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HPV? Does she believe that she has a “license” for sex? Does she believe that her parents
condone sex before marriage since they vaccinated her against an STD? The answers to these
questions can be answered by looking at what factors influence teenage girls to initiate sexual
behavior.
Sexuality is one of the most salient and psychological issues for adolescents and young
adults (Katchadourin, 1990). A number of studies have linked early initiation of sexual activity
in adolescents with poor-quality relations between mother and fathers, and between adolescents
and their parents (McLaughlin, Chen, Greenberger, and Biermeier, 1997). For example,
Newcomer and Udry (1987) found that parental characteristics such as marital disruption and
lack of parental control were associated with adolescent sexual activity; and along the same
lines, Inazu and Fox (1980) found that Caucasian and African-American girls (14-16) who
reported high-quality relationships with their mothers were much less likely to have become
sexually active. Whitebeck, Hoyt, Miller, and Kao’s (1992) study of 13- to 18-year olds
suggested that adolescent daughter’s level of depressed mood was a possible mechanism by
which the quality of the mother-daughter relationship might influence the timing of first sexual
intercourse; girls who had more supportive mothers were less depressed, and in turn were less
likely to engage in first intercourse before age 18. Furthermore, adolescents’ sexual activity is
related to peer factors such as association with sexually active peers, peer endorsement of sexual
activity, and peer rejection during childhood (Benda & DiBlaso, 1994). An interesting study by
Jessor, S., Costa, Jessor, L., and Donovan (1983) found that individuals who remained virgins
into young adulthood had been adolescents who, in an earlier assessment, reported themselves to
be less physically attractive and less successful at forming romantic relationships. Each of these
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studies indicate that a girl’s decision to become sexually active is much more complicated than
deciding to have sex because she received a vaccine for an STD.
Even though the majority of Americans have sex before they are married, there is a small
percentage (less than 10%) who abstain (Finer, 2007). Even young women who have abstained
from sex until marriage have contracted HPV from their husbands and faced the difficult task of
defeating cervical cancer (Gilman, M., Gilman, S., & Johns, 2009). Unfortunately, a woman’s
sexually healthy premarital lifestyle does not protect her from contracting HPV – even faithful,
monogamous women can get infected with HPV. She has no control over her future husband’s
premarital lifestyle. With this being said, abstinence does not protect against an HPV infection
unless both the husband and wife are virgins when they marry.
With the introduction of the HPV vaccine for 11-and 12-year olds, a window of
opportunity has been opened for parents and health-care providers to give some anticipatory
behavioral guidance to adolescents. Krishnan has stated, “The HPV vaccine cannot, will not, and
should not replace proper parenting and discussions with your children about sexuality” (2008, p.
153).
Summary
Based on the current scientific evidence, vaccinating girls against HPV before they are
sexually active appears to provide significant protection against cervical cancer. The vaccine
thus represents a significant public health advance. Nevertheless, mandating HPV vaccination at
the present time would be premature and ill advised. The vaccine is relatively new, and longterm safety and effectiveness in the general population is unknown. Vaccination outcomes of
those voluntarily vaccinated should be followed for several years before mandates are imposed.
Additionally, the HPV vaccine does not represent a public health necessity of the type that has
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justified previous vaccine mandates. State mandates could therefore lead to a public backlash
that will undermine both HPV vaccination efforts and existing vaccination programs.
Furthermore, the economic consequence of mandating HPV are significant and could
have a negative impact on financial support for other vaccines as well as other public health
programs. These consequences should be considered before HPV is mandated. Additionally,
HPV cannot be contracted through a cough or sneeze. It is a sexually transmitted disease that is
contracted through, for the most part, a behavioral decision. Placing the HPV vaccine on the
mandated vaccines list with polio, measles, and chicken pox is premature. Finally, using the
illogical position that vaccinating adolescent girls will cause them to be more promiscuous is
unfounded. Studies have shown that teenagers with involved parents are more likely to delay the
initiation of sexual activity than those teenagers who do not have any parental guidance on sexrelated topics such as abstinence and on the psychological and physiological side effects of
sexual activity (Krishnan, 2008).
The next chapter has taken the debate out of the political and social realm and into the
bioethical sphere. Chapter 7 focused on the ethical and moral ramifications that the HPV vaccine
incites within the bioethical feminist literature.
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CHAPTER 7
CRITICAL ANALYSIS – THE ETHICAL DEBATE
When I first heard of the HPV vaccine and what it prevents I was excited for all women; I
was excited that science and medicine has now focused on an important woman’s health issue.
We finally have a vaccine that prevents 70% of the cases of cervical cancer and 90% of the cases
of genital warts. Women have a weapon against the second leading cause of cancer death in
developed countries and the first leading cause of cancer death in developing countries.
However, an investigation into the role of the HPV vaccine in our society raises some bioethical
feminist issues that must be discussed in order to present a transparent picture of the
immunization and its significance for women. Bioethical feminist theory “sees oppression based
on gender as a serious wrong and critically investigates the workings of power and gender (Wolf,
1996, p. 8). The HPV vaccine is a medicine that is used to remedy a disease that often affects
those that are marginalized – women and minorities. With this being said, the HPV vaccine is the
most expensive vaccine on the market. So how are the women who need the drug the most going
to afford it? Furthermore, this drug could make a huge impact in developing countries. How will
women in those countries access this vaccine? This chapter investigated how this vaccine
marginalizes women and what can be done about it.
HPV-induced Cervical Cancer is a Health Inequity Issue
Ninety-nine percent of cervical cancer in women can be directly attributed to HPV; the
cause of the other 1% is unknown (Walboomers et al., 1999). Cervical cancer is a disease of
social inequality. Women with access to effective screening and treatment rarely die from
cervical cancer (Krishnan, 2008). The burden of cervical cancer mortality falls most heavily
among the poorer women of the world. Cervical cancer represents the second most common

171

gynecologic malignancy diagnosed in the United States. Approximately 11,270 new cases of
invasive cervical cancer were diagnosed in 2009, with an estimated 4,070 deaths (American
Cancer Society, 2009). Disparities, treatment, and outcome for cancers in minorities and
Caucasians have been documented (Brookfield, Cheung, Lucci, Fleming, & Koniaris, 2009).
According to the CDC, between the years 1998-2003 the incidence of cervical cancer deaths was
highest for Hispanic women (14.2 per 100,000), followed by African American women (12.6 per
100,000, and Caucasian women (8.4 per 100,000; CDC, 2009f; see Appendix E). More African
American and Hispanic women get cervical cancer and are diagnosed at later stages of the
disease than Caucasian women, possibly because of decreased access to Pap smear screening or
follow-up treatment (CDC, 2009f). If the government truly wants to prevent cervical cancer they
should mandate annual exams for women. If caught early enough cervical cancer is a treatable
disease.
While cervical cancer rates have drastically fallen in developed countries due to effective
preventive methods and treatments, socially disadvantaged women within these countries remain
disproportionately more likely to develop and die of cervical cancer (World Health Organization,
2007). Further, in most developing countries, in contrast cervical cancer rates have risen or
remained unchanged (World Health Organization, 2007). More than 83% of the 493,000 incident
cases of cervical cancer, and an even higher proportion of the 273,000 related annual deaths,
occur in the developing countries of sub-Saharan Africa, Latin America and the Caribbean,
South and South-East Asia, and Melanesia (World Health Organization, 2007). Cervical cancer
is the primary cause of cancer-related deaths and years of life lost among women in developing
countries (Parkin & Bray, 2006). These women are more likely to be diagnosed with late-stage
disease, receive either no treatment or treatment that does not meet currently accepted standards

172

of care, and suffer without the benefit of pain control and other palliative care (Parkin & Bray,
2006). These social disparities in prevention, incidence, detection, treatment, and survival are
avoidable, but are not avoided. For these reasons, cervical cancer is a health inequity.
Margaret Whitehead has defined health inequity as, “differences in health that are not
only unnecessary and avoidable, but in addition unfair and unjust” (1992, p. 429). Paula
Braveman (2006) has argued that healthcare inequity is identified by the systematic tracking of
health disparities within the social hierarchy, which consists of the different relative positions of
social advantage and disadvantage as defined by race, class, gender, wealth, income, education,
occupation, and geographic residence. Where there is health inequity, groups who have
persistently experienced social disadvantage or discrimination in the past systematically
experience greater health risk and worse health outcomes than the most advantaged social groups
(Braveman, 2006). With this being said, cervical cancer is a striking case of health inequity.
Women belonging to disadvantaged social groups are disproportionately more likely to develop
and die from cervical cancer across and within countries. The vast majority of the incident cases
of cervical cancer and related deaths annually occur in developing countries (World Health
Organization, 2007).
Cervical cancer is often a preventable disease. The prevention of cervical cancer is based
on the discovery that infection with one or more high-risk types of HPV is a necessary cause of
cervical cancer (Walboomers et al., 1999). HPV infection is a highly prevalent STD and most
women will be infected during their lifetime, with high rates in young women following sexual
debut (Krishnan, 2008). While most infections are asymptomatic and transient, persistent or
chronic infection over decades with the high-risk HPV type is associated with pre-cancerous
lesions of the cervix that may progress to cervical cancer (Krishnan, 2008).
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Several factors are associated with increased risk of both initial infection with high-risk
HPV types and developing cervical cancer once infected. These individual factors include both
biological factors, such as coinfection with other STDs or immunodeficiency; and behavioral
factors, such as nonuse of condoms, multiple sexual partners, and young age at sexual debut
(World Health Organization, 2007).
While differences in individual factors may have some effect on social disparities of
cervical cancer, they are not considered the dominant cause of the inequitable social distribution.
The most important determinant of social disparities in cervical cancer is the access to cervical
screening and preventive vaccines (Denny, 2008).
Cervical screening allows for the early detection, follow-up and treatment of
precancerous cervical abnormalities. It is a viable and highly effective preventive strategy
because of the prolonged progression from infection to disease. In countries that have
implemented high-quality screening programs using the Pap smear exam, societal average
cervical cancer incidence and mortality rates have dramatically decreased (World Health
Organization, 2007). Screening programs in most developing countries are insufficiently
available and of poor quality, which results in much lower screening coverage and contributes to
higher cervical cancer incidence and mortality (Denny, 2008). Screening coverage in developing
countries is, on average, 19% compared to 63% in developed countries (Denny, 2008). In
countries with screening programs, disadvantage social groups are disproportionately represented
among the unscreened and the untreated (Denny, 2008).
Social disparities in demand and utilization result from government failure to ensure
screening programs are accessible and acceptable to all (Erdman, 2009). Programs are
implemented without sufficient attention to the conditions that render screening less or
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inaccessible to disadvantaged social groups, including: lack of information, undervaluing of
preventive care, lack of public health care facilities, sexual health stigma and related privacy
concerns.
Information is an important dimension of accessibility (Erdman, 2009). Underutilization
of screening services is commonly attributed to poor awareness of and information about
cervical cancer and the benefits of screening in prevention and early detection (Erdman, 2009).
Failure to appropriately distinguish among screening, diagnosis, and treatment, for example, may
adversely affect demand for screening. A positive HPV test may be mistaken as a diagnosis for
cancer and as such, falsely regarded as an untreatable disease. The psychological and financial
burden of a perceived fatal diagnosis may deter women from screening. A mistaken
understanding of cervical cancer screening means that this preventive care can itself be a barrier
to access, given the low priority assigned to asymptomatic screening. Economic barriers and
social norms contribute to the under valuing of preventive care (Erdman, 2009). Given that
screening does not provide any immediate health benefits, its value may be discounted and
deemed insufficient to warrant expenditure of scarce healthcare resources.
A second and complementary alternative measure focuses on the primary prevention of
cervical cancer: the HPV vaccine. Studies indicate that the HPV vaccine, if made accessible to
adolescent women in developing counties, can prevent almost 4 million cervical cancer deaths in
the next decade (Goldie, O’Shea, Diaz, & Kim, 2008). And yet, the HPV vaccine is the most
expensive vaccine in human history, priced at approximately $360 wholesale for the currently
recommended regime of three doses.
The statistics regarding the disparity of cervical cancer is not new information. This data
has been collected for over 30 years. Yet, Merck has priced the vaccine at such a high rate that
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the women who need it the most do not have economical access to it. The vaccine is being sold
to the very people who need it least: the well-insured daughters of the middle class in the United
States and wealthy developed countries. The vaccine is marketed to those with social and
financial capital to access vaccination programs, the very women most likely to also have access
to effective screening and treatment (Outterson, 2009). Liz Szabo, a journalist for USA Today,
has written, “Some doctors now question whether the vaccine has been overpromoted to affluent
women who need it least instead of patients most at risk of dying from the disease” (2009, ¶1).
Merck’s marketing campaign suggests that all women are at risk of contracting cervical cancer –
a strategy that helps them sell as many vaccines as possible. Because cervical cancer does not
strike women equally, Charlotte Haug, editor of the Journal of The Norwegian Medical
Association, states, “Vaccinating women who already get annual exams does little to reduce the
number of deaths” (Szabo, 2009, ¶6). With this knowledge, Merck seems motivated by more
than altruism. It is estimated that is Merck’s HPV vaccine becomes mandated it will generate
annual sales of $3.2 billion by 2010 (Allen, T., 2007).
The U.S. government does not regulate drug prices as do many other countries; Merck
can set the price of its vaccine at a rate it thinks the market will bear (Angell, 2005). In other
words, the vaccine is prioritized to the women who can pay the high price but need it least.
Paradoxically, the circumstances of the HPV vaccine contribute unfavorably to the maintenance
of existing health disparities rather than to enhancing the likelihood of overcoming them.
Adding to this travesty is what issue dominates the HPV vaccine literature. In most of the
articles that discuss the HPV vaccine controversy there is some pronouncement to the claim that
this vaccination will increase the sexual promiscuity of adolescent girls; very little is written on
the glaring global health inequity that HPV and cervical cancer pose to disadvantaged women.
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The discussion needs to be moved away from the “license to have sex” discourse and on to what
can be done to distribute this vaccine to the women who need it most – women who are members
of disadvantaged minorities.
Challenges in Introducing HPV Vaccine in Developing Countries
Affecting relatively young women, cervical cancer is the largest single cause of years of
life lost to cancer in the developing world. The deaths of women who are in their most
productive years have a devastating effect on the well-being of their families, resulting, for
example, in decreases in school attendance and nutritional status among their children (Agosti &
Goldie, 2007).
In order to decrease the number of cervical cancer deaths in developing countries a
screening program complemented by access to the HPV vaccine must be implemented. The
United States and Europe both experienced high rates of cervical cancer well into the twentieth
century, until screening and treatment programs were established by national health services
(Gustafsson, Ponten, Bergstrom, & Adami, 1997). In the United States, for example, rates have
fallen by 75% or more since the 1960s, when screening was instituted (Kitchener, Castle, & Cox,
2006).
The differences in disease burden are due primarily to stark differences in both the
availability and the utilization of screening and treatment services. While screening with Pap
smear exams has become a staple of women’s health care in the developed world, very few
women in the developing world have access to such screening (Kitchener et al., 2006). This is
due in large part to the difficulties governments face in establishing complex laboratory services
that require coordinated, multi-visit screening and treatment services, and the inherent limitations
in the screening procedure itself (Kitchener et al., 2006). In addition, cultural, social, and
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economic constraints keep women from taking advantage of these services when they are
available (Outterson, 2009). These constraints include the social stigma associated with STDs
and with gynecological exams, the low status of women and their health needs in many societies,
and the direct and indirect costs associated with clinic visits (Outterson, 2009). These constraints
could be narrowed with the introduction of the HPV vaccine in developing countries.
Consideration for policymakers debating the use of the HPV vaccine in any particular
country will include that country’s disease burden, its health care infrastructure, and its capacity
for initiating and sustaining an immunization program for adolescents. Other considerations
include the affordability and cost-effectiveness of vaccination relative to other programs
competing for resources and the likelihood of cultural acceptability, political will, and public
support.
Ultimately, the effectiveness of the HPV vaccine will require improved systems for
providing health care to adolescents. Sociocultural sensitivities in the area abound, although
concern about vaccinating adolescents against a sexually transmitted disease have been tempered
by an emphasis on the vaccine’s role in cancer prevention. Yet in countries characterized by
mistrust of governmental health care initiatives, vaccination programs targeted toward young
women may be misunderstood as attempts to control fertility – misapprehensions in some
countries have occurred even with the polio and tetanus vaccines. If such fears can be alleviated,
an adolescent immunization program, possibly school-based or a community outreach program,
could be designed to deliver adolescent health services and immunizations against tetanus,
measles, rubella, meningococcus, typhoid, as well as HPV. In areas where the rate of school
enrollment among girls is low, community-based efforts to reach girls outside school must be
evaluated.

178

The factors with the greatest influence on the cost-effectiveness of vaccination will be the
price of the vaccine and the costs of a program to reach adolescents. First and foremost the price
of the HPV vaccine will need to be addressed. Dramatic price tiering will be required to facilitate
its timely use in developing countries. According to the WHO, manufacturers of the HPV
vaccine have declared that they are willing to set different prices for countries with different
economic conditions (World Health Organization, 2007).
The GAVI Alliance (formerly known as the Global Alliance for Vaccines and
Immunizations) – a partnership of national governments, the WHO, The World Bank, The Bill
and Melinda Gates Foundation, the vaccine industry, public health institutions, and
nongovernmental organizations – provides technical assistance and financial support for vaccines
in countries with a gross national income of less than $1,000 per capitia, as well as in China,
India, and Indonesia. With subsidies from GAVI, HPV vaccine can be brought to the poorest
parts of the world. In October 2008, the GAVI Alliance board agreed to prioritize HPV vaccines
along with new vaccines against typhoid, Japanese encephalitis, and rubella (GAVI Alliance,
2009).
Through large-scale purchasing power, GAVI estimates it can bring the cost of the HPV
vaccination down to a fraction of the current price. In Kenya, for example, it is estimated to cost
$8-$25 per vaccinated girl, including delivery and administration (GAVI Alliance, 2009).
Physician Lob-Levyt described a recent recommendation on cervical cancer by the WHO’s
Strategic Advisory Group of Experts (SAGE) as a “stepping stone on the way to more equity in
global health” (GAVI Alliance, 2009, ¶9).
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Mandating the HPV Vaccine for Girls Only Violates Title IX
Having played college basketball for a Division I university, I have some experience with
Title IX of the Education Amendments of 1972. Currently, ACIP recommends that all 11- and
12-year old girls be vaccinated, as well as all females 13 to 26 not previously vaccinated, and
upon recommendation of their physicians (CDC, 2009a). Although the ACIP recommendations
do not translate into vaccination requirements by individual states or mandatory insurance
coverage, state health authorities and private insurers usually follow the ACIP’s suggestions
(Cook, 2008).
If state governments mandate the HPV vaccine for school enrollment it will violate Title
IX. A girls-only mandate could also violate the Equal Protection Clause of the Fourteenth
Amendment of the United States Constitution.
Title IX of the Education Amendments of 1972 has stated that, “[n]o person in the United
States shall, on the basis of sex, be excluded from participation in, be denied the benefits of, or
be subjected to discrimination under any education program or activity receiving Federal
financial assistance” (Education Amendment of 1972). The Department of Education’s Office
for Civil Rights, which has been delegated the task of interpreting Title IX, has stated, “Title IX
applies to all public and private educational institutions that receive federal funds, i.e., recipients,
including, but not limited to, elementary and secondary schools, school districts, proprietary
schools, colleges, and universities” (Cook, 2008, p. 221). Nearly all educational institutions
receive federal financial assistance of some sort, even if through only one program like the
school lunch program. This federal financial assistance brings the educational institution under
the purview of Title IX.
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Since most schools receive federal funding, it could be argued that legislation compelling
only girls to be vaccinated for HPV as a condition for school enrollment is a violation of Title IX
because it denies girls participation in school based on gender. Currently, there is no reported
case law addressing an issue comparable to legislation requiring only single-sex vaccination as a
condition of school attendance, so it is unclear how a state court would analyze such a case
(Cook, 2008).
The Equal Protection Clause of the Fourteenth Amendment of the United States
Constitution states that no person shall be denied “the equal protection of the laws.” The
Supreme Court has interpreted the Equal Protection Clause to require that, when a law or policy
imposes a different standard or burden on one gender, the government must prove an
“exceedingly persuasive justification” for that sex-based classification (Cook, 2008). Obligating
girls to receive an HPV vaccination could potentially violate the Equal Protection Clause if the
legislation has no such exceedingly persuasive justification for its sex discrimination.
Until the HPV vaccine is approved for boys, and a mandated HPV vaccine law is gender
neutral, the rights of girls under Title IX and the Equal Protection Clause are protected.
Vaccination of Males May Protect Them
The HPV vaccine is the first to be mandated for only one gender. This is likely because
the vaccine was approved for girls and not boys, and most research has focused on HPV
infection in women because of the association between HPV infection and cervical cancer
(Dunne, Nielson, Stone, Markowitz, & Giuliano, 2006). Data demonstrating the safety and
immunogenicity of the vaccine are available for males aged 9-15 years. Three Phase 1 studies
demonstrated that safety, tolerance, and immunogenicity of the HPV vaccine were similar to
men and women (Partridge & Koutsky, 2006). The first two studies focused on HPV 16 and 11
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respectively, while the third study demonstrated high levels of immunogenicity to the HPV
vaccine 6/11/16/18 vaccine in 10-15-year-old males. Phase III clinical trials examining the
vaccine’s efficacy in men and adolescent boys are currently underway, with results available in
the next couple of years (Partridge & Koutsky, 2006). On September 9, 2009, an advisory panel
of the FDA voted in favor of the safety and efficacy of Gardasil to inhibit genital warts in boys
and men ages 9 to 26 (Singer, 2009). The FDA typically has followed the recommendations of
such panels on drug approvals.
HPV infection is common among men. One percent of the male population aged 15-49
years had genital warts, with peak incidence in the 20-24-year-old age group. A recent cohort
study found the 24-month cumulative incidence HPV infection among 240 men aged 18-20 years
to be 62.4%, nearly double the incidence of their female counterparts. This result may have been
due to the increased sensitivity of HPV testing procedures used in the study. Nonetheless, the
results reaffirm that HPV is common and multifocal in males. Men are also at risk for HPVrelated anogenital cancers. Up to 76% of penile cancers are caused by "high-risk” types of HPV.
Fifty-eight percent of anal cancers in heterosexual men and 100% percent among homosexual
men are positive for the “high-risk” types of HPV. Therefore, assuming vaccine efficacy is
confirmed in males, they also could be protected through HPV vaccination. Men are assumed to
be the major reservoirs of genital HPV infection for women, although comparatively little is
known about the natural history of HPV in men (Hernandez et al., 2008).
After viewing the literature on vaccinating boys with the HPV vaccine, I found an
interesting paradigm that is worth noting. When the HPV vaccine was approved for girls as
young as 9-years-old in 2006, some critics touted that the drug might encourage girls to be more
promiscuous and practice risky sexual behavior (Krishnan, 2008). Now that the drug is being
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considered for boys of the same age, the issue has shifted to cost effectiveness and safety. Not
one piece of literature that I read indicated a concern for an increase in male promiscuity. “We
are still more worried about the promiscuity of girls than the promiscuity of boys,” said Susan
Reverby, a Wellesley College professor (Should the FDA Approve Gardasil for Boys, 2009, p.
9). She continued to assert the “There’s a double standard” (p. 9). This is another example how
women are devalued in our society by placing more emphasis on our sexual lifestyle and not our
safety. Delores Liston and Regina Moore-Rahimi (2005) write:
Based on our research, we are convinced that shifting and oftentimes mutually
contradictory criteria form a double standard that perpetuates the marginalization of
women in our contemporary landscapes and holds women in condemnation almost
regardless of what they do or say. (p. 212)
Vaccinating Both Sexes May Better Protect the Public
Bioethical feminists Adrienne Asch and Gail Geller (1996) have written, “Because
women’s lives are inextricably intertwined with those of their intimate partners, there are no
women’s issues that are not also issues for those partners” (p. 334). Since HPV is transmitted
between sexual partners, some experts think the virus will not be sufficiently contained until
boys also receive HPV vaccinations also (Krishnan, 2008).
Early studies have shown Merck’s HPV vaccine to be both effective at producing
immunity in boys and safe to use. A 2007 study tested the safety and immunogenicity of the
HPV vaccine on preadolescents and adolescents of both sexes (Reisinger et al., 2007). The study
found the in 9- to 15-year old adolescents, the HPV vaccine was generally well tolerated and
induced persistent immune responses in the majority of subjects for at least 12 months following
the completion of the third dose (Reisinger et al., 2007). They concluded that the vaccine
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durability supports universal HPV vaccination programs in adolescents to reduce the burden of
HPV disease, particularly cervical cancer and precancers (Reisinger et al., 2007). It has been
licensed for males in 25 nations of the European Union and in Australia. In the United States,
however, the FDA requires proof that the vaccine actually prevents infection. Currently, the FDA
is considering approval of Merck’s HPV vaccine for the prevention of genital warts in males
(Singer, 2009). Merck is hoping to expand its drug licensing to include the prevention of HPVrelated cancers in males (Singer, 2009).
Studies have identified HPV DNA on male genitalia, anal mucus and in the oral cavity.
Peak incidence was found in men between ages 30 and 39 (Dunne et al., 2006). Penile HPV
prevalence rose with increasing number of sexual partners (Dunne et al., 2006). Overall, HPV
prevalence appeared to be lower in men than women, suggesting penile tissue could be less
receptive to high-risk HPV (Dunne et al., 2006).
When one evaluates the mode of transmission of HPV, it stands to reason that a
population would be more efficient at reducing infection that both males and females can
transmit if they are both protected with the vaccine. A mathematical modeling study was
published in 2007 that assessed HPV vaccination strategies. The authors concluded that that
vaccinating 70% of girls before age 12 years would reduce the incidence of genital warts (83%)
and cervical cancer (78%) due to HPV types 6, 11, 16, and 18 (Elbasha, Dasbach, & Insinga,
2007). When they added vaccinating boys and men to this model, they concluded that there
would be further reduction of the incidence of genital warts (97%), cervical dysplasia (91%), and
cervical cancer (91%) (Elbasha et al., 2007). This model was limited to cervical cancer, cervical
dysplasia, and genital warts. This model did not take into account a possible reduction in HPVrelated anal, head, and neck cancers. As more favorable data are collected in relation to
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vaccinating both genders, the FDA could eventually recommend that all boys be vaccinated with
the HPV vaccine in the near future.
These last two sections focused on how HPV and the vaccine relates to boys and men.
One might wonder why I chose to include these sections in a bioethical feminist inquiry. From
all the reading I have done on bioethics and feminism I have come to realize that bioethical
feminist theory does not discriminate based on class, race, and gender. Its goal is to end
oppression, discrimination, and marginalization of all people, not just women. I chose to add the
sections about HPV and men because if the vaccine could be useful in preventing genital warts,
anal, penile, or throat cancers then they should be afforded every opportunity to have access to
the vaccine. Withholding this vaccine from men also marginalizes them.
The current FDA approval for the vaccine is for women only. This sequestering of a
single gender also highlights how women are punished for their sexual behavior whereas men are
excluded from taking any responsibility for the spread of the disease. Men should be included as
viable recipients for the vaccine to ensure the reduction of the four types of HPV being spread
throughout the population.
Summary
Cervical cancer is a classic example of inequity, in the differential impact it has on
women in low- and middle- income countries, with higher incidence and higher mortality than in
wealthy countries. Cervical cancer remains a major killer of women globally, even though the
disease has declined dramatically in developed countries with the advent of reliable Pap smear
testing. The HPV vaccine could have its biggest impact in high-risk areas. But the poverty that
limits Pap smear screening in the developing world – causing the disparities in global cervical
cancer rates – will also affect vaccine distribution. The advent of new vaccines that could prevent
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more than half the cases of this deadly disease raises the possibility that this disparity could be
reduced eventually, even without massive investments in cervical screening services. However,
the promise that the vaccine offers can only be realized if it reaches those who need it most, and
without delay that often befalls new health technologies. While clearly there are challenges that
could cause delays or leave important groups of girls without the protection they need, there are
also potential remedies for these barriers that are feasible. Vaccine delivery through schools and
perhaps community outreach mechanisms appears to be both affordable and acceptable methods
of distribution. Financing remains a substantial challenge, especially in light of the current
economic crisis. Low-income countries must look to the GAVI Alliance for subsidies both to
purchase vaccine and the operational costs of vaccine delivery.
Another bioethical feminist issue that arises when discussing the possibility of mandating
the HPV vaccine for girls and not boys in the United States is the fact that it would violate their
constitutional rights afforded to them through Title IX and the Fourteenth Amendment.
The final bioethical feminist issue is the impact of the HPV vaccine on boys and men.
Like women, men suffer from HPV-related cancer and genital warts. Early clinical trials with
boys show a significant immune response to the HPV vaccine. There are also data that shows the
vaccine to be safe and well tolerated in males. With this being said, men should be afforded the
opportunity to receive the HPV vaccine in order to protect them from genital warts and HPVrelated cancers.
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CHAPTER 8
CONCLUSION
Human papillomavirus, or HPV, is a highly contagious sexually transmitted disease that
causes cervical cancer in women. Gardasil, The HPV vaccine produced by Merck & Company,
prevents four types of HPV, including two of the most dangerous variants that are responsible for
70% of cervical cancer and two types that cause 90% of the cases of genital warts. In the summer
of 2006, a federal vaccine advisory panel to the FDA voted unanimously to recommend the HPV
vaccine for women and adolescent girls. In one respect, this new vaccine is a common-sense
addition to an established national vaccine schedule as lengthy as it is routine. Unlike already
familiar vaccines that target all children entering school, the FDA advisory panel recommends
the HPV vaccination only for girls and young women ages 11 to 26. Gardasil combats an STD
that, often asymptomatically, hides itself in women, potentially triggering a deadly cancer. The
HPV vaccine is therefore without precedent in that it forces the American public to evaluate
what it means to protect women, what women need protection from, and what price our society
is willing to pay to provide that protection.
The Connection to Curriculum Studies
The completion of this dissertation encompasses the very goal of curriculum studies.
William Pinar (2004) states, “The school curriculum communicates what we choose to
remember about our past, what we believe about our present, what we hope for the future” (p.
20). By sharing my pathography I have helped readers remember the past. By discussing the
current HPV vaccine debate I have invited readers to focus on the present. I have likewise
invited readers to join me in the hope for the future that includes the reduction of cervical cancer
worldwide.
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In completing this dissertation I hope to have made a niche in the curriculum studies field
for medicine, science, and bioethics. The kinds of debate I presented in this dissertation must be
discussed in the curriculum studies field. Science and medicine are such a big part of American
society that as educators we would be remiss not to critically discuss these topics within the
walls of our schools. William Pinar has written:
If public education is the education of the public, then public education is, by definition, a
political, psycho-social, fundamentally intellectual reconstruction of self and society, a
process in which educators occupy public and private spaces in-between the academic
disciplines and the state (and problems) of mass culture, between intellectual
development and social engagement, between erudition and everyday life. (2004, p. 15)
As educators we must engage our students in conversations that involve the political, social, and
ethical dilemmas of our society. If we do not, we are educating a class of mindless, non-critical
thinkers who will become a drain on society instead of becoming productive members of a
community.
Possible Future Studies
When I was in the process of orally defending this dissertation to my committee, the FDA
recommended Gardasil® for boys and men in order to prevent genital warts. According to the
FDA, genital warts affect 2 out of every 1,000 men in the United States (Food and Drug
Administration, 2009. It would be interesting to conduct a study ascertaining how many parents
would be willing to vaccinate their boys against a disease that is not life threatening.
I would also like to do a qualitative analysis on what girls and women know about HPV
and its connection to cervical cancer. It would be interesting to see how many women understand
the importance of having annual exams.
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Summation
Following FDA approval, the National Advisory Committee on Immunization Practices
(ACIP) recommended routine vaccination for girls ages 11-12 with three doses of the HPV
vaccine. Thereafter, state legislatures around the country engaged in an intense effort to pass
laws mandating vaccination of young girls against HPV. This activity was spurred in part by an
intense lobbying campaign by Merck.
The United States has a robust state-based infrastructure for mandatory vaccination that
has its roots in the nineteenth century. Mandating vaccination as a condition for school entry
began in the early 1800s and is currently required by all 50 states for several common childhood
infectious diseases. Some suggest that mandatory HPV vaccination for minor females fits
squarely within this tradition.
Nonetheless, state efforts to mandate HPV vaccination in minors has raised a variety of
concerns on political, social and bioethical grounds. Unlike other diseases for which state
legislatures have mandated vaccination for children, HPV is neither transmittable through casual
contact nor potentially fatal during childhood. It also would be the first vaccine to be mandated
for use exclusively in one gender. As such, HPV vaccine presents a new context for considering
vaccine mandates.
In this bioethical feminist theory inquiry, I reviewed the scientific evidence supporting
the HPV vaccine’s approval and legislative actions in the states that followed. I presented the
reasoning behind the government’s push to mandate the vaccine for adolescent girls. The logic
for mandating the HPV vaccine begins with the fact that it is a remarkable biomedical and public
health achievement. Research confirms that HPV is responsible for 99% of the cases cervical
cancer, and the technology now exists to help prevent women from developing HPV-16 and -18
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induced cervical cancer. Second, administering the HPV vaccine is cost effective and
significantly saves health care dollars otherwise spent on diagnosis and treatment of this
preventable disease. Furthermore, it eliminates the negative emotional and psychological feelings
that can follow such a diagnosis. In addition, school-aged children are the appropriate population
to whom to administer this vaccine because it must be given before the onset of the first sexual
experience. Moreover, previous school-wide vaccination programs demonstrate that this is the
optimal venue for rapid and widespread immunity. Finally, the medical community claims that
the HPV vaccination is not synonymous with support and approval of promiscuity, but rather a
cry to rally together to eradicate cervical cancer worldwide. Therefore, this public health
breakthrough should not be associated with promoting sexual activity in adolescent girls, but
rather promoted as a responsible and necessary step in protecting children’s future health. Cancer
is a public health challenge that needs to be conquered; it is not an appropriate venue for political
or ideological debate.
I then argued that mandatory HPV vaccination at this time is both unwarranted and
unwise. While the emergence of an HPV vaccine reflects a potentially significant public health
advance, the vaccine raises several concerns. First, long term safety and effectiveness of the
vaccine are unclear. Second, the legal and ethical justifications that have historically supported
state mandated vaccination do not support mandating the HPV vaccine. Specifically, HPV does
not threaten an imminent and significant risk to the health of others. Mandating the HPV vaccine
would therefore constitute an expansion of the state authority to interfere with individual and
parental autonomy. Engaging in such expansion in the absence of robust public discussion runs
the risk of creating a public backlash that may undermine the goal of widespread HPV vaccine
coverage and lead to public distrust of established childhood vaccine programs for other
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diseases. Third, the current sex-based HPV vaccination mandates present constitutional concerns
because they require only girls to be vaccinated. Such concerns could lead to costly and
protracted legal challenges. Finally, vaccination mandates will pose economic burdens on federal
and state governments and individual practitioners that may have a negative impact on the
provision of other health services.
Finally, I moved the debate to the ethical issues that arise when discussing mandating the
HPV vaccine for girls and how cervical cancer is a disease that produces a health inequity.
Globally, 80% of cervical cancer cases arise in developing countries due to disparities in access
to cancer screening resources. Similar disparities exist in the United States, where the impact of
cervical cancer on minority populations is disproportionate. Compounding the access problem,
Merck’s HPV vaccine’s $360 price tag makes its three-shot, 6-month regimen among the most
expensive vaccines ever marketed. In absence of government intervention, therefore, those most
in need of this vaccine will also be those least able to afford it.
In discussing the political, social, and bioethical controversies that surround the HPV
vaccine, I have presented a complete picture of a significant health issue that affects not only
women, but all of us.
Implications for the Future- Comes Down to Open and Clear Communication
There were legitimate scientific reasons to promote the use of this vaccine. It is very
effective and has minimal known side effects. It needs to be administered before exposure to
HPV, so giving it to children makes sense. The HPV vaccine could have especially huge benefits
if it were used widely in developing countries, where Pap smears are not common and cervical
cancer kills hundreds of thousands of women. But the push to mandate its use in the U.S. was too
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early, too aggressive, and – most important came from the wrong advocate (politicians and a
large drug company).
This vaccine still faces plenty of scrutiny. The marketing of this vaccine as a cancer
vaccine is inaccurate. It is not a cancer vaccine. It is a vaccine against a virus that may cause
cancer; the types of HPV not covered by the vaccine cause approximately 50% of abnormal Pap
smears and 30% of cervical cancers (Krishnan, 2008). Indeed, according to the FDA, the studies
used to approve Gardasil proved it prevented development of pre-cancerous lesions but could
not prove it prevents cancer, since “the study period was not long enough for cervical cancer to
develop” (FDA, 2006, ¶2). One must hope that being vaccinated won’t lead women to a sense of
complacency about getting yearly Pap smears, since that could lead to an increase in deadly
cancers (Bevington, 2007). Given these indiscretions, Merck started to feel pushback first from
anti-vaccination groups, then concerned parents and citizens. Merck has since decreased its
marketing and lobbying effects.
The biggest future challenge that the HPV vaccine will face is in communication of
information between the patient and the medical and political communities. The entire
controversy surrounding the HPV vaccine is a result of a communication gap between those
making the medical decisions, those enforcing public health policy, and those on the receiving
end of those policies. Matthew Wynia (2007b) has written, “Success in public health relies on
public trust” (p. 4). Even with the trust of the public, communicating about vaccines poses a
number of special challenges.
First, like other vaccines, they are often seen as “treatment” for a disease one doesn’t
have (Allen, A., 2007). Convincing someone to receive treatment to prevent a future disease can
be difficult. Some might say this is a moot point because vaccine compliance rates are very high
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in the United States. This is true for the vaccines that prevent contagious diseases. When dealing
with the HPV vaccine and the disease it prevents the issue is more problematic because some
may say, contracting an STD was based on a behavioral choice and not by chance. Overcoming
this issue will have to come from a trusted health authority. Bioethics attempts to foster positive
and personal relationships between patient and physician. This personal relationship based on
trust and confidence will be imperative to improve uptake of the HPV vaccine especially when
dealing with parents and their adolescent children.
Second, the diseases in question may be scarce or, ironically, become scarce because
vaccination ensures their demise. This makes it increasingly difficult to convince people that any
perceived risk of vaccination is worth it, since the infection in question eventually comes to be
perceived as not a threat. In short, vaccines can become victims of their own success. For
example, when is the last time you saw a child crippled by polio or disfigured by smallpox? HPV
is not a scarce disease, in fact is the most prevalent STD in the United States. The issue with
cervical cancer is that it is not found in epidemic portions in the United States. Far more women
die from heart disease (approximately 329, 238 heart disease related deaths in women in the
United States in 2005) and breast cancer (approximately 41,116 deaths in 2005) than from
cervical cancer (approximately 3600 deaths in 2005; CDC, 2009g). Convincing parents to
vaccinate their young daughters for a disease that is not perceived as immediately life threatening
will be difficult.
Third, because vaccination is so common, it is often blamed for other, random events. It
is very difficult – some say impossible – for us as humans to understand or accept randomness in
our lives. As a result, we create links and patterns even where there are none. So when we
receive a flu vaccine and the next day come down with a cold, we perceive a link even though
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the flu vaccine contains no virus and is typically delivered at just the time when catching cold is
common. This becomes even more of an issue when a child receives a vaccine and then has a
seizure, or is diagnosed with autism, or develops liver failure. Scientific based studies that
disprove claims of causality in such situations are virtually impossible to believe for parents who
see an obvious pattern staring them in the face. As it stands now, the CDC claims that the HPV
vaccine is safe and causes no major complications upon administration. With the HPV vaccine
being so newly introduced on the market long-term data are not available. Physicians and parents
will need to continue to monitor the CDC’s vaccine website for any major complications or side
effects due to the HPV vaccine. The website is http://www.cdc.gov/vaccinesafety/vaers/gardasil
.htm. The CDC also produces a vaccine information sheet that summarizes all pertinent
information pertaining to the vaccine (see Appendix F).
Finally, Merck has faced a special problem communicating to the public about this
vaccine – namely because it protects against an STD. Religious conservatives were bound to
play the promiscuity card and argue against vaccination of girls without raising promiscuity
issues about vaccinating boys, just as they did with the Hepatitis B vaccine. To vaccinate girls
against an STD, the argument goes, is to give them a license to have sex. Of course by this same
argument, a vaccine for heart disease should be opposed because it would encourage unhealthy
eating, and wearing a motorcycle helmet would promote reckless driving. There is simply no
evidence that vaccination against an STD increases sexual promiscuity (Monk & Wiley, 2006).
What I have found more egregious is the fact that promoting abstinence should rely on
threatening those who decline to be abstinent with the risk of getting cancer. Merck will need to
re-educate the public with the latest efficacy and safety findings. They will need to be more
transparent to the public about why the vaccine has a $360 price tag, especially when we review
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the incidence of HPV infection and cervical cancer. The facts state that that the women who have
the highest incidence of cervical cancer are the ones with the least amount of money.
Overcoming communication challenges like these demands clear and effective
communication by a trusted health authority. Lack of trust will breed both fear and nonadherence. Public health is, after all, a public endeavor (Wynia, 2007b). Public health institutions
and those in the pharmaceutical industry should be concerned with maintaining their
trustworthiness not their bank accounts. They should be prepared to back up their
recommendations with rock-solid science, especially in making recommendations. Ensuring that
information is consistent and clear is also key. Bioethical feminists Alisa Carse and Hilde Nelson
(1999) write, “When we are in conditions of dependency, we must often place presumptive faith
in those entrusted with our welfare, relying on them not to exploit our vulnerability or to abuse
the power we have given them” (p. 26). That’s where Merck lost its way. Some in the public
health community warned Merck not to pursue an aggressive lobbying campaign because they
knew that, in the end, it could tarnish the entire public health communication endeavor. Public
trust relies on a clear separation between those making the money on vaccination and those
making the decisions about which vaccines to recommend or mandate.
Suggestions
Before government officials decide whether the HPV vaccine should be mandated,
ethical concerns must be alleviated. There are three complementary steps that can help calm
parental fears and promote the purpose of this vaccine: to save the lives of women. First, the
public must realize that the HPV vaccine has the potential for decreasing the number of women
who contract HPV-related cervical cancer. There must be a clear understanding by the public
that HPV is a sexually transmitted disease that is linked to several different cancers found in both
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men and women. How is this accomplished? Not through abstinence-only education programs.
Schools must be realistic in today’s world where adolescents are exposed to tremendous amounts
of media that promote promiscuity, physical beauty, and sexual innuendoes. Schools and
community organizations where adolescent education takes place must incorporate a
comprehensive sexual education program that includes abstinence education, but also includes
educating about safe sex practices; teen pregnancy; positive self-image; and incidence of
sexually transmitted diseases, especially the link between HPV and cervical cancer.
Second, public health officials need to stress that the reason it must be given early in life
is that inoculation at that point provides that best chance of lifetime protection. Last and most
important, there must be a complete separation of the medical matter of preventing cancer from
the moral matter regarding premarital sex. Health officials must make serious attempts to reach
out to the religious community, which has moral qualms. Perhaps Merck can circumvent this
controversy. While promoting the inclusion of Gardasil as a standard or required form of
vaccination, the company might also work with family-focused groups who oppose sex outside
of marriage to co-develop educational tools for discouraging premature sexual relationships
citing medical, emotional, and practical reasons for doing so. If these three issues are addressed,
the government will not have to mandate Gardasil, because parents will understand that they are
protecting their daughters against the second leading cause of cancer death in women.
The HPV vaccine is an important part of the cervical cancer management picture, but not
the whole solution. Greater awareness of disease risks, safe sex, condom use, and improved “optin” cervical cancer screening should also have been promoted. If Merck had run a public health
education campaign, rather than simply plugging its product, Gardasil might have had a better
reception, and the real issue of saving women’s lives could be realized.
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One Last Thought
I truly believe that the HPV vaccine is a great medical advancement for all men, women,
and children. It is the first vaccine that has the potential of preventing cancer. After 2 years of
reading, research, and thorough scrutiny of the vaccine, I do not believe that this immunization
should be mandated. The decision to receive this particular vaccine must be left up to parents and
family health providers. I do have concern for the marginalized girls who need this vaccine the
most, and am comforted in knowing as long as the government provides the funds for the
Vaccines for Children program they will have access to the HPV immunization. If this financing
ever changes, I would ultimately support a government mandate to ensure that all girls will have
access to the vaccine. My question to Merck would be, “Why is Gardasil® still being sold in the
U.S for $360 when the GAVI Alliance acquires the vaccine for roughly $25 per immunization?”
For some families this vaccine is a welcome advancement; for others it poses an intrusion
on family values and morals. Deciding to vaccinate one’s 11- or 12-year old daughter is a very
personal issue and needs to stay within the family unit. Intrusion from the government represents
a complete disrespect of one’s autonomy to make personal health care decisions. Even with my
personal history of cervical dysplasia, I welcome this vaccine with open arms, but I want that to
be my decision not the decision of my local politician.
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Appendix A
Current introduced state-by-state legislation of the HPV vaccine
State
Alabama

Legislative Summary
House Bill 42 – States that parents have the
option to immunize; requires HHS to mail
information to parents about relationship
between HPV and cervical cancer.

Status
Passed

Alaska

Requires offering a voluntary vaccination
program

Passed

Arizona

Legislation introduced in 2006-2007
Senate Bill 1437—Allocate money for outreach
and education programs;
House Bill- 2086/ Senate Bill 1502 – requires
insurance to pay for vaccine;
Senate Bill 1093 – prohibit health departments
from requiring vaccine

Pending

California

Requires health insurance plans that cover the
treatment of cervical cancer to also cover the
vaccine (Vetoed in 2008); Reintroduced in 20092010 term and is pending.

Passed by Senate;
vetoed by Governor on
9/30/08. Now sits in a
suspense file as of
07/09

Colorado

Senate Bill 80 – Require information to be given
to parents about the HPV vaccine and requires
the vaccine be given to girls before age 12 in
order to attend school, does allow exemption if
parent objects.
House Bill 1016 – Request a Medicaid waiver
from the federal government to provide HPV
vaccine for girls 12-18 with parental consent
Co Chapter No. 41 (2007) – Allocates 4% of
state tobacco settlement money to cervical
cancer immunization fund.
Co. Chapter No. 212 (2007) – Include
information on HPV and its link to cervical
cancer along with information about the vaccine
in sexual education classes at schools.
Co. Chapter No. 318 (2007) – Creates cervical
cancer immunization program. Adds vaccine to
Medicaid benefits. Requires certain insurance
programs to cover the vaccine.

Passed

Connecticut

House Bill 6977 – Would require the first dose
of the HPV vaccine for girls entering 6th grade.

Passed
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Delaware

No legislation proposed.

District of
Columbia

Mandates that all girls receive the vaccine before
that age of 13. Parents may opt-out.

Florida

Georgia

Hawaii

Idaho

Illinois

Indiana

Senate Bill 660 – proposed that certain students
receive the HPV vaccine before entering school
and would require public and private school to
provide information on HPV and the HPV
vaccine.
No new legislation proposed.
House Bill 736 – Would require public schools
to offer parents of 6th grade girls with
information concerning HPV and the
immunization.
House Committee Resolution 51 – Requests the
health department to expand its educational
programs to increase awareness by both men and
women and suggest new and innovative
measures to better distribute information in order
to prevent cervical cancer with the goal of
eventual eradication.

Passed

Died in committee

Pending

Pending

No legislation proposed.
House Bill 115 – Would create an awareness
campaign on HPV and cervical cancer; provides
parents with information; would require girls to
receive the HPV vaccine upon entrance into the
6th grade. Bill allows parents to opt out.
Senate Bill 10 – Would require the HPV vaccine
for 11 and 12 year old girls, but allows parents to
opt out. Also requires the school to track the
number of immunized children attending school.
Public Act 095-0422 (2007) – Requires
insurance companies to provide coverage for the
HPV vaccine.
Public Law No. 80 (2007) (Senate Bill 0327) –
requires parents of girls entering the sixth grade
to receive information about the link between
HPV and cervical cancer and the availability of
the HPV vaccine. Parents of 6th graders must
sign a statement notifying the school of their
decision to vaccinate or not vaccinate their child.
School must provide this information to the state
Health Department. Does not mandate the
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Passed

Passed

vaccine for school entrance.

Iowa

Kansas

Kentucky

Louisiana

Maine

Maryland

Massachusetts

Michigan

House File 661 – would require insurance
providers to cover the cost of the HPV vaccine
for females 9-26 of age.
House File 611 – Requires that educational
materials for 7th graders also include information
on HPV and the availability of the vaccine.
House Resolution 6019 – Urges the FDA to use
caution in approving new vaccines such as
Gardasil.
House Bill 2227 – Would require vaccination for
girls entering the 6th grade. Also requires parents
to receive information on the link between HPV
and cervical cancer.
House Bill 396 – Would require immunization
against HPV for school-age children; requires
parental statements to withhold consent to be
filed with the immunization certificate.
House Bill 357 – Would require insurance
companies to cover HPV vaccine.
House Bill 359 – Would require schools to offer
HPV information and vaccines under certain
circumstances.
Maine Chapter No. 73 – Establishes financial
coverage of the HPV vaccine through the
MaineCare program and improve public
awareness of vaccine.
Senate Bill 54 – Would require all girls entering
6th grade to be vaccinated.
Md. Chapter No. 191 – Establishes a task force
for the HPV vaccine.
Senate Bill 102 – Would require all 6th grade
girls to receive the HPV vaccine. Allows parents
to opt out.
House Bill 4164/4104 – Would require the HPV
vaccine.
House Bill 5171 – Would require all pupils and
parents receive information regarding the HPV
vaccine.
House Bill 5322 – Would require schools to
provide HPV information and vaccines under
certain circumstances.
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Pending
Passed

Pending
Passed

Passed, sent to senate
Pending
Passed House and
Senate; Gov. did not
sign
Passed
Withdrawn
Passed
Pending
Pending
Pending

Passed

Missouri

Minnesota

House Bill 802 – Mandates that girls entering the
6th grade receive the vaccine. Parents may opt
out.
Senate Bill 514 – Would provide parents
information on HPV, cervical cancer, and the
HPV vaccine.
Would require health insurers to provide
coverage for HPV screenings for cervical cancer.
Senate File 243 – Would require the HPV
vaccine for girls entering school at age 12.
Provides parents with information and allows
exemptions.
MN Laws, Chapter 147 – Created a study to
closely review the risks, benefits, availability,
efficacy, and coverage of HPV vaccine.

Pending

Pending

Pending
Passed

Mississippi

House Bill 895 – Would require all girls entering
6th grade to be vaccinated.

Montana

No proposed legislation.

Nebraska

Legislative Resolution 170 – Would create an
interim study of the HPV vaccine.

Pending

Nevada

NV Chapter No. 527 – Requires insurance
companies to cover the cost of the HPV vaccine.

Passed

New Hampshire

Created a voluntary program which can provide
the vaccine free to girls between 11-18.

Passed

New Jersey

New Mexico

New York

North Carolina

Would require Medicaid, NJ FamilyCare, and
the State Benefits Program to cover the cost of
HPV vaccines.
Senate Bill 407 – Requires insurance plans in the
state to cover the FDA-approved HPV vaccine
for girls 9 to 14.
Senate Bill 1174 – Would require the HPV
vaccine for girls between 9 and 14. Allows
parents to opt out.
Would require girls born after January 1, 1996 to
be vaccinated. Provides opt out clause for
parents.
Would require insurance companies that cover
well-child visits and cervical screening to cover
vaccine
Requires health department to provide
educational information to parents of children in
grades 5-12.
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Died in committee

Pending
Passed
Vetoed
Pending
Passed
Passed

North Dakota

Provides funding for distribution of educational
materials on HPV and the HPV vaccine.

Passed

Ohio

Would require all girls entering the 6th grade to
be vaccinated. Schools will not allow any
student to attend classes for more than 14 days
without written information on when they are
receiving the vaccine. Parents are allowed to opt
out.

Pending

Oklahoma

Senate Bill 487 – Would require HPV vaccine
for al girls entering the 6th grade.

Pending

Oregon

Pennsylvania

Rhode Island
South Carolina
South Dakota

Tennessee

Texas

Utah

House Bill 3253 – Would require health benefits
plans to cover the cost of the vaccine for girls 11
years or older.
House Bill 524 – Would require insurance
policies to provide coverage for vaccine.
House Resolution 42 – Would designate January
as cervical cancer awareness month.
House Bill 5061 – Would require insurance
companies to cover vaccine.
House Bill 3136 – Would require 6th grade girls
to receive the vaccine. Allows for parents to opt
out.
House Bill 1061 – Fives the Department of
Health $9.2 million to offer the HPV vaccine to
girls between 11 and 18.
House Bill 1517 – Would require the
Department of Health to report on the
populations by age affected by HPV and report
to the legislature with a recommendation
concerning the HPV vaccine.
House Bill 2220 – Would allow the Executive
Commissioner of Health and Human Services
Commission to require immunization against
HPV for person’s admission to elementary or
middle school.
Senate Bill 110 – Would provide information to
parents and would require the HPV vaccine for
girls entering 6th grade.
House Bill 1379 – Requires the Department of
Health to develop and distribute education
materials.
House Bill 358 – Establishes an awareness
campaign on the causes, prevention, and risks of
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Pending

Pending

Passed
Pending
Passed

Pending

Pending

Pending

Passed

Passed

cervical cancer.

Vermont

Virginia

Washington
West Virginia

House Bill 256 – Requires all female students
entering the 6th grade to receive the HPV
vaccine. Allows parents to opt out.
Senate Bill 722 – Would remove the requirement
or girls to receive vaccine for school attendance.
Senate Bill 1230 – Requires the HPV vaccine for
girls entering 6th grade.
House Bill 1802 – Provides all parents of 6th
graders with information on HPV and where
they can get the vaccine.
House Bill 2835 – Would require the HPV
vaccine for girls entering the 6th grade. Allows
for exemptions.

Wisconsin

Senate Bill 252 – Would require schools to
provide HPV information.

Wyoming

No proposed legislation.

Pending
Pending
Passed
Passed
Pending
Failed

Source: Data compiled from National Conference of State Legislators. Retrieved September
18, 2009, from
http://www.ncsl.org/IssuesResearch/Health/HPVVaccineStateLegislation/tabid?14381?D
efault.aspx
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Appendix B
Political Cartoon Depicting Merck’s Greed

Source: Picture by Khalil Bendib. No copyright information provided. Retrieved October 4,
2009, from http://www.corpwatch.org/article.php?id=14401
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Appendix C

Source: CDC website. Retrieved September 30, 2009, from
http://www.cdc.gov/vaccines/recs/schedules/downloads/child/2009/09_06yrs_schedule_pr.pdf
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Appendix D

Source: CDC website. Retrieved September 30, 2009, from
http://www.cdc.gov/vaccines/recs/schedules/downloads/child/2009/09_718yrs_schedule_pr.pdf
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Appendix E

Source: Data compiled from the CDC website. Retrieved September 30, 2009, from
http://www.cdc.gov/cancer/hpv/statistics/cervical.htm
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Appendix F
CDC’s HPV vaccine information sheet (VIS)

235

Source: CDC website. Retrieved September 30, 2009, from
http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-hpv.pdf
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